<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialResultsOutput hits="10" offset="1" totalResults="458"><Filters total="48"><Filter label="Trial Technologies" name="trialTechnologies" total="100"><FilterOption id="762" count="294" label="Small molecule therapeutic"/><FilterOption id="585" count="215" label="Oral formulation"/><FilterOption id="648" count="211" label="Intravenous formulation"/><FilterOption id="761" count="206" label="Biological therapeutic"/><FilterOption id="740" count="184" label="Infusion"/><FilterOption id="746" count="147" label="Solution"/><FilterOption id="595" count="143" label="Tablet formulation"/><FilterOption id="573" count="136" label="Immunoglobulin-G"/><FilterOption id="586" count="118" label="Capsule formulation"/><FilterOption id="85" count="111" label="Protein recombinant"/><FilterOption id="898" count="97" label="Formulation powder"/><FilterOption id="169" count="97" label="Monoclonal antibody humanized"/><FilterOption id="751" count="96" label="Film coating"/><FilterOption id="750" count="92" label="Freeze drying"/><FilterOption id="647" count="71" label="Subcutaneous formulation"/><FilterOption id="1263" count="60" label="Immuno-oncology"/><FilterOption id="1647" count="56" label="Natural product"/><FilterOption id="1652" count="41" label="Prodrug"/><FilterOption id="168" count="32" label="Monoclonal antibody human"/><FilterOption id="180" count="29" label="Antibody fragment"/><FilterOption id="902" count="27" label="Orally disintegrating tablet"/><FilterOption id="589" count="26" label="Sustained release formulation"/><FilterOption id="651" count="25" label="Intramuscular formulation"/><FilterOption id="80" count="25" label="Peptide"/><FilterOption id="805" count="22" label="Daily dosing"/><FilterOption id="745" count="21" label="Suspension"/><FilterOption id="766" count="20" label="Parenteral formulation unspecified"/><FilterOption id="166" count="19" label="Chimeric monoclonal antibody"/><FilterOption id="175" count="18" label="Drug combination"/><FilterOption id="594" count="18" label="Oral suspension formulation"/><FilterOption id="593" count="17" label="Oral liquid formulation"/><FilterOption id="894" count="15" label="Liquid formulation"/><FilterOption id="171" count="14" label="Monoclonal antibody conjugated"/><FilterOption id="599" count="14" label="Nanoparticle formulation injectable"/><FilterOption id="207" count="14" label="Protein conjugated"/><FilterOption id="128" count="13" label="Cell culture technique"/><FilterOption id="112" count="13" label="DNA technology"/><FilterOption id="756" count="13" label="Pharmaceutical carrier"/><FilterOption id="127" count="12" label="Cell culture"/><FilterOption id="596" count="12" label="Injectable formulation"/><FilterOption id="620" count="12" label="Ophthalmic formulation"/><FilterOption id="90" count="11" label="Steroid"/><FilterOption id="66" count="10" label="Antibiotic"/><FilterOption id="74" count="10" label="Glycoprotein"/><FilterOption id="852" count="10" label="Intravesical formulation"/><FilterOption id="603" count="10" label="Systemic formulation unspecified"/><FilterOption id="641" count="9" label="Controlled release formulation"/><FilterOption id="348" count="9" label="PEGylated formulation"/><FilterOption id="1164" count="8" label="Antibody drug conjugate"/><FilterOption id="558" count="8" label="Transdermal formulation"/><FilterOption id="649" count="7" label="Intraperitoneal formulation"/><FilterOption id="167" count="7" label="Monoclonal antibody murine"/><FilterOption id="901" count="7" label="Recombinant enzyme"/><FilterOption id="659" count="6" label="Ophthalmic liquid formulation"/><FilterOption id="630" count="6" label="Stereochemistry"/><FilterOption id="770" count="6" label="Transdermal gel formulation"/><FilterOption id="1663" count="5" label="Gel formulation"/><FilterOption id="743" count="5" label="Granule"/><FilterOption id="753" count="5" label="Microparticle formulation"/><FilterOption id="962" count="4" label="Biosimilar product"/><FilterOption id="680" count="4" label="Buccal formulation systemic"/><FilterOption id="598" count="4" label="Liposome formulation injectable"/><FilterOption id="51" count="4" label="Monoclonal antibody"/><FilterOption id="701" count="4" label="Nucleoside synthesis"/><FilterOption id="660" count="4" label="Oral sustained release formulation"/><FilterOption id="667" count="4" label="Peptidomimetic"/><FilterOption id="84" count="4" label="Protein fusion"/><FilterOption id="662" count="4" label="Quick release formulation"/><FilterOption id="1" count="3" label="Antibody"/><FilterOption id="67" count="3" label="Antigen"/><FilterOption id="111" count="3" label="Cloning technology"/><FilterOption id="611" count="3" label="Dermatological formulation"/><FilterOption id="590" count="3" label="Enteric coated formulation"/><FilterOption id="538" count="3" label="Humanized antibody"/><FilterOption id="616" count="3" label="Inhalant formulation"/><FilterOption id="569" count="3" label="Oligonucleotide antisense"/><FilterOption id="159" count="3" label="Oligosaccharide"/><FilterOption id="724" count="3" label="Radiolabeling"/><FilterOption id="211" count="2" label="Anti-idiotype monoclonal antibody"/><FilterOption id="537" count="2" label="Chimeric antibody"/><FilterOption id="723" count="2" label="Drug coating"/><FilterOption id="72" count="2" label="Enzyme"/><FilterOption id="1646" count="2" label="Injectable controlled release formulation"/><FilterOption id="851" count="2" label="Intradermal formulation"/><FilterOption id="807" count="2" label="Monthly dosing"/><FilterOption id="102" count="2" label="Nucleotide and derivatives"/><FilterOption id="103" count="2" label="Oligonucleotide"/><FilterOption id="772" count="2" label="Ophthalmic gel formulation"/><FilterOption id="776" count="2" label="Oral gel formulation"/><FilterOption id="661" count="2" label="Oral quick release formulation"/><FilterOption id="742" count="2" label="Pellet"/><FilterOption id="208" count="2" label="Protein conjugation"/><FilterOption id="62" count="2" label="Virus recombinant"/><FilterOption id="615" count="1" label="Aerosol formulation dermatological"/><FilterOption id="617" count="1" label="Aerosol formulation inhalant"/><FilterOption id="216" count="1" label="Antibody conjugated"/><FilterOption id="856" count="1" label="Autologous stem cell therapy"/><FilterOption id="769" count="1" label="Buccal gel formulation"/><FilterOption id="775" count="1" label="Dermatological gel formulation"/><FilterOption id="749" count="1" label="Drying"/></Filter><Filter label="Indications" name="indications" total="100"><FilterOption id="2399" count="30" label="Adenocarcinoma"/><FilterOption id="1069" count="29" label="Metastasis"/><FilterOption id="3657" count="29" label="Metastatic breast cancer"/><FilterOption id="49" count="28" label="Breast tumor"/><FilterOption id="3665" count="24" label="Metastatic non small cell lung cancer"/><FilterOption id="3658" count="20" label="Metastatic colorectal cancer"/><FilterOption id="1828" count="14" label="Multiple myeloma"/><FilterOption id="84" count="13" label="Crohns disease"/><FilterOption id="307" count="13" label="Squamous cell carcinoma"/><FilterOption id="3246" count="12" label="Hormone refractory prostate cancer"/><FilterOption id="1128" count="12" label="Neuroendocrine tumor"/><FilterOption id="4250" count="11" label="Metastatic renal cell carcinoma"/><FilterOption id="1771" count="11" label="Transitional cell carcinoma"/><FilterOption id="3666" count="10" label="Metastatic stomach cancer"/><FilterOption id="3667" count="9" label="Metastatic esophageal cancer"/><FilterOption id="3669" count="9" label="Metastatic pancreas cancer"/><FilterOption id="291" count="9" label="Rheumatoid arthritis"/><FilterOption id="337" count="8" label="Ulcerative colitis"/><FilterOption id="55" count="7" label="Cardiac failure"/><FilterOption id="1749" count="7" label="Diffuse large B-cell lymphoma"/><FilterOption id="1731" count="6" label="Acute myelogenous leukemia"/><FilterOption id="1542" count="6" label="Atrial fibrillation"/><FilterOption id="224" count="6" label="Myocardial infarction"/><FilterOption id="3147" count="6" label="Open angle glaucoma"/><FilterOption id="799" count="6" label="Ovary tumor"/><FilterOption id="1261" count="6" label="Small-cell lung cancer"/><FilterOption id="3378" count="6" label="Soft tissue sarcoma"/><FilterOption id="1767" count="5" label="Hepatocellular carcinoma"/><FilterOption id="158" count="5" label="HIV infection"/><FilterOption id="1272" count="5" label="Myelodysplastic syndrome"/><FilterOption id="1262" count="5" label="Non-small-cell lung cancer"/><FilterOption id="240" count="5" label="Ocular hypertension"/><FilterOption id="249" count="5" label="Pancreas tumor"/><FilterOption id="3257" count="5" label="Stage IV melanoma"/><FilterOption id="3678" count="5" label="Urethral cancer"/><FilterOption id="3713" count="4" label="Advanced solid tumor"/><FilterOption id="57" count="4" label="Cardiovascular disease"/><FilterOption id="1734" count="4" label="Chronic lymphocytic leukemia"/><FilterOption id="2975" count="4" label="Ewing sarcoma"/><FilterOption id="2243" count="4" label="Fallopian tube cancer"/><FilterOption id="1745" count="4" label="Follicle center lymphoma"/><FilterOption id="132" count="4" label="Gaucher disease"/><FilterOption id="2245" count="4" label="Gauchers disease type I"/><FilterOption id="153" count="4" label="Hepatitis C virus infection"/><FilterOption id="836" count="4" label="Insulin dependent diabetes"/><FilterOption id="2447" count="4" label="Liposarcoma"/><FilterOption id="3466" count="4" label="Metastatic bladder cancer"/><FilterOption id="3083" count="4" label="Peritoneal tumor"/><FilterOption id="330" count="4" label="Restenosis"/><FilterOption id="2380" count="3" label="Bladder cancer"/><FilterOption id="2444" count="3" label="Chondrosarcoma"/><FilterOption id="1185" count="3" label="Chronic obstructive pulmonary disease"/><FilterOption id="80" count="3" label="Coronary artery disease"/><FilterOption id="97" count="3" label="Diabetes mellitus"/><FilterOption id="1705" count="3" label="Endometrioid carcinoma"/><FilterOption id="3205" count="3" label="Gastrointestinal stromal tumor"/><FilterOption id="2535" count="3" label="Growth hormone deficiency"/><FilterOption id="623" count="3" label="Head and neck tumor"/><FilterOption id="159" count="3" label="HIV-1 infection"/><FilterOption id="174" count="3" label="Hypercholesterolemia"/><FilterOption id="3676" count="3" label="Ischemic stroke"/><FilterOption id="2446" count="3" label="Leiomyosarcoma"/><FilterOption id="584" count="3" label="Lipid metabolism disorder"/><FilterOption id="652" count="3" label="Malnutrition"/><FilterOption id="3664" count="3" label="Metastatic prostate cancer"/><FilterOption id="319" count="3" label="Non-Hodgkin lymphoma"/><FilterOption id="837" count="3" label="Non-insulin dependent diabetes"/><FilterOption id="3439" count="3" label="Partial seizure"/><FilterOption id="455" count="3" label="Premature labor"/><FilterOption id="1584" count="3" label="Unstable angina"/><FilterOption id="4265" count="3" label="Ureter cancer"/><FilterOption id="1107" count="2" label="Allergic rhinitis"/><FilterOption id="1755" count="2" label="Anaplastic large cell lymphoma"/><FilterOption id="23" count="2" label="Angina"/><FilterOption id="2443" count="2" label="Angiosarcoma"/><FilterOption id="316" count="2" label="B-cell lymphoma"/><FilterOption id="651" count="2" label="Cancer"/><FilterOption id="989" count="2" label="Colorectal tumor"/><FilterOption id="3440" count="2" label="Complex partial seizure"/><FilterOption id="89" count="2" label="Cytomegalovirus infection"/><FilterOption id="3203" count="2" label="Diabetic gastroparesis"/><FilterOption id="576" count="2" label="Diabetic retinopathy"/><FilterOption id="119" count="2" label="Epilepsy"/><FilterOption id="121" count="2" label="Factor VIII deficiency"/><FilterOption id="3204" count="2" label="Familial hypercholesterolemia"/><FilterOption id="1706" count="2" label="Granulosa cell tumor"/><FilterOption id="140" count="2" label="Growth disorder"/><FilterOption id="161" count="2" label="Hodgkins disease"/><FilterOption id="175" count="2" label="Hyperlipidemia"/><FilterOption id="3455" count="2" label="Influenza virus A infection"/><FilterOption id="1252" count="2" label="Iron overload"/><FilterOption id="637" count="2" label="Ischemia"/><FilterOption id="56" count="2" label="Ischemic heart disease"/><FilterOption id="3198" count="2" label="Larynx tumor"/><FilterOption id="1744" count="2" label="Mantle cell lymphoma"/><FilterOption id="3673" count="2" label="Metastatic head and neck cancer"/><FilterOption id="3462" count="2" label="Metastatic liver cancer"/><FilterOption id="3866" count="2" label="Metastatic ovary cancer"/><FilterOption id="213" count="2" label="Multiple sclerosis"/><FilterOption id="238" count="2" label="Obesity"/></Filter><Filter label="Endpoint Index" name="trialEndpointIndex" total="100"><FilterOption id="8712" count="35" label="Breast tumor - Assessment of Overall Survival (OS)"/><FilterOption id="8719" count="26" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="8489" count="26" label="Lung tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8998" count="25" label="Breast tumor - Assessment of adverse events"/><FilterOption id="8713" count="24" label="Breast tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8721" count="23" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="8481" count="23" label="Lung tumor - Assessment of Overall Survival (OS)"/><FilterOption id="8505" count="20" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"/><FilterOption id="8714" count="19" label="Breast tumor - Assessment of Disease Free Survival (DFS)"/><FilterOption id="8522" count="19" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="8722" count="18" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)"/><FilterOption id="8720" count="18" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="8996" count="18" label="Breast tumor - Assessment of Safety and Tolerability"/><FilterOption id="9153" count="17" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="8738" count="16" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response"/><FilterOption id="8640" count="16" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"/><FilterOption id="8639" count="15" label="Lung tumor - Assessment of Safety and Tolerability"/><FilterOption id="8744" count="14" label="Breast tumor - Assessment of Disease Progression"/><FilterOption id="8725" count="14" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"/><FilterOption id="8999" count="14" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria"/><FilterOption id="8163" count="14" label="Colorectal tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8663" count="14" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="8151" count="13" label="Colorectal tumor - Assessment of Overall Survival (OS)"/><FilterOption id="7538" count="13" label="Lymphoma - Assessment of Overall Survival (OS)"/><FilterOption id="7547" count="13" label="Lymphoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7045" count="13" label="Prostate tumor - Assessment of Overall Survival (OS)"/><FilterOption id="8187" count="12" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)"/><FilterOption id="7879" count="12" label="Leukemia - Assessment of Overall Survival (OS)"/><FilterOption id="13352" count="12" label="Pancreas tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="11722" count="11" label="Bladder cancer - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8754" count="11" label="Breast tumor - Assessment of Mortality/Death Rates"/><FilterOption id="8430" count="11" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="7360" count="11" label="Multiple myeloma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="11542" count="11" label="Soft tissue sarcoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="11717" count="10" label="Bladder cancer - Assessment of Overall Survival (OS)"/><FilterOption id="11728" count="10" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)"/><FilterOption id="8902" count="10" label="Breast tumor - Assessment of Biomarkers"/><FilterOption id="8997" count="10" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of serious adverse events"/><FilterOption id="8523" count="10" label="Lung tumor - Assessment of Disease Progression"/><FilterOption id="8514" count="10" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="8513" count="10" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="7049" count="10" label="Prostate tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="10545" count="10" label="Renal cell carcinoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="11735" count="9" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="37159" count="9" label="Breast tumor - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="9122" count="9" label="Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="8189" count="9" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="2622" count="9" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"/><FilterOption id="6339" count="9" label="Crohns disease - Crohn's Disease Activity Assessed by Indices/Scores - Crohn's disease activity index (CDAI) score"/><FilterOption id="8555" count="9" label="Lung tumor - Assessment of Mortality/Death Rates"/><FilterOption id="7563" count="9" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="7354" count="9" label="Multiple myeloma - Assessment of Overall Survival (OS)"/><FilterOption id="13435" count="9" label="Pancreas tumor - Assessment of adverse events"/><FilterOption id="6407" count="8" label="Crohns disease - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="20857" count="8" label="Gaucher disease - Clinical Assessments - Assessment of spleen"/><FilterOption id="7569" count="8" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="19617" count="8" label="Lysosome storage disease - Clinical Assessments - Assessment of spleen"/><FilterOption id="7489" count="8" label="Multiple myeloma - Assessment of Safety and Tolerability - Assessment of other adverse events"/><FilterOption id="11643" count="8" label="Neuroendocrine tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="13344" count="8" label="Pancreas tumor - Assessment of Overall Survival (OS)"/><FilterOption id="11780" count="7" label="Bladder cancer - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="8745" count="7" label="Breast tumor - Assessment of Disease Progression - Assessment of Time to Tumor Progression (TTP)"/><FilterOption id="8739" count="7" label="Breast tumor - Assessment of Disease Relapse/Recurrence"/><FilterOption id="9001" count="7" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of cardiac toxicity"/><FilterOption id="8764" count="7" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-C30"/><FilterOption id="8759" count="7" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="9147" count="7" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of toxicities"/><FilterOption id="8077" count="7" label="Leukemia - Assessment of Safety and Tolerability"/><FilterOption id="7679" count="7" label="Lymphoma - Assessment of Safety and Tolerability"/><FilterOption id="7680" count="7" label="Lymphoma - Assessment of adverse events"/><FilterOption id="19612" count="7" label="Lysosome storage disease - Clinical Assessments - Assessment of liver function"/><FilterOption id="10828" count="7" label="Ovary tumor - Assessment of Overall Survival (OS)"/><FilterOption id="13357" count="7" label="Pancreas tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"/><FilterOption id="3883" count="7" label="Rheumatoid arthritis - American College of Rheumatology (ACR) 20 Response"/><FilterOption id="11773" count="6" label="Bladder cancer - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="19282" count="6" label="Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="19412" count="6" label="Cancer supportive care - Protocol Specified Other Endpoints - Assessment of Other Treatment or Procedure Related Outcomes"/><FilterOption id="8383" count="6" label="Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="6313" count="6" label="Crohns disease - Assessment of Clinical Response - Clinical response measured by crohn's disease activity index (CDAI) score by &gt; or = 100 points"/><FilterOption id="8078" count="6" label="Leukemia - Assessment of adverse events"/><FilterOption id="8483" count="6" label="Lung tumor - Assessment of Overall Survival (OS) - Assessment of global/overall survival at 1 year"/><FilterOption id="28159" count="6" label="Lung tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ LC 13"/><FilterOption id="28069" count="6" label="Lung tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)"/><FilterOption id="7395" count="6" label="Multiple myeloma - Assessment of Disease Progression - Assessment of time to disease progression (TTP)"/><FilterOption id="7488" count="6" label="Multiple myeloma - Assessment of Safety and Tolerability"/><FilterOption id="11687" count="6" label="Neuroendocrine tumor - Assessment of Safety and Tolerability"/><FilterOption id="11539" count="6" label="Soft tissue sarcoma - Assessment of Overall Survival (OS)"/><FilterOption id="11778" count="5" label="Bladder cancer - Assessment of Mortality/Death Rates"/><FilterOption id="8730" count="5" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of histo-pathologic response"/><FilterOption id="9043" count="5" label="Breast tumor - Protocol Specified Other Endpoints"/><FilterOption id="6349" count="5" label="Crohns disease - Crohn's Disease Activity Assessed by Capsule Endoscopy/Endoscopy - Simple endoscopic index for crohn's disease (SES-CD)"/><FilterOption id="20876" count="5" label="Gaucher disease - Assessment of Laboratory/Diagnostic Measures - Assessment of hematologic parameters"/><FilterOption id="23916" count="5" label="Hypercholesterolemia - Assessment of Low-Density Lipoprotein (LDL)"/><FilterOption id="23914" count="5" label="Hypercholesterolemia - Assessment of lipid profiles - Assessment of Total Cholesterol"/><FilterOption id="23917" count="5" label="Hypercholesterolemia - Assessment of lipid profiles - Assessment of Triglycerides"/><FilterOption id="23921" count="5" label="Hypercholesterolemia - Assessment of lipid profiles - Assessment of apolipoprotein B"/><FilterOption id="19631" count="5" label="Lysosome storage disease - Assessment of Laboratory/Diagnostic Measures - Assessment of hematologic parameters"/><FilterOption id="7367" count="5" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="11685" count="5" label="Neuroendocrine tumor - Assessment of Disease Progression"/><FilterOption id="11640" count="5" label="Neuroendocrine tumor - Assessment of Overall Survival (OS)"/></Filter><Filter label="Trial Drug Phase Highest" name="trialDrugPhaseHighest" total="9"><FilterOption id="L" count="318" label="Launched"/><FilterOption id="C3" count="47" label="Phase 3 Clinical"/><FilterOption id="DX" count="22" label="Discontinued"/><FilterOption id="C2" count="20" label="Phase 2 Clinical"/><FilterOption id="PR" count="13" label="Pre-registration"/><FilterOption id="NDR" count="7" label="No Development Reported"/><FilterOption id="R" count="7" label="Registered"/><FilterOption id="C1" count="1" label="Phase 1 Clinical"/><FilterOption id="W" count="1" label="Withdrawn"/></Filter><Filter label="Trial Company Sponsor" name="trialCompaniesSponsor" total="100"><FilterOption id="19446" count="49" label="Roche Holding AG"/><FilterOption id="26178" count="43" label="F Hoffmann-La Roche AG"/><FilterOption id="15331" count="28" label="Celgene Corp"/><FilterOption id="18767" count="28" label="Pfizer Inc"/><FilterOption id="15414" count="19" label="Chugai Pharmaceutical Co Ltd"/><FilterOption id="1042061" count="15" label="Spanish Breast Cancer Research Group"/><FilterOption id="14881" count="13" label="Boehringer Ingelheim International GmbH"/><FilterOption id="1045582" count="11" label="Grupo Espanol de Investigacion en Sarcomas"/><FilterOption id="1038736" count="10" label="PETHEMA Foundation"/><FilterOption id="1042371" count="10" label="Spanish Oncology Genito-Urinary Group"/><FilterOption id="17259" count="8" label="Ipsen"/><FilterOption id="1043659" count="7" label="Grupo Espanol Multidisciplinario del Cancer Digestivo"/><FilterOption id="1059410" count="7" label="Grupo Espanol de Tumores Neuroendocrinos"/><FilterOption id="1090417" count="7" label="Roche Singapore Pte Ltd"/><FilterOption id="22546" count="6" label="Boehringer Ingelheim GmbH"/><FilterOption id="17810" count="6" label="Eli Lilly &amp; Co"/><FilterOption id="19453" count="6" label="Genentech Inc"/><FilterOption id="1045513" count="6" label="Spanish Lung Cancer Group"/><FilterOption id="1154033" count="5" label="Aragonese Institute of Health Sciences"/><FilterOption id="1103352" count="5" label="Boehringer Ingelheim Espana Sa"/><FilterOption id="1056053" count="5" label="Celgene International Sarl"/><FilterOption id="1084801" count="5" label="Medica Scientia Innovation Research"/><FilterOption id="23780" count="4" label="Actelion Ltd"/><FilterOption id="1088700" count="4" label="Allergan plc"/><FilterOption id="22545" count="4" label="Boehringer Ingelheim AB"/><FilterOption id="16450" count="4" label="Gilead Sciences Inc"/><FilterOption id="1089015" count="4" label="Grupo Espanol Multidisciplinar de Melanoma"/><FilterOption id="1042252" count="4" label="Grupo Espanol de Linfomas y Transplante Autologo de Medula Osea"/><FilterOption id="19461" count="4" label="Hoffmann-La Roche Inc"/><FilterOption id="1082374" count="4" label="ROCHE Espana"/><FilterOption id="14042" count="3" label="Allergan Inc"/><FilterOption id="1063251" count="3" label="BeiGene Co Ltd"/><FilterOption id="22555" count="3" label="Boehringer Ingelheim Ellas AE"/><FilterOption id="22560" count="3" label="Boehringer Ingelheim Italia SpA"/><FilterOption id="27847" count="3" label="Boston Scientific Corp"/><FilterOption id="15065" count="3" label="Bristol-Myers Squibb Co"/><FilterOption id="1017946" count="3" label="Centro Nacional de Investigaciones Oncologicas"/><FilterOption id="1067616" count="3" label="Clinica Universidad de Navarra"/><FilterOption id="1020322" count="3" label="Daiichi Sankyo Inc"/><FilterOption id="14913" count="3" label="Eisai Ltd"/><FilterOption id="1047068" count="3" label="Grupo Español de Tratamiento de Tumores de Cabeza y Cuello"/><FilterOption id="1034433" count="3" label="Hospital Miguel Servet"/><FilterOption id="1072647" count="3" label="Institut de Recherches Internationales Servier (France)"/><FilterOption id="1067538" count="3" label="Janssen Research &amp; Development LLC"/><FilterOption id="1091809" count="3" label="Janssen-Cilag International NV (BE)"/><FilterOption id="18101" count="3" label="Merck KGaA"/><FilterOption id="1089865" count="3" label="PAREXEL International (Singapore) Pte Ltd"/><FilterOption id="1065375" count="3" label="Puma Biotechnology Inc"/><FilterOption id="1125936" count="3" label="Quintiles Research India Pvt Ltd"/><FilterOption id="1091820" count="3" label="Roche China Co Ltd"/><FilterOption id="26327" count="3" label="Roche Diagnostics GmbH"/><FilterOption id="1109598" count="3" label="Roche Products India Pvt Ltd"/><FilterOption id="24652" count="3" label="Shire plc"/><FilterOption id="1063946" count="3" label="Syneos Health Inc"/><FilterOption id="22598" count="3" label="Unilfarma Lda"/><FilterOption id="13601" count="2" label="Abbott Laboratories"/><FilterOption id="28611" count="2" label="Actelion Pharmaceuticals Ltd"/><FilterOption id="1144031" count="2" label="Allergan Limited"/><FilterOption id="1090105" count="2" label="Allergan Singapore PTE Ltd"/><FilterOption id="20972" count="2" label="Astellas Pharma Europe Ltd"/><FilterOption id="1013295" count="2" label="Astellas Pharma Inc"/><FilterOption id="14190" count="2" label="AstraZeneca plc"/><FilterOption id="14455" count="2" label="Bayer AG"/><FilterOption id="22549" count="2" label="Boehringer Ingelheim Austria GmbH"/><FilterOption id="22554" count="2" label="Boehringer Ingelheim BV"/><FilterOption id="22556" count="2" label="Boehringer Ingelheim France SARL"/><FilterOption id="22563" count="2" label="Boehringer Ingelheim Ltd"/><FilterOption id="1038949" count="2" label="Boston Biomedical Inc"/><FilterOption id="15141" count="2" label="Bristol-Myers Squibb (Singapore) Pte Ltd"/><FilterOption id="19620" count="2" label="Eisai Inc"/><FilterOption id="1050177" count="2" label="Fondazione Michelangelo"/><FilterOption id="1046331" count="2" label="Fundacion SEIMC-GESIDA"/><FilterOption id="1161122" count="2" label="Fundación EPIC"/><FilterOption id="1052299" count="2" label="Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla"/><FilterOption id="1039086" count="2" label="Germans Trias i Pujol Hospital"/><FilterOption id="1143376" count="2" label="Gilead Sciences Singapore Pte Ltd"/><FilterOption id="1047062" count="2" label="Grupo de Investigación Clínica en Oncología Radioterapia"/><FilterOption id="1056260" count="2" label="Grupo Espanol de Investigacion en Cancer de Ovario"/><FilterOption id="1094662" count="2" label="Grupo Espanol de Tumores Huerfanos e Infrecuentes"/><FilterOption id="1053468" count="2" label="Grupo Español de Investigación en Neurooncología"/><FilterOption id="1040940" count="2" label="Hospital Universitari de Bellvitge"/><FilterOption id="1089948" count="2" label="INC RESEARCH CRO SINGAPORE"/><FilterOption id="1173059" count="2" label="IQVIA RDS India Private Limited"/><FilterOption id="26953" count="2" label="Kowa Research Europe Ltd"/><FilterOption id="18008" count="2" label="MedImmune LLC"/><FilterOption id="1059823" count="2" label="Merck Sharp &amp; Dohme Corp"/><FilterOption id="18799" count="2" label="Pfizer (India) Ltd"/><FilterOption id="17927" count="2" label="PharmaMar SA"/><FilterOption id="1089748" count="2" label="PPD Development (S) Pte Ltd"/><FilterOption id="1093732" count="2" label="Quintiles Philippines, Inc"/><FilterOption id="1050513" count="2" label="Receptos Inc"/><FilterOption id="1125025" count="2" label="Servier Research and Development"/><FilterOption id="20436" count="2" label="Shire Human Genetic Therapies Inc"/><FilterOption id="30259" count="2" label="SIRTeX Medical Ltd"/><FilterOption id="1073757" count="2" label="Spanish Society of Cardiology"/><FilterOption id="24232" count="2" label="Spectrum Pharmaceuticals Inc"/><FilterOption id="14199" count="2" label="Wyeth Pharmaceuticals"/><FilterOption id="1066474" count="1" label="Abbott Nutrition"/><FilterOption id="1061163" count="1" label="Abbott Vascular"/><FilterOption id="29218" count="1" label="AbbVie Deutschland GmbH &amp; Co KG"/></Filter><Filter label="Trial Recruitment Status" name="trialRecruitmentStatus" total="6"><FilterOption id="4" count="184" label="Completed"/><FilterOption id="2" count="132" label="Recruiting"/><FilterOption id="3" count="88" label="No longer recruiting"/><FilterOption id="6" count="41" label="Terminated"/><FilterOption id="1" count="9" label="Not yet recruiting"/><FilterOption id="5" count="4" label="Suspended"/></Filter><Filter label="Trial Commercially Significant" name="trialIsCommerciallySignificant" total="2"><FilterOption id="YES" count="283" label="Yes"/><FilterOption id="NO" count="175" label="No"/></Filter><Filter label="Trial Indications Pioneer" name="trialIndicationsPioneer" total="97"><FilterOption id="2399" count="6" label="Adenocarcinoma"/><FilterOption id="3658" count="5" label="Metastatic colorectal cancer"/><FilterOption id="3669" count="5" label="Metastatic pancreas cancer"/><FilterOption id="1069" count="4" label="Metastasis"/><FilterOption id="224" count="4" label="Myocardial infarction"/><FilterOption id="3657" count="3" label="Metastatic breast cancer"/><FilterOption id="3665" count="3" label="Metastatic non small cell lung cancer"/><FilterOption id="291" count="3" label="Rheumatoid arthritis"/><FilterOption id="1584" count="3" label="Unstable angina"/><FilterOption id="3713" count="2" label="Advanced solid tumor"/><FilterOption id="2443" count="2" label="Angiosarcoma"/><FilterOption id="2380" count="2" label="Bladder cancer"/><FilterOption id="49" count="2" label="Breast tumor"/><FilterOption id="651" count="2" label="Cancer"/><FilterOption id="57" count="2" label="Cardiovascular disease"/><FilterOption id="576" count="2" label="Diabetic retinopathy"/><FilterOption id="2975" count="2" label="Ewing sarcoma"/><FilterOption id="1706" count="2" label="Granulosa cell tumor"/><FilterOption id="175" count="2" label="Hyperlipidemia"/><FilterOption id="3676" count="2" label="Ischemic stroke"/><FilterOption id="2446" count="2" label="Leiomyosarcoma"/><FilterOption id="2447" count="2" label="Liposarcoma"/><FilterOption id="3666" count="2" label="Metastatic stomach cancer"/><FilterOption id="1128" count="2" label="Neuroendocrine tumor"/><FilterOption id="799" count="2" label="Ovary tumor"/><FilterOption id="4166" count="2" label="Small intestine cancer"/><FilterOption id="1261" count="2" label="Small-cell lung cancer"/><FilterOption id="3378" count="2" label="Soft tissue sarcoma"/><FilterOption id="307" count="2" label="Squamous cell carcinoma"/><FilterOption id="4265" count="2" label="Ureter cancer"/><FilterOption id="3678" count="2" label="Urethral cancer"/><FilterOption id="7" count="1" label="Adenovirus infection"/><FilterOption id="1648" count="1" label="Adrenal cortical carcinoma"/><FilterOption id="3504" count="1" label="Aggressive fibromatosis"/><FilterOption id="2193" count="1" label="Anal tumor"/><FilterOption id="1755" count="1" label="Anaplastic large cell lymphoma"/><FilterOption id="17" count="1" label="Anemia"/><FilterOption id="3148" count="1" label="Angle closure glaucoma"/><FilterOption id="791" count="1" label="Burkitts lymphoma"/><FilterOption id="2444" count="1" label="Chondrosarcoma"/><FilterOption id="3138" count="1" label="Choroidal neovascularization"/><FilterOption id="3440" count="1" label="Complex partial seizure"/><FilterOption id="84" count="1" label="Crohns disease"/><FilterOption id="97" count="1" label="Diabetes mellitus"/><FilterOption id="102" count="1" label="Diarrhea"/><FilterOption id="2024" count="1" label="Erythema"/><FilterOption id="2243" count="1" label="Fallopian tube cancer"/><FilterOption id="3204" count="1" label="Familial hypercholesterolemia"/><FilterOption id="3795" count="1" label="Febrile neutropenia"/><FilterOption id="2717" count="1" label="Fibroma"/><FilterOption id="2445" count="1" label="Fibrosarcoma"/><FilterOption id="1127" count="1" label="Fibrosis"/><FilterOption id="2716" count="1" label="Fibrous tissue neoplasm"/><FilterOption id="137" count="1" label="Gram negative bacterium infection"/><FilterOption id="623" count="1" label="Head and neck tumor"/><FilterOption id="626" count="1" label="Heart disease"/><FilterOption id="2103" count="1" label="Hemangiopericytoma"/><FilterOption id="2104" count="1" label="Hemangiosarcoma"/><FilterOption id="153" count="1" label="Hepatitis C virus infection"/><FilterOption id="189" count="1" label="Inflammatory bowel disease"/><FilterOption id="3948" count="1" label="Inflammatory breast cancer"/><FilterOption id="765" count="1" label="Intestine tumor"/><FilterOption id="584" count="1" label="Lipid metabolism disorder"/><FilterOption id="2318" count="1" label="Liver fibrosis"/><FilterOption id="755" count="1" label="Lung tumor"/><FilterOption id="2404" count="1" label="Lupus nephritis"/><FilterOption id="3352" count="1" label="Macular edema"/><FilterOption id="3667" count="1" label="Metastatic esophageal cancer"/><FilterOption id="3460" count="1" label="Metastatic gastrointestinal cancer"/><FilterOption id="3673" count="1" label="Metastatic head and neck cancer"/><FilterOption id="3465" count="1" label="Metastatic urinary tract cancer"/><FilterOption id="1115" count="1" label="Mycosis fungoides"/><FilterOption id="1814" count="1" label="Neoplastic meningitis"/><FilterOption id="1262" count="1" label="Non-small-cell lung cancer"/><FilterOption id="3209" count="1" label="Oral mucositis"/><FilterOption id="1772" count="1" label="Osteosarcoma"/><FilterOption id="20" count="1" label="Pain"/><FilterOption id="1507" count="1" label="Pancreatic ductal adenocarcinoma"/><FilterOption id="1791" count="1" label="Penis tumor"/><FilterOption id="3083" count="1" label="Peritoneal tumor"/><FilterOption id="455" count="1" label="Premature labor"/><FilterOption id="3510" count="1" label="Pulmonary artery hypertension"/><FilterOption id="999" count="1" label="Renal tumor"/><FilterOption id="2656" count="1" label="Retinal venous occlusion"/><FilterOption id="1756" count="1" label="Sezary syndrome"/><FilterOption id="725" count="1" label="Solid tumor"/><FilterOption id="3256" count="1" label="Stage III melanoma"/><FilterOption id="65" count="1" label="Stroke"/><FilterOption id="318" count="1" label="Systemic lupus erythematosus"/><FilterOption id="324" count="1" label="Thrombocytopenia"/><FilterOption id="1076" count="1" label="Thrombosis"/><FilterOption id="2992" count="1" label="Tonic clonic epilepsy"/><FilterOption id="1771" count="1" label="Transitional cell carcinoma"/><FilterOption id="2980" count="1" label="Transplantation"/><FilterOption id="738" count="1" label="Urinary tract tumor"/><FilterOption id="3354" count="1" label="Wet age related macular degeneration"/><FilterOption id="3016" count="1" label="Xerophthalmia"/></Filter><Filter label="Registry Id" name="trialRegistries" total="23"><FilterOption id="1000" count="454" label="CT.gov"/><FilterOption id="1001" count="322" label="EudraCT"/><FilterOption id="1030" count="88" label="RSRM CTR"/><FilterOption id="1006" count="56" label="JapicCTI"/><FilterOption id="1023" count="35" label="UKCRN"/><FilterOption id="1012" count="34" label="CTRI"/><FilterOption id="1035" count="34" label="Singapore HSA CTR"/><FilterOption id="1019" count="29" label="DRKS"/><FilterOption id="1021" count="23" label="NMRR"/><FilterOption id="1004" count="20" label="WHO ICTRP"/><FilterOption id="1039" count="19" label="CDE"/><FilterOption id="1033" count="15" label="Mexico CTR"/><FilterOption id="1038" count="15" label="PHRR"/><FilterOption id="1009" count="14" label="HKClinicalTrials.com"/><FilterOption id="1002" count="8" label="ISRCTN"/><FilterOption id="1011" count="4" label="ANZCTR"/><FilterOption id="1020" count="2" label="ReBec"/><FilterOption id="1018" count="2" label="SLCTR"/><FilterOption id="1003" count="2" label="UMIN"/><FilterOption id="1010" count="1" label="CRiS"/><FilterOption id="1008" count="1" label="Hong Kong CCTCTR"/><FilterOption id="1036" count="1" label="JAZMP CTR"/><FilterOption id="1040" count="1" label="REec"/></Filter><Filter label="Trial Reason for Discontinuation" name="trialReasonForDiscontinuation" total="7"><FilterOption id="2" count="12" label="Not Reported"/><FilterOption id="1" count="10" label="Lack of Efficacy"/><FilterOption id="4" count="6" label="Other"/><FilterOption id="8" count="6" label="Sponsor/Business Decision"/><FilterOption id="5" count="5" label="Patient Enrollment Issues"/><FilterOption id="7" count="3" label="Safety Issues"/><FilterOption id="3" count="1" label="Operational Issues"/></Filter><Filter label="Active Controls" name="trialActiveControls" total="89"><FilterOption id="2953" count="18" label="docetaxel"/><FilterOption id="44383" count="16" label="carboplatin"/><FilterOption id="3199" count="15" label="gemcitabine"/><FilterOption id="3803" count="14" label="paclitaxel"/><FilterOption id="12205" count="10" label="capecitabine"/><FilterOption id="3792" count="9" label="oxaliplatin"/><FilterOption id="8047" count="8" label="bevacizumab"/><FilterOption id="6386" count="8" label="trastuzumab"/><FilterOption id="3536" count="7" label="pemetrexed disodium"/><FilterOption id="13022" count="5" label="epirubicin"/><FilterOption id="3313" count="5" label="fulvestrant"/><FilterOption id="29016" count="5" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="3072" count="4" label="etoposide phosphate"/><FilterOption id="2871" count="4" label="irinotecan"/><FilterOption id="2784" count="4" label="letrozole"/><FilterOption id="6736" count="4" label="rituximab"/><FilterOption id="33591" count="3" label="lapatinib"/><FilterOption id="27572" count="3" label="lenalidomide"/><FilterOption id="22395" count="3" label="ranibizumab"/><FilterOption id="29831" count="3" label="sorafenib"/><FilterOption id="4577" count="3" label="topotecan"/><FilterOption id="15130" count="3" label="vinflunine"/><FilterOption id="6408" count="3" label="vinorelbine"/><FilterOption id="14163" count="2" label="adalimumab"/><FilterOption id="3321" count="2" label="anastrozole"/><FilterOption id="72699" count="2" label="atezolizumab"/><FilterOption id="47000" count="2" label="bendamustine"/><FilterOption id="15954" count="2" label="bortezomib"/><FilterOption id="55798" count="2" label="crizotinib"/><FilterOption id="32981" count="2" label="darunavir"/><FilterOption id="13239" count="2" label="decitabine"/><FilterOption id="7934" count="2" label="doxorubicin (liposomal, STEALTH), Alza"/><FilterOption id="3130" count="2" label="filgrastim"/><FilterOption id="7456" count="2" label="imiglucerase"/><FilterOption id="48181" count="2" label="lamivudine + abacavir, GlaxoSmithKline"/><FilterOption id="13460" count="2" label="oseltamivir"/><FilterOption id="8747" count="2" label="palivizumab"/><FilterOption id="21374" count="2" label="pegfilgrastim"/><FilterOption id="70667" count="2" label="pembrolizumab"/><FilterOption id="28532" count="2" label="pertuzumab"/><FilterOption id="7310" count="2" label="ritonavir"/><FilterOption id="12973" count="2" label="sunitinib"/><FilterOption id="49219" count="2" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"/><FilterOption id="8050" count="2" label="thalidomide, Celgene"/><FilterOption id="44315" count="2" label="timolol"/><FilterOption id="10309" count="1" label="abiraterone"/><FilterOption id="53547" count="1" label="aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer"/><FilterOption id="2807" count="1" label="atorvastatin"/><FilterOption id="37370" count="1" label="azacitidine"/><FilterOption id="55126" count="1" label="bimatoprost + timolol (ophthalmic, glaucoma), Allergan"/><FilterOption id="2836" count="1" label="clopidogrel"/><FilterOption id="2992" count="1" label="donepezil hydrochloride"/><FilterOption id="13928" count="1" label="enoxaparin sodium"/><FilterOption id="53981" count="1" label="enzalutamide"/><FilterOption id="28773" count="1" label="eribulin mesylate"/><FilterOption id="11961" count="1" label="erlotinib"/><FilterOption id="4567" count="1" label="etanercept"/><FilterOption id="6156" count="1" label="fludarabine"/><FilterOption id="3195" count="1" label="ganciclovir (oral), Roche Bioscience"/><FilterOption id="11603" count="1" label="gefitinib"/><FilterOption id="8832" count="1" label="glimepiride"/><FilterOption id="6850" count="1" label="infliximab"/><FilterOption id="10411" count="1" label="insulin aspart"/><FilterOption id="10252" count="1" label="insulin glargine"/><FilterOption id="3353" count="1" label="insulin lispro"/><FilterOption id="3360" count="1" label="interferon beta-1a, Biogen"/><FilterOption id="3488" count="1" label="leflunomide"/><FilterOption id="14681" count="1" label="lopinavir + ritonavir"/><FilterOption id="3616" count="1" label="meropenem"/><FilterOption id="64783" count="1" label="mesalazine (oral delayed-release, ulcerative colitis), Tillotts/Allergan"/><FilterOption id="10634" count="1" label="milrinone"/><FilterOption id="11519" count="1" label="mitoxantrone"/><FilterOption id="3669" count="1" label="mycophenolate mofetil"/><FilterOption id="54804" count="1" label="nivolumab"/><FilterOption id="53227" count="1" label="obinutuzumab"/><FilterOption id="43738" count="1" label="pazopanib"/><FilterOption id="23625" count="1" label="peginterferon alfa-2a"/><FilterOption id="54624" count="1" label="regorafenib"/><FilterOption id="5369" count="1" label="ribavirin"/><FilterOption id="55759" count="1" label="somatropin, Pfizer"/><FilterOption id="44314" count="1" label="tamoxifen"/><FilterOption id="10084" count="1" label="tegafur + gimeracil + oteracil potassium"/><FilterOption id="36332" count="1" label="ticagrelor"/><FilterOption id="23239" count="1" label="ulipristal"/><FilterOption id="25182" count="1" label="valganciclovir"/><FilterOption id="54469" count="1" label="vemurafenib"/><FilterOption id="12150" count="1" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"/><FilterOption id="44375" count="1" label="warfarin"/><FilterOption id="8424" count="1" label="zanamivir"/></Filter><Filter label="Exclusion Criteria Index" name="trialExclusionCriteriaIndex" total="100"><FilterOption id="6294" count="43" label="Breast tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6258" count="34" label="Breast tumor - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="5193" count="26" label="Lung tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6272" count="25" label="Breast tumor - Subjects co-morbid with inflammatory disorders"/><FilterOption id="20282" count="23" label="Lung tumor - Subjects co-morbid with inflammatory disorders"/><FilterOption id="6331" count="22" label="Breast tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="6377" count="22" label="Breast tumor - Subjects with history of/planned radiotherapy"/><FilterOption id="6302" count="21" label="Breast tumor - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Subjects with hypersensitivity/contraindication to any investigational agents"/><FilterOption id="5132" count="21" label="Lung tumor - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="6247" count="20" label="Breast tumor - Subjects by disease severity - Subjects with Brain/Leptomeningeal metastases"/><FilterOption id="6328" count="19" label="Breast tumor - Subjects with History of/Scheduled for Anti-neoplastic Therapy"/><FilterOption id="20290" count="19" label="Breast tumor - Subjects with History of/Scheduled for Intervention/Surgery - Subjects with history of/scheduled for surgery"/><FilterOption id="6393" count="19" label="Breast tumor - Subjects with History of/Scheduled to Receive Therapy"/><FilterOption id="6253" count="18" label="Breast tumor - Subjects with Co-morbid Conditions - Subjects with central nervous system diseases"/><FilterOption id="20289" count="18" label="Breast tumor - Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy - Subjects with history of biologic therapy"/><FilterOption id="5841" count="18" label="Colorectal tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="5365" count="18" label="Lung tumor - Protocol Specified Other Exclusion Criteria - Protocol specified exclusion criteria for females"/><FilterOption id="5139" count="18" label="Lung tumor - Subjects co-morbid with Respiratory Diseases/Disorders - Subjects co-morbid with pulmonary diseases/disorders"/><FilterOption id="17557" count="17" label="Breast tumor - Subjects with Abnormal Laboratory Findings"/><FilterOption id="6252" count="17" label="Breast tumor - Subjects with Co-morbid Conditions"/><FilterOption id="5125" count="17" label="Lung tumor - Subjects with Evidence of Metastasis - Subjects with central nervous system metastases"/><FilterOption id="6246" count="16" label="Breast tumor - Subjects by disease severity - Metastatic/TNM Stage IV Breast Cancer"/><FilterOption id="5163" count="16" label="Lung tumor - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"/><FilterOption id="5345" count="16" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled to receive an investigational drug"/><FilterOption id="5270" count="15" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="4702" count="15" label="Lymphoma - Subjects with Co-morbid Conditions"/><FilterOption id="6259" count="14" label="Breast tumor - Subjects co-morbid with Respiratory Diseases/Disorders - Subjects co-morbid with pulmonary diseases/disorders"/><FilterOption id="6260" count="14" label="Breast tumor - Subjects co-morbid with gastrointestinal diseases/disorders"/><FilterOption id="6361" count="14" label="Breast tumor - Subjects with History of/Scheduled for Anti-neoplastic Therapy - Subjects with history of/scheduled for targeted therapy"/><FilterOption id="5282" count="14" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for radiation therapy"/><FilterOption id="10378" count="14" label="Pancreas tumor - Subjects with Co-morbid Conditions"/><FilterOption id="6474" count="13" label="Breast tumor - Protocol Specified Other Exclusion Criteria - Protocol specified exclusion criteria for females"/><FilterOption id="6217" count="13" label="Breast tumor - Subjects with Other forms of Breast Cancer - Subjects with bilateral breast cancer"/><FilterOption id="5848" count="13" label="Colorectal tumor - Subjects co-morbid with gastrointestinal diseases/disorders"/><FilterOption id="5856" count="13" label="Colorectal tumor - Subjects co-morbid with inflammatory disorders"/><FilterOption id="20292" count="12" label="Breast tumor - Subjects with History of/Scheduled for Anti-neoplastic Therapy - Subjects with history of/scheduled to receive an investigational drug"/><FilterOption id="5879" count="12" label="Colorectal tumor - Subjects with Co-morbid Conditions"/><FilterOption id="5954" count="12" label="Colorectal tumor - Subjects with History of/Scheduled for Intervention/Surgery"/><FilterOption id="6554" count="12" label="Leukemia - Subjects with Co-morbid Conditions"/><FilterOption id="6257" count="11" label="Breast tumor - Subjects co-morbid with endocrine/metabolic diseases/disorders"/><FilterOption id="6418" count="11" label="Breast tumor - Subjects with Protocol Specified Compliance Status - Subjects with noncompliance to study protocol"/><FilterOption id="5921" count="11" label="Colorectal tumor - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Hypersensitivity/Contraindications to study medications or its excipients"/><FilterOption id="5826" count="11" label="Colorectal tumor - Subjects with Metastatic Colorectal Cancer - Subjects with brain metastases or leptomeningeal carcinomatosis"/><FilterOption id="5128" count="11" label="Lung tumor - Subjects with Co-morbid Conditions - Subjects with central nervous system diseases/disorders"/><FilterOption id="5291" count="11" label="Lung tumor - Subjects with History of/Scheduled for Other Treatments"/><FilterOption id="5349" count="11" label="Lung tumor - Subjects with Protocol Specified Compliance Status - Subjects unable/unwilling to comply with protocol requirements"/><FilterOption id="4692" count="11" label="Lymphoma - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6265" count="10" label="Breast tumor - Subjects with Co-morbid Conditions - Subjects co-morbid with hematological disease/disorders"/><FilterOption id="6261" count="10" label="Breast tumor - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"/><FilterOption id="6301" count="10" label="Breast tumor - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients"/><FilterOption id="5864" count="10" label="Colorectal tumor - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="5934" count="10" label="Colorectal tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="5949" count="10" label="Colorectal tumor - Subjects with history of/scheduled to receive radiation therapy"/><FilterOption id="5962" count="10" label="Colorectal tumor - Subjects with history of/scheduled to receive therapy for other indication"/><FilterOption id="6534" count="10" label="Leukemia - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="4909" count="10" label="Prostate tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="9003" count="9" label="Bladder cancer - Subjects with Co-morbid Conditions"/><FilterOption id="5876" count="9" label="Colorectal tumor - Subjects co-morbid with Respiratory Diseases/Disorders"/><FilterOption id="5989" count="9" label="Colorectal tumor - Subjects with Protocol Specified Reproductive Status - Pregnant/lactating women"/><FilterOption id="4769" count="9" label="Lymphoma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="10409" count="9" label="Pancreas tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of radiotherapy"/><FilterOption id="8836" count="9" label="Soft tissue sarcoma - Subjects with Co-morbid Conditions"/><FilterOption id="8835" count="9" label="Soft tissue sarcoma - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="8870" count="9" label="Soft tissue sarcoma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled to receive an investigational drug"/><FilterOption id="9002" count="8" label="Bladder cancer - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="9037" count="8" label="Bladder cancer - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled to receive an investigational drug"/><FilterOption id="6440" count="8" label="Breast tumor - Protocol Specified Other Exclusion Criteria - Subjects unfit as per principal investigator (PI)"/><FilterOption id="6245" count="8" label="Breast tumor - Subjects with specific disease - Subjects with Inflammatory Breast cancer"/><FilterOption id="5886" count="8" label="Colorectal tumor - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"/><FilterOption id="5928" count="8" label="Colorectal tumor - Subjects with History of/Scheduled to Receive Colorectal Cancer Therapy"/><FilterOption id="16144" count="8" label="Gaucher disease - Subjects with Co-morbid Conditions"/><FilterOption id="5269" count="8" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy"/><FilterOption id="4762" count="8" label="Lymphoma - Subjects with History of/Scheduled to Receive Therapy - Subject with history of radiotherapy"/><FilterOption id="14498" count="8" label="Lysosome storage disease - Subjects with Co-morbid Conditions"/><FilterOption id="10881" count="7" label="Cancer supportive care - Subjects with Co-morbid Conditions"/><FilterOption id="5860" count="7" label="Colorectal tumor - Subjects co-morbid with CNS disorders"/><FilterOption id="5885" count="7" label="Colorectal tumor - Subjects with Co-morbid Conditions - Subjects co-morbid with hematological disease/disorders"/><FilterOption id="5945" count="7" label="Colorectal tumor - Subjects with history of/scheduled to receive biological therapy"/><FilterOption id="9842" count="7" label="Ovary tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of radiotherapy"/><FilterOption id="10410" count="7" label="Pancreas tumor - Subjects with History of/Scheduled to Receive Therapy - Patient with history of surgical interventions/procedure"/><FilterOption id="4864" count="7" label="Prostate tumor - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="10704" count="7" label="Solid tumor - Subjects with Co-morbid Conditions"/><FilterOption id="6214" count="6" label="Breast tumor - Male Subjects with Breast Cancer"/><FilterOption id="7811" count="6" label="Colorectal tumor - Protocol Specified Other Exclusion Criteria - Subjects with concurrent/history of toxicity to prior therapies"/><FilterOption id="5887" count="6" label="Colorectal tumor - Subjects co-morbid with renal disease/disorder"/><FilterOption id="1662" count="6" label="Coronary artery disease - Subjects co-morbid with cardiovascular diseases/disorders - Subjects co-morbid with congestive heart failure (Killip class II-IV/NYHA Class II-IV)/Failure of the right ventricle/Decompensated heart failure"/><FilterOption id="6065" count="6" label="Multiple myeloma - Subjects with Co-morbid Conditions"/><FilterOption id="8929" count="6" label="Neuroendocrine tumor - Subjects with Co-morbid Conditions"/><FilterOption id="8928" count="6" label="Neuroendocrine tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="4847" count="6" label="Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer - Subjects with brain metastasis"/><FilterOption id="4970" count="6" label="Prostate tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects on prior/concurrent biologics/immunotherapy"/><FilterOption id="8864" count="6" label="Soft tissue sarcoma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="6308" count="5" label="Breast tumor - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Subjects with hypersensitivity/contraindication to chemotherapeutic agents"/><FilterOption id="6904" count="5" label="Breast tumor - Subjects with Other forms of Breast Cancer - Contralateral breast cancer"/><FilterOption id="20284" count="5" label="Colorectal tumor - Subjects with History of/Scheduled to Receive Colorectal Cancer Therapy - Subjects with history of/scheduled to receive intervention/surgery"/><FilterOption id="5981" count="5" label="Colorectal tumor - Subjects with Protocol Specified Compliance Status - Subjects who are unable to follow study procedures/comply with protocol requirements"/><FilterOption id="16149" count="5" label="Gaucher disease - Subjects co-morbid with hepatobiliary disorders/diseases - Subjects co-morbid with hepatic diseases/disorders"/><FilterOption id="6859" count="5" label="HIV infection - Pregnant or Breast Feeding Subjects"/><FilterOption id="18586" count="5" label="Hypercholesterolemia - Subjects co-morbid with Cerebrovascular Disorders/Diseases"/><FilterOption id="5344" count="5" label="Lung tumor - Protocol Specified Other Exclusion Criteria"/></Filter><Filter label="Trial Date Enrollment End By Month" name="trialDateEnrollmentEndByMonth" total="100"><FilterOption count="7" label="201803"/><FilterOption count="6" label="201809"/><FilterOption count="6" label="201902"/><FilterOption count="5" label="201202"/><FilterOption count="5" label="201503"/><FilterOption count="5" label="201806"/><FilterOption count="4" label="201110"/><FilterOption count="4" label="201505"/><FilterOption count="4" label="201510"/><FilterOption count="4" label="201512"/><FilterOption count="4" label="201612"/><FilterOption count="4" label="201710"/><FilterOption count="4" label="201804"/><FilterOption count="4" label="201808"/><FilterOption count="4" label="201901"/><FilterOption count="3" label="201304"/><FilterOption count="3" label="201309"/><FilterOption count="3" label="201310"/><FilterOption count="3" label="201410"/><FilterOption count="3" label="201508"/><FilterOption count="3" label="201511"/><FilterOption count="3" label="201603"/><FilterOption count="3" label="201606"/><FilterOption count="3" label="201607"/><FilterOption count="3" label="201608"/><FilterOption count="3" label="201609"/><FilterOption count="3" label="201703"/><FilterOption count="3" label="201705"/><FilterOption count="3" label="201706"/><FilterOption count="3" label="201801"/><FilterOption count="3" label="201802"/><FilterOption count="3" label="201811"/><FilterOption count="3" label="201812"/><FilterOption count="3" label="201904"/><FilterOption count="3" label="201905"/><FilterOption count="2" label="200508"/><FilterOption count="2" label="200807"/><FilterOption count="2" label="200912"/><FilterOption count="2" label="201010"/><FilterOption count="2" label="201111"/><FilterOption count="2" label="201209"/><FilterOption count="2" label="201210"/><FilterOption count="2" label="201305"/><FilterOption count="2" label="201308"/><FilterOption count="2" label="201311"/><FilterOption count="2" label="201404"/><FilterOption count="2" label="201412"/><FilterOption count="2" label="201605"/><FilterOption count="2" label="201610"/><FilterOption count="2" label="201611"/><FilterOption count="2" label="201704"/><FilterOption count="2" label="201708"/><FilterOption count="2" label="201709"/><FilterOption count="2" label="201712"/><FilterOption count="2" label="201807"/><FilterOption count="2" label="201906"/><FilterOption count="1" label="200403"/><FilterOption count="1" label="200601"/><FilterOption count="1" label="200603"/><FilterOption count="1" label="200604"/><FilterOption count="1" label="200612"/><FilterOption count="1" label="200702"/><FilterOption count="1" label="200801"/><FilterOption count="1" label="200803"/><FilterOption count="1" label="200808"/><FilterOption count="1" label="200810"/><FilterOption count="1" label="200812"/><FilterOption count="1" label="200903"/><FilterOption count="1" label="200905"/><FilterOption count="1" label="200909"/><FilterOption count="1" label="201001"/><FilterOption count="1" label="201003"/><FilterOption count="1" label="201005"/><FilterOption count="1" label="201008"/><FilterOption count="1" label="201012"/><FilterOption count="1" label="201102"/><FilterOption count="1" label="201105"/><FilterOption count="1" label="201106"/><FilterOption count="1" label="201109"/><FilterOption count="1" label="201112"/><FilterOption count="1" label="201201"/><FilterOption count="1" label="201203"/><FilterOption count="1" label="201204"/><FilterOption count="1" label="201205"/><FilterOption count="1" label="201206"/><FilterOption count="1" label="201207"/><FilterOption count="1" label="201211"/><FilterOption count="1" label="201301"/><FilterOption count="1" label="201302"/><FilterOption count="1" label="201303"/><FilterOption count="1" label="201306"/><FilterOption count="1" label="201307"/><FilterOption count="1" label="201312"/><FilterOption count="1" label="201401"/><FilterOption count="1" label="201402"/><FilterOption count="1" label="201408"/><FilterOption count="1" label="201501"/><FilterOption count="1" label="201502"/><FilterOption count="1" label="201504"/><FilterOption count="1" label="201506"/></Filter><Filter label="Funder Type" name="trialFunderType" total="5"><FilterOption id="CMP" count="353" label="Company"/><FilterOption id="ACA" count="175" label="Academic"/><FilterOption id="GOV" count="7" label="Government"/><FilterOption id="OTH" count="7" label="Others"/><FilterOption id="NGO" count="2" label="Non-Government"/></Filter><Filter label="Trial Region" name="trialRegions" total="10"><FilterOption id="NSWE" count="458" label="Northern, Southern &amp; Western Europe"/><FilterOption id="EEUR" count="220" label="Eastern Europe"/><FilterOption id="USCA" count="219" label="US &amp; Canada"/><FilterOption id="AUNZ" count="156" label="Australia &amp; New Zealand"/><FilterOption id="EAPO" count="152" label="East Asia &amp; Pacific Ocean"/><FilterOption id="MENA" count="145" label="Middle East &amp; North Africa"/><FilterOption id="SOAM" count="127" label="South America"/><FilterOption id="CAAC" count="97" label="Central America &amp; Caribbean"/><FilterOption id="CSAF" count="52" label="Central &amp; Southern Africa"/><FilterOption id="SOCA" count="47" label="Southern &amp; Central Asia"/></Filter><Filter label="Patient Segment Index" name="trialPatientSegmentIndex" total="100"><FilterOption id="3954" count="27" label="Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer"/><FilterOption id="3952" count="26" label="Breast tumor - Subjects with Locally Advanced Breast Cancer"/><FilterOption id="3937" count="24" label="Breast tumor - Subjects with HER-2 Negative Breast Cancer"/><FilterOption id="3634" count="24" label="Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer"/><FilterOption id="3824" count="19" label="Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer"/><FilterOption id="10295" count="19" label="Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with locally advanced/stage III lung cancer"/><FilterOption id="3617" count="19" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)"/><FilterOption id="3936" count="17" label="Breast tumor - Subjects with HER-2 Positive Breast Cancer"/><FilterOption id="3931" count="17" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer"/><FilterOption id="3965" count="15" label="Breast tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="3950" count="13" label="Breast tumor - Subjects with Early Stage Breast Cancer"/><FilterOption id="3944" count="13" label="Breast tumor - Subjects with Stage II Breast Cancer"/><FilterOption id="3932" count="12" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Progesterone receptor positive (PR+) breast cancer"/><FilterOption id="3564" count="12" label="Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer"/><FilterOption id="7810" count="11" label="Bladder cancer - Subjects with Metastatic Bladder Cancer"/><FilterOption id="8073" count="11" label="Pancreas tumor - Subjects with Advanced/Metastatic Pancreatic Cancer"/><FilterOption id="7806" count="10" label="Bladder cancer - Subjects with Locally Advanced Bladder Cancer"/><FilterOption id="3970" count="10" label="Breast tumor - Others - Subjects with node positive breast cancer"/><FilterOption id="3945" count="10" label="Breast tumor - Subjects with Stage III Breast Cancer"/><FilterOption id="3956" count="10" label="Breast tumor - Subjects with Un-resectable/Non-operable Breast Cancer"/><FilterOption id="3404" count="10" label="Crohns disease - Subjects with Active Crohns Disease"/><FilterOption id="12053" count="10" label="Lung tumor - Treatment Naive Subjects"/><FilterOption id="8953" count="10" label="Soft tissue sarcoma - Subjects with Advanced/Metastatic Soft Tissue Sarcoma"/><FilterOption id="11954" count="9" label="Bladder cancer - Subjects with Urothelial cell/Transitional Cell Bladder Cancer"/><FilterOption id="3946" count="9" label="Breast tumor - Subjects with Stage III Breast Cancer - TNM stage IIIA Breast cancer"/><FilterOption id="3938" count="9" label="Breast tumor - Subjects with Triple Negative Breast Cancer"/><FilterOption id="12845" count="9" label="Breast tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification"/><FilterOption id="3472" count="9" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with diffuse large B cell lymphoma"/><FilterOption id="9706" count="9" label="Lysosome storage disease - Subjects with Neutral Glycosphingolipidoses - Subjects with Gaucher disease"/><FilterOption id="3870" count="9" label="Multiple myeloma - Subjects with Symptomatic Disease"/><FilterOption id="7415" count="9" label="Renal cell carcinoma - Subjects with Metastatic Renal Cell Carcinoma"/><FilterOption id="3955" count="8" label="Breast tumor - Subjects with Resectable/Operable Breast Cancer"/><FilterOption id="3754" count="8" label="Crohns disease - Subjects with Moderate to Severe Crohns Disease"/><FilterOption id="3623" count="8" label="Lung tumor - Subjects with Advanced Stage Lung Cancer"/><FilterOption id="3650" count="8" label="Lung tumor - Subjects with Recurrent/Relapsed Lung Cancer"/><FilterOption id="3502" count="8" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Aggressive (high grade) Lymphoma"/><FilterOption id="8079" count="8" label="Pancreas tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="3586" count="8" label="Prostate tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="8010" count="8" label="Stomach tumor - Subjects with Advanced/Metastatic Gastric Cancer"/><FilterOption id="7814" count="7" label="Bladder cancer - Subjects with Unresectable Bladder Cancer"/><FilterOption id="3934" count="7" label="Breast tumor - Subjects with Hormone Receptor Negative Breast Cancer - Estrogen receptor negative (ER-) breast cancer"/><FilterOption id="3935" count="7" label="Breast tumor - Subjects with Hormone Receptor Negative Breast Cancer - Progesterone receptor negative (PR-) breast cancer"/><FilterOption id="3947" count="7" label="Breast tumor - Subjects with Stage III Breast Cancer - TNM stage IIIB Breast cancer"/><FilterOption id="3814" count="7" label="Colorectal tumor - Subjects with Colon Cancer"/><FilterOption id="3860" count="7" label="Colorectal tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="3426" count="7" label="Crohns disease - Subjects with Treatment Resistant Disease"/><FilterOption id="7126" count="7" label="HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection"/><FilterOption id="7756" count="7" label="Hypercholesterolemia - Subjects with Primary Hypercholesterolemia"/><FilterOption id="3977" count="7" label="Leukemia - Subjects with Acute Myeloid Leukemia (AML)"/><FilterOption id="7877" count="7" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC) - Subjects with non-squamous cell lung cancer"/><FilterOption id="3530" count="7" label="Lymphoma - Subjects with Treatment Resistant Disease"/><FilterOption id="9933" count="7" label="Neuroendocrine tumor - Subjects with Advanced/Metastatic Neuroendocrine Tumor"/><FilterOption id="8072" count="7" label="Pancreas tumor - Subjects with Locally Advanced Pancreatic Cancer"/><FilterOption id="8966" count="7" label="Soft tissue sarcoma - Subjects with Treatment Resistant Disease"/><FilterOption id="3943" count="6" label="Breast tumor - Subjects with Stage I Breast Cancer"/><FilterOption id="3948" count="6" label="Breast tumor - Subjects with Stage III Breast Cancer - TNM stage IIIC Breast cancer"/><FilterOption id="12005" count="6" label="Breast tumor - Subjects with invasive breast cancer"/><FilterOption id="12055" count="6" label="Breast tumor - Treatment Naive Subjects"/><FilterOption id="3813" count="6" label="Colorectal tumor - Subjects with Rectal Cancer"/><FilterOption id="10646" count="6" label="Gaucher disease - Subjects with Type 1 Gaucher Disease"/><FilterOption id="11301" count="6" label="Lipid metabolism disorder - Subjects with Primary Hypercholesterolemia"/><FilterOption id="3647" count="6" label="Lung tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="7879" count="6" label="Ovary tumor - Subjects with Ovarian Epithelial Tumor"/><FilterOption id="12018" count="6" label="Prostate tumor - Subjects with adenocarcinoma of prostate"/><FilterOption id="8776" count="6" label="Ulcerative colitis - Subjects with Moderate to Severe Ulcerative Colitis"/><FilterOption id="7204" count="5" label="Atrial fibrillation - Subjects with Nonvalvular Atrial Fibrillation"/><FilterOption id="7809" count="5" label="Bladder cancer - Subjects with Stage IV Bladder Cancer"/><FilterOption id="7874" count="5" label="Colorectal tumor - Subjects with KRAS Wild-type Colorectal Cancer"/><FilterOption id="3774" count="5" label="Head and neck tumor - Subjects with Advanced/Metastatic Head and Neck Cancer"/><FilterOption id="7772" count="5" label="Hypercholesterolemia - Subjects with Increased LDL-cholesterol Levels"/><FilterOption id="10129" count="5" label="Lung tumor - Subjects with EGFR Positive Lung Cancer"/><FilterOption id="3473" count="5" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with follicular lymphoma"/><FilterOption id="3525" count="5" label="Lymphoma - Subjects with Relapse/Recurrent Lymphoma"/><FilterOption id="3500" count="5" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Indolent (slow-growing, low grade) Lymphoma"/><FilterOption id="3501" count="5" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Moderately Aggressive (intermediate grade) Lymphoma"/><FilterOption id="3667" count="5" label="Melanoma - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="3698" count="5" label="Melanoma - Subjects with Surgically Non-resectable Melanoma"/><FilterOption id="3926" count="5" label="Multiple myeloma - Subjects with Relapsed/Recurrent Multiple Myeloma"/><FilterOption id="3923" count="5" label="Multiple myeloma - Subjects with Treatment Resistant Disease"/><FilterOption id="9935" count="5" label="Neuroendocrine tumor - Subjects with Unresectable Neuroendocrine Tumor"/><FilterOption id="8075" count="5" label="Pancreas tumor - Subjects with Unresectable Pancreatic Cancer"/><FilterOption id="3590" count="5" label="Prostate tumor - Subjects with Recurrent/Relapsed Prostate Cancer"/><FilterOption id="3565" count="5" label="Prostate tumor - Subjects with Stage IV Prostate Cancer"/><FilterOption id="3571" count="5" label="Prostate tumor - Subjects with Treatment Resistant Disease - Subjects with progressive disease despite therapy"/><FilterOption id="502" count="5" label="Rheumatoid arthritis - Active Rheumatoid Arthritis"/><FilterOption id="8951" count="5" label="Soft tissue sarcoma - Subjects with Locally Advanced Soft Tissue Sarcoma"/><FilterOption id="8025" count="5" label="Stomach tumor - Subjects with adenocarcinoma of the gastroesophageal junction"/><FilterOption id="7512" count="4" label="Anemia - Subjects with specific disease - Subjects with Cancer/Cancer Chemotherapy Induced Anemia"/><FilterOption id="3942" count="4" label="Breast tumor - Subjects at Risk of Developing Invasive Breast Cancer - Ductal carcinoma in situ/Intraductal carcinoma (DCIS)"/><FilterOption id="3930" count="4" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer"/><FilterOption id="9010" count="4" label="Cancer supportive care - Solid tumor subjects for supportive care"/><FilterOption id="201" count="4" label="Coronary artery disease - Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)"/><FilterOption id="243" count="4" label="Coronary artery disease - Subjects with Abnormal Angiographic Findings"/><FilterOption id="9485" count="4" label="Esophagus tumor - Subjects with Advanced/Metastatic Esophageal Cancer"/><FilterOption id="9491" count="4" label="Esophagus tumor - Subjects with Unresectable Esophageal Cancer"/><FilterOption id="9163" count="4" label="Glaucoma - Subjects with Primary Open-Angle Glaucoma(POAG)"/><FilterOption id="10289" count="4" label="Head and neck tumor - Subjects with TNM Stage III Head and Neck Cancer"/><FilterOption id="7770" count="4" label="Hypercholesterolemia - Subjects with Increased Triglyceride Levels"/><FilterOption id="600" count="4" label="Kidney transplantation - Renal Transplant Recipients"/><FilterOption id="11314" count="4" label="Lipid metabolism disorder - Subjects with Increased LDL-cholesterol Levels"/></Filter><Filter label="Primary Completion Filter by Month" name="trialPrimaryCompletionDateByMonth" total="100"><FilterOption count="13" label="201812"/><FilterOption count="9" label="201910"/><FilterOption count="9" label="202011"/><FilterOption count="8" label="201712"/><FilterOption count="8" label="201803"/><FilterOption count="8" label="201912"/><FilterOption count="7" label="201612"/><FilterOption count="7" label="201703"/><FilterOption count="7" label="201808"/><FilterOption count="7" label="201810"/><FilterOption count="7" label="201909"/><FilterOption count="7" label="201911"/><FilterOption count="7" label="202005"/><FilterOption count="7" label="202009"/><FilterOption count="7" label="202109"/><FilterOption count="6" label="201502"/><FilterOption count="6" label="201512"/><FilterOption count="6" label="201804"/><FilterOption count="6" label="201907"/><FilterOption count="6" label="201908"/><FilterOption count="5" label="201212"/><FilterOption count="5" label="201505"/><FilterOption count="5" label="201811"/><FilterOption count="5" label="201905"/><FilterOption count="5" label="202002"/><FilterOption count="5" label="202006"/><FilterOption count="4" label="201207"/><FilterOption count="4" label="201309"/><FilterOption count="4" label="201402"/><FilterOption count="4" label="201408"/><FilterOption count="4" label="201604"/><FilterOption count="4" label="201609"/><FilterOption count="4" label="201702"/><FilterOption count="4" label="201705"/><FilterOption count="4" label="201706"/><FilterOption count="4" label="201709"/><FilterOption count="4" label="201801"/><FilterOption count="4" label="201906"/><FilterOption count="4" label="202001"/><FilterOption count="4" label="202004"/><FilterOption count="3" label="200906"/><FilterOption count="3" label="201205"/><FilterOption count="3" label="201312"/><FilterOption count="3" label="201506"/><FilterOption count="3" label="201603"/><FilterOption count="3" label="201607"/><FilterOption count="3" label="201610"/><FilterOption count="3" label="201704"/><FilterOption count="3" label="201807"/><FilterOption count="3" label="201809"/><FilterOption count="3" label="201901"/><FilterOption count="3" label="201903"/><FilterOption count="3" label="202010"/><FilterOption count="3" label="202012"/><FilterOption count="3" label="202104"/><FilterOption count="3" label="202106"/><FilterOption count="3" label="202110"/><FilterOption count="3" label="202112"/><FilterOption count="3" label="202204"/><FilterOption count="3" label="202209"/><FilterOption count="2" label="200807"/><FilterOption count="2" label="200812"/><FilterOption count="2" label="200905"/><FilterOption count="2" label="200908"/><FilterOption count="2" label="200909"/><FilterOption count="2" label="201006"/><FilterOption count="2" label="201008"/><FilterOption count="2" label="201009"/><FilterOption count="2" label="201103"/><FilterOption count="2" label="201112"/><FilterOption count="2" label="201201"/><FilterOption count="2" label="201208"/><FilterOption count="2" label="201211"/><FilterOption count="2" label="201302"/><FilterOption count="2" label="201307"/><FilterOption count="2" label="201310"/><FilterOption count="2" label="201401"/><FilterOption count="2" label="201510"/><FilterOption count="2" label="201511"/><FilterOption count="2" label="201602"/><FilterOption count="2" label="201707"/><FilterOption count="2" label="201711"/><FilterOption count="2" label="201802"/><FilterOption count="2" label="201902"/><FilterOption count="2" label="201904"/><FilterOption count="2" label="202003"/><FilterOption count="2" label="202103"/><FilterOption count="2" label="202105"/><FilterOption count="2" label="202107"/><FilterOption count="2" label="202202"/><FilterOption count="2" label="202205"/><FilterOption count="2" label="202207"/><FilterOption count="2" label="202208"/><FilterOption count="2" label="202212"/><FilterOption count="1" label="200001"/><FilterOption count="1" label="200204"/><FilterOption count="1" label="200503"/><FilterOption count="1" label="200507"/><FilterOption count="1" label="200512"/><FilterOption count="1" label="200605"/></Filter><Filter label="Trial Country" name="trialCountries" total="95"><FilterOption id="ES" count="456" label="Spain"/><FilterOption id="IT" count="225" label="Italy"/><FilterOption id="DE" count="219" label="Germany"/><FilterOption id="GB" count="213" label="UK"/><FilterOption id="FR" count="210" label="France"/><FilterOption id="US" count="207" label="US"/><FilterOption id="PL" count="167" label="Poland"/><FilterOption id="BE" count="160" label="Belgium"/><FilterOption id="CA" count="160" label="Canada"/><FilterOption id="AU" count="153" label="Australia"/><FilterOption id="NL" count="132" label="Netherlands"/><FilterOption id="CZ" count="131" label="Czech Republic"/><FilterOption id="HU" count="130" label="Hungary"/><FilterOption id="RU" count="128" label="Russian Federation"/><FilterOption id="AT" count="121" label="Austria"/><FilterOption id="IL" count="119" label="Israel"/><FilterOption id="KR" count="116" label="South Korea"/><FilterOption id="BR" count="98" label="Brazil"/><FilterOption id="TW" count="96" label="Taiwan"/><FilterOption id="SE" count="93" label="Sweden"/><FilterOption id="PT" count="91" label="Portugal"/><FilterOption id="MX" count="88" label="Mexico"/><FilterOption id="AR" count="85" label="Argentina"/><FilterOption id="DK" count="82" label="Denmark"/><FilterOption id="CH" count="82" label="Switzerland"/><FilterOption id="JP" count="78" label="Japan"/><FilterOption id="GR" count="75" label="Greece"/><FilterOption id="RO" count="74" label="Romania"/><FilterOption id="BG" count="64" label="Bulgaria"/><FilterOption id="CN" count="64" label="China"/><FilterOption id="TR" count="63" label="Turkey"/><FilterOption id="UA" count="63" label="Ukraine"/><FilterOption id="SG" count="60" label="Singapore"/><FilterOption id="HK" count="57" label="Hong Kong"/><FilterOption id="SK" count="56" label="Slovakia"/><FilterOption id="NZ" count="54" label="New Zealand"/><FilterOption id="IE" count="52" label="Ireland"/><FilterOption id="ZA" count="52" label="South Africa"/><FilterOption id="RS" count="49" label="Serbia"/><FilterOption id="FI" count="47" label="Finland"/><FilterOption id="HR" count="45" label="Croatia"/><FilterOption id="IN" count="45" label="India"/><FilterOption id="CL" count="41" label="Chile"/><FilterOption id="CO" count="39" label="Colombia"/><FilterOption id="LT" count="36" label="Lithuania"/><FilterOption id="PE" count="36" label="Peru"/><FilterOption id="TH" count="35" label="Thailand"/><FilterOption id="NO" count="34" label="Norway"/><FilterOption id="LV" count="32" label="Latvia"/><FilterOption id="MY" count="31" label="Malaysia"/><FilterOption id="EE" count="30" label="Estonia"/><FilterOption id="SI" count="27" label="Slovenia"/><FilterOption id="X5" count="25" label="Europe"/><FilterOption id="PH" count="25" label="Philippines"/><FilterOption id="PR" count="25" label="Puerto Rico"/><FilterOption id="BA" count="17" label="Bosnia and Herzegovina"/><FilterOption id="GE" count="17" label="Georgia"/><FilterOption id="BY" count="14" label="Belarus"/><FilterOption id="SA" count="14" label="Saudi Arabia"/><FilterOption id="PA" count="12" label="Panama"/><FilterOption id="GT" count="11" label="Guatemala"/><FilterOption id="LB" count="10" label="Lebanon"/><FilterOption id="EG" count="9" label="Egypt"/><FilterOption id="CR" count="7" label="Costa Rica"/><FilterOption id="XD" count="7" label="North America"/><FilterOption id="IS" count="5" label="Iceland"/><FilterOption id="MD" count="5" label="Moldova, Republic of"/><FilterOption id="X2" count="4" label="Asia"/><FilterOption id="KP" count="4" label="North Korea"/><FilterOption id="VN" count="4" label="Vietnam"/><FilterOption id="SV" count="3" label="El Salvador"/><FilterOption id="MT" count="3" label="Malta"/><FilterOption id="XE" count="3" label="South America"/><FilterOption id="LK" count="3" label="Sri Lanka"/><FilterOption id="TN" count="3" label="Tunisia"/><FilterOption id="DZ" count="2" label="Algeria"/><FilterOption id="EU" count="2" label="EU"/><FilterOption id="ID" count="2" label="Indonesia"/><FilterOption id="JO" count="2" label="Jordan"/><FilterOption id="MA" count="2" label="Morocco"/><FilterOption id="PY" count="2" label="Paraguay"/><FilterOption id="VE" count="2" label="Venezuela"/><FilterOption id="AM" count="1" label="Armenia"/><FilterOption id="BS" count="1" label="Bahamas"/><FilterOption id="BD" count="1" label="Bangladesh"/><FilterOption id="CY" count="1" label="Cyprus"/><FilterOption id="DO" count="1" label="Dominican Republic"/><FilterOption id="KZ" count="1" label="Kazakhstan"/><FilterOption id="LI" count="1" label="Liechtenstein"/><FilterOption id="LU" count="1" label="Luxembourg"/><FilterOption id="MK" count="1" label="Macedonia, The Former Yugoslav Republic of"/><FilterOption id="MC" count="1" label="Monaco"/><FilterOption id="ME" count="1" label="Montenegro"/><FilterOption id="AE" count="1" label="United Arab Emirates"/><FilterOption id="XW" count="1" label="Western Europe"/></Filter><Filter label="Trial Patient Selection" name="trialTermsPatientSelection" total="16"><FilterOption id="EAAAD" count="413" label="Aged Adults (65-79 yrs)"/><FilterOption id="EAMAA" count="413" label="Middle-aged Adults (45-64 yrs)"/><FilterOption id="EAYAD" count="410" label="Young Adults (18-44 yrs)"/><FilterOption id="EAELD" count="366" label="Elderly Adults (80 and over)"/><FilterOption id="EGFEM" count="54" label="Female"/><FilterOption id="EAADL" count="31" label="Adolescents (13-17 yrs)"/><FilterOption id="EACHI" count="30" label="Children (6-12 yrs)"/><FilterOption id="EAPRE" count="25" label="Preschool Children (2-5 yrs)"/><FilterOption id="EGMAL" count="19" label="Male"/><FilterOption id="EAINF" count="15" label="Infants (6-23 months)"/><FilterOption id="EANEW" count="11" label="Newborn Infants (up to 5 months)"/><FilterOption id="EVHVA" count="10" label="Healthy volunteers accepted"/><FilterOption id="ECJAP" count="8" label="Japanese Ancestry"/><FilterOption id="ECASI" count="7" label="Asian Ancestry"/><FilterOption id="ECEUR" count="2" label="European Ancestry"/><FilterOption id="EVHVO" count="2" label="Healthy volunteers only"/></Filter><Filter label="Trial Terms Design" name="trialTermsDesign" total="23"><FilterOption id="SSTINV" count="390" label="Interventional"/><FilterOption id="SIPTRE" count="369" label="Treatment"/><FilterOption id="SIARND" count="281" label="Randomized"/><FilterOption id="SISPRL" count="278" label="Parallel Assignment"/><FilterOption id="SIMOPN" count="247" label="Open Label"/><FilterOption id="SIMMBD" count="132" label="Multiple Blind"/><FilterOption id="SICACT" count="128" label="Active Control"/><FilterOption id="SICPLC" count="110" label="Placebo Control"/><FilterOption id="SISSNG" count="100" label="Single Group Assignment"/><FilterOption id="SIANON" count="77" label="Non-Randomized"/><FilterOption id="SICNOC" count="68" label="No Control"/><FilterOption id="SSTOBS" count="67" label="Observational"/><FilterOption id="SOTPRO" count="44" label="Prospective"/><FilterOption id="SOSCOH" count="40" label="Cohort"/><FilterOption id="SIPPRE" count="19" label="Prevention"/><FilterOption id="SOTRET" count="14" label="Retrospective"/><FilterOption id="SODXSC" count="11" label="Cross-sectional"/><FilterOption id="SOSCSC" count="9" label="Case Control"/><FilterOption id="SIMSBD" count="8" label="Single Blind"/><FilterOption id="SISXOV" count="4" label="Crossover Assignment"/><FilterOption id="SIPDIA" count="2" label="Diagnosis"/><FilterOption id="SICDSC" count="1" label="Dose Comparison"/><FilterOption id="SODLNG" count="1" label="Longitudinal"/></Filter><Filter label="Trial Source" name="trialSources" total="3"><FilterOption id="CTGOVOTHERS" count="280" label="ClinicalTrials.gov and others"/><FilterOption id="CTGOV" count="170" label="ClinicalTrials.gov only"/><FilterOption id="OTHERS" count="5" label="Others only"/></Filter><Filter label="Trial Actions Secondary Interventions Primary" name="trialActionsSecondaryInterventionsPrimary" total="100"><FilterOption id="1545" count="209" label="Anticancer"/><FilterOption id="55685" count="113" label="Anticancer monoclonal antibody"/><FilterOption id="62255" count="102" label="Anticancer protein kinase inhibitor"/><FilterOption id="2953" count="96" label="Anti-inflammatory"/><FilterOption id="767" count="76" label="Cell cycle inhibitor"/><FilterOption id="61" count="74" label="Angiogenesis inhibitor"/><FilterOption id="1589" count="66" label="Apoptosis stimulator"/><FilterOption id="991" count="47" label="Antiviral"/><FilterOption id="393" count="47" label="Immunostimulant"/><FilterOption id="7761" count="47" label="T-lymphocyte stimulator"/><FilterOption id="140" count="44" label="DNA synthesis inhibitor"/><FilterOption id="7293" count="41" label="Synergist"/><FilterOption id="50" count="38" label="Anticancer alkylating agent"/><FilterOption id="1596" count="33" label="Immunomodulator"/><FilterOption id="1569" count="29" label="Anticancer antimetabolite"/><FilterOption id="2575" count="29" label="Microtubule inhibitor"/><FilterOption id="2576" count="27" label="Microtubule stabilizer"/><FilterOption id="2657" count="22" label="Antihypertensive"/><FilterOption id="2660" count="21" label="Vasoprotectant"/><FilterOption id="382" count="20" label="TNF alpha synthesis inhibitor"/><FilterOption id="2946" count="17" label="Analgesic"/><FilterOption id="399" count="14" label="Hypoglycemic agent"/><FilterOption id="750" count="12" label="DNA intercalator"/><FilterOption id="15184" count="12" label="Systemic antipsoriatic product"/><FilterOption id="62254" count="11" label="Anticancer hormone antagonist"/><FilterOption id="396" count="9" label="Immunosuppressant"/><FilterOption id="539" count="9" label="Immunotoxin"/><FilterOption id="1332" count="8" label="Gastrointestinal system agent"/><FilterOption id="449" count="7" label="Antiarrhythmic agent"/><FilterOption id="71" count="7" label="Antihypercholesterolemic agent"/><FilterOption id="3272" count="6" label="Growth hormone release inhibitor"/><FilterOption id="937" count="5" label="Androgen synthesis inhibitor"/><FilterOption id="1594" count="5" label="Antibacterial"/><FilterOption id="70" count="5" label="Anticonvulsant agent"/><FilterOption id="72" count="5" label="Antihyperlipidemic agent"/><FilterOption id="7018" count="5" label="Antihypertriglyceridemic agent"/><FilterOption id="747" count="5" label="HIV replication inhibitor"/><FilterOption id="12379" count="5" label="Therapeutic vaccine"/><FilterOption id="59620" count="5" label="Unspecified drug target"/><FilterOption id="2516" count="4" label="LDL cholesterol modulator"/><FilterOption id="695" count="4" label="Metastasis inhibitor"/><FilterOption id="15148" count="4" label="Ocular antineovascularisation agent"/><FilterOption id="15128" count="4" label="Ophthalmological agent"/><FilterOption id="12378" count="4" label="Prophylactic vaccine"/><FilterOption id="388" count="4" label="Vasodilator"/><FilterOption id="55684" count="3" label="Anticancer antibody"/><FilterOption id="2941" count="3" label="Antidepressant"/><FilterOption id="15135" count="3" label="Antiglaucoma agent"/><FilterOption id="74" count="3" label="Antioxidant agent"/><FilterOption id="2947" count="3" label="Antiparkinsonian"/><FilterOption id="1590" count="3" label="Apoptosis inhibitor"/><FilterOption id="11593" count="3" label="DNA repair inhibitor"/><FilterOption id="664" count="3" label="Fibrosuppressant"/><FilterOption id="805" count="3" label="Folate modulator"/><FilterOption id="1129" count="3" label="Non-steroid hormone receptor antagonist"/><FilterOption id="312" count="3" label="Platelet aggregation inhibitor"/><FilterOption id="12372" count="3" label="Protein subunit vaccine"/><FilterOption id="1552" count="3" label="Radioimmunotherapeutic"/><FilterOption id="1532" count="3" label="Viral replication inhibitor"/><FilterOption id="7292" count="3" label="Vulnerary agent"/><FilterOption id="1570" count="2" label="Allergen"/><FilterOption id="62" count="2" label="Angiogenesis stimulator"/><FilterOption id="2667" count="2" label="Antiarteriosclerotic"/><FilterOption id="62253" count="2" label="Anticancer hormone"/><FilterOption id="2942" count="2" label="Anxiolytic"/><FilterOption id="1839" count="2" label="Appetite stimulator"/><FilterOption id="1535" count="2" label="Beta lactam antibiotic"/><FilterOption id="646" count="2" label="Bronchodilator"/><FilterOption id="1260" count="2" label="Calcium metabolism modulator"/><FilterOption id="2659" count="2" label="Cardioprotectant"/><FilterOption id="1276" count="2" label="Chemoprotectant"/><FilterOption id="968" count="2" label="Coagulation stimulator"/><FilterOption id="803" count="2" label="DNA modulator"/><FilterOption id="38439" count="2" label="DPP IV inhibitor antidiabetic product"/><FilterOption id="170" count="2" label="Free radical scavenger"/><FilterOption id="1748" count="2" label="Fungicide"/><FilterOption id="793" count="2" label="Gastroprokinetic"/><FilterOption id="610" count="2" label="Hematopoietic stimulator"/><FilterOption id="38211" count="2" label="Human insulin fast acting product"/><FilterOption id="38215" count="2" label="Human insulin long acting product"/><FilterOption id="211" count="2" label="Inotropic agent"/><FilterOption id="7751" count="2" label="Macrophage stimulator"/><FilterOption id="1615" count="2" label="Neuroprotectant"/><FilterOption id="1758" count="2" label="Nucleic acid metabolism modulator"/><FilterOption id="12373" count="2" label="Polysaccharide subunit vaccine"/><FilterOption id="959" count="2" label="Protectant"/><FilterOption id="1467" count="2" label="Renal system agent"/><FilterOption id="439" count="2" label="RNA synthesis inhibitor"/><FilterOption id="5717" count="2" label="Sensitizer"/><FilterOption id="26035" count="2" label="siRNA agent"/><FilterOption id="53560" count="2" label="Stem cell inhibitor"/><FilterOption id="15187" count="2" label="Systemic dermatological antibacterial product"/><FilterOption id="7760" count="2" label="T-lymphocyte inhibitor"/><FilterOption id="15137" count="2" label="Topical antiglaucoma agent"/><FilterOption id="15180" count="2" label="Topical antipruritic product"/><FilterOption id="12375" count="2" label="Toxoid vaccine"/><FilterOption id="2593" count="2" label="Vitamin D analog"/><FilterOption id="3" count="1" label="5-HT uptake inhibitor"/><FilterOption id="524" count="1" label="Adjuvant"/><FilterOption id="2970" count="1" label="Anti-emetic"/></Filter><Filter label="Trial Endpoint Achieved" name="trialEndpointsAchieved" total="3"><FilterOption id="UNSPECIFIED" count="111" label="Unspecified"/><FilterOption id="YES" count="73" label="Yes"/><FilterOption id="NO" count="22" label="No"/></Filter><Filter label="Endpoint Index Secondary" name="trialEndpointIndexSecondary" total="100"><FilterOption id="8712" count="34" label="Breast tumor - Assessment of Overall Survival (OS)"/><FilterOption id="8489" count="20" label="Lung tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8719" count="19" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="8998" count="19" label="Breast tumor - Assessment of adverse events"/><FilterOption id="8522" count="17" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="8721" count="16" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="8481" count="16" label="Lung tumor - Assessment of Overall Survival (OS)"/><FilterOption id="9153" count="16" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="8714" count="14" label="Breast tumor - Assessment of Disease Free Survival (DFS)"/><FilterOption id="8722" count="14" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)"/><FilterOption id="8738" count="14" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response"/><FilterOption id="8720" count="13" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="8999" count="13" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria"/><FilterOption id="8713" count="12" label="Breast tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8996" count="12" label="Breast tumor - Assessment of Safety and Tolerability"/><FilterOption id="8151" count="12" label="Colorectal tumor - Assessment of Overall Survival (OS)"/><FilterOption id="8663" count="12" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="8505" count="11" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"/><FilterOption id="8640" count="11" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"/><FilterOption id="7538" count="11" label="Lymphoma - Assessment of Overall Survival (OS)"/><FilterOption id="11722" count="10" label="Bladder cancer - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8725" count="10" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"/><FilterOption id="8430" count="10" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="11735" count="9" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="8163" count="9" label="Colorectal tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8187" count="9" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)"/><FilterOption id="8189" count="9" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="2622" count="9" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"/><FilterOption id="8639" count="9" label="Lung tumor - Assessment of Safety and Tolerability"/><FilterOption id="11539" count="9" label="Soft tissue sarcoma - Assessment of Overall Survival (OS)"/><FilterOption id="11728" count="8" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)"/><FilterOption id="8754" count="8" label="Breast tumor - Assessment of Mortality/Death Rates"/><FilterOption id="8523" count="8" label="Lung tumor - Assessment of Disease Progression"/><FilterOption id="11778" count="7" label="Bladder cancer - Assessment of Mortality/Death Rates"/><FilterOption id="11780" count="7" label="Bladder cancer - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="8902" count="7" label="Breast tumor - Assessment of Biomarkers"/><FilterOption id="8745" count="7" label="Breast tumor - Assessment of Disease Progression - Assessment of Time to Tumor Progression (TTP)"/><FilterOption id="8744" count="7" label="Breast tumor - Assessment of Disease Progression"/><FilterOption id="37159" count="7" label="Breast tumor - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="8764" count="7" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-C30"/><FilterOption id="7879" count="7" label="Leukemia - Assessment of Overall Survival (OS)"/><FilterOption id="11643" count="7" label="Neuroendocrine tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="11793" count="6" label="Bladder cancer - Assessment of Disease Progression"/><FilterOption id="11773" count="6" label="Bladder cancer - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="9122" count="6" label="Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="9001" count="6" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of cardiac toxicity"/><FilterOption id="8759" count="6" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="2492" count="6" label="Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)"/><FilterOption id="6313" count="6" label="Crohns disease - Assessment of Clinical Response - Clinical response measured by crohn's disease activity index (CDAI) score by &gt; or = 100 points"/><FilterOption id="6339" count="6" label="Crohns disease - Crohn's Disease Activity Assessed by Indices/Scores - Crohn's disease activity index (CDAI) score"/><FilterOption id="20857" count="6" label="Gaucher disease - Clinical Assessments - Assessment of spleen"/><FilterOption id="8514" count="6" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="8513" count="6" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="28159" count="6" label="Lung tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ LC 13"/><FilterOption id="28069" count="6" label="Lung tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)"/><FilterOption id="7563" count="6" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="7680" count="6" label="Lymphoma - Assessment of adverse events"/><FilterOption id="10828" count="6" label="Ovary tumor - Assessment of Overall Survival (OS)"/><FilterOption id="13352" count="6" label="Pancreas tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7045" count="6" label="Prostate tumor - Assessment of Overall Survival (OS)"/><FilterOption id="7049" count="6" label="Prostate tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7067" count="6" label="Prostate tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response (ORR)"/><FilterOption id="12151" count="6" label="Stomach tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="2981" count="5" label="Acute coronary syndrome - Assessment of Mortality/Death Rates - Cardiovascular mortality"/><FilterOption id="2957" count="5" label="Acute coronary syndrome - Assessment of Reperfusion/Revascularization"/><FilterOption id="11763" count="5" label="Bladder cancer - Assessment of Antibodies"/><FilterOption id="8757" count="5" label="Breast tumor - Assessment of Mortality/Death Rates - Assessment of time to all cause mortality"/><FilterOption id="8997" count="5" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of serious adverse events"/><FilterOption id="19282" count="5" label="Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="9386" count="5" label="Colorectal tumor - Assessment of Biomarkers"/><FilterOption id="9147" count="5" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of toxicities"/><FilterOption id="8383" count="5" label="Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="2565" count="5" label="Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Stent thrombosis"/><FilterOption id="2704" count="5" label="Coronary artery disease - Assessment of Vascular Indices or Parameters - Target vessel revascularization (TVR)"/><FilterOption id="6349" count="5" label="Crohns disease - Crohn's Disease Activity Assessed by Capsule Endoscopy/Endoscopy - Simple endoscopic index for crohn's disease (SES-CD)"/><FilterOption id="20876" count="5" label="Gaucher disease - Assessment of Laboratory/Diagnostic Measures - Assessment of hematologic parameters"/><FilterOption id="7569" count="5" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="19631" count="5" label="Lysosome storage disease - Assessment of Laboratory/Diagnostic Measures - Assessment of hematologic parameters"/><FilterOption id="7354" count="5" label="Multiple myeloma - Assessment of Overall Survival (OS)"/><FilterOption id="11685" count="5" label="Neuroendocrine tumor - Assessment of Disease Progression"/><FilterOption id="11640" count="5" label="Neuroendocrine tumor - Assessment of Overall Survival (OS)"/><FilterOption id="11657" count="5" label="Neuroendocrine tumor - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="11717" count="4" label="Bladder cancer - Assessment of Overall Survival (OS)"/><FilterOption id="26531" count="4" label="Bladder cancer - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EQ-5D"/><FilterOption id="9012" count="4" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of treatment induced toxicity"/><FilterOption id="8718" count="4" label="Breast tumor - Assessment of Survival - Assessment of Relapse/Recurrence Free Survival"/><FilterOption id="29766" count="4" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-BR23"/><FilterOption id="9103" count="4" label="Breast tumor - Protocol Specified Other Endpoints - Assessment of Rate of Breast Conserving Surgery"/><FilterOption id="43849" count="4" label="Colorectal tumor - Assessment of Mortality/Death Rates"/><FilterOption id="9375" count="4" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)"/><FilterOption id="2654" count="4" label="Coronary artery disease - Assessment of Hemorrhagic Complications - Major/minor bleeding"/><FilterOption id="2774" count="4" label="Coronary artery disease - Assessment of hospitalization"/><FilterOption id="23916" count="4" label="Hypercholesterolemia - Assessment of Low-Density Lipoprotein (LDL)"/><FilterOption id="23914" count="4" label="Hypercholesterolemia - Assessment of lipid profiles - Assessment of Total Cholesterol"/><FilterOption id="23917" count="4" label="Hypercholesterolemia - Assessment of lipid profiles - Assessment of Triglycerides"/><FilterOption id="23921" count="4" label="Hypercholesterolemia - Assessment of lipid profiles - Assessment of apolipoprotein B"/><FilterOption id="7908" count="4" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="7898" count="4" label="Leukemia - Assessment of Survival - Assessment of event free survival (EFS)"/><FilterOption id="8555" count="4" label="Lung tumor - Assessment of Mortality/Death Rates"/><FilterOption id="28074" count="4" label="Lung tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-C30"/></Filter><Filter label="Biomarker" name="trialBiomarkerNames" total="100"><FilterOption id="3" count="51" label="HER2"/><FilterOption id="1211" count="36" label="Alanine transaminase"/><FilterOption id="5" count="35" label="Estrogen receptor"/><FilterOption id="2527" count="31" label="Aspartate aminotransferase"/><FilterOption id="12058" count="30" label="Total body mass"/><FilterOption id="2054" count="27" label="Blood platelets"/><FilterOption id="1236" count="27" label="Hemoglobin"/><FilterOption id="6" count="27" label="Progesterone receptor"/><FilterOption id="824" count="25" label="Programmed cell death 1 ligand 1"/><FilterOption id="213" count="23" label="Creatinine"/><FilterOption id="217" count="22" label="Triglycerides"/><FilterOption id="1735" count="21" label="Glucose"/><FilterOption id="7" count="20" label="Antigen KI-67"/><FilterOption id="46" count="20" label="C-reactive protein"/><FilterOption id="1925" count="20" label="Neutrophils"/><FilterOption id="133" count="20" label="Total cholesterol"/><FilterOption id="2387" count="19" label="Bilirubin"/><FilterOption id="153" count="19" label="High-density lipoprotein cholesterol"/><FilterOption id="1945" count="19" label="Left ventricular ejection fraction"/><FilterOption id="152" count="19" label="Low-density lipoprotein cholesterol"/><FilterOption id="8" count="18" label="Epidermal growth factor receptor"/><FilterOption id="2586" count="17" label="Blood pressure"/><FilterOption id="5700" count="16" label="ALK receptor"/><FilterOption id="125" count="16" label="Leukocyte count"/><FilterOption id="28899" count="14" label="Alkaline phosphatase"/><FilterOption id="289" count="14" label="Hemoglobin A, glycosylated"/><FilterOption id="1904" count="13" label="Heart rate"/><FilterOption id="4806" count="13" label="Lymphocytes"/><FilterOption id="38" count="12" label="Prostate-specific antigen"/><FilterOption id="1289" count="11" label="Tumor mass"/><FilterOption id="82" count="10" label="B-Raf proto-oncogene serine/threonine-protein kinase"/><FilterOption id="52" count="10" label="GTPase KRas"/><FilterOption id="46506" count="10" label="T-Lymphocytes"/><FilterOption id="118" count="9" label="Albumin"/><FilterOption id="215" count="9" label="Apolipoprotein B-100"/><FilterOption id="17697" count="9" label="Body height"/><FilterOption id="3098" count="9" label="Calprotectin"/><FilterOption id="57" count="9" label="Chromogranin-A"/><FilterOption id="8024" count="9" label="Creatine kinase"/><FilterOption id="46505" count="9" label="Cytotoxic T-Lymphocytes"/><FilterOption id="8458" count="9" label="gamma-Glutamyltransferase"/><FilterOption id="176" count="9" label="Interleukin-6"/><FilterOption id="18315" count="9" label="Visual acuity"/><FilterOption id="214" count="8" label="Apolipoprotein A-I"/><FilterOption id="113" count="8" label="Body Mass Index"/><FilterOption id="2417" count="8" label="Calcium"/><FilterOption id="4522" count="8" label="Erythrocytes"/><FilterOption id="154" count="8" label="Lactate dehydrogenase"/><FilterOption id="2053" count="8" label="Non-high density lipoprotein cholesterol"/><FilterOption id="10" count="8" label="Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN"/><FilterOption id="2098" count="8" label="Potassium"/><FilterOption id="274" count="8" label="Tumor necrosis factor"/><FilterOption id="6663" count="7" label="B-lymphocytes"/><FilterOption id="44216" count="7" label="Body temperature"/><FilterOption id="22" count="7" label="Breast cancer type 1 susceptibility protein"/><FilterOption id="41" count="7" label="Breast cancer type 2 susceptibility protein"/><FilterOption id="64" count="7" label="Circulating Tumor Cells"/><FilterOption id="10753" count="7" label="Intraocular pressure"/><FilterOption id="92" count="7" label="Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform"/><FilterOption id="2662" count="7" label="Sodium"/><FilterOption id="3447" count="7" label="T-cell surface glycoprotein CD8 alpha chain"/><FilterOption id="1731" count="6" label="B-lymphocyte antigen CD20"/><FilterOption id="70" count="6" label="CA19-9 antigen"/><FilterOption id="1827" count="6" label="Cell-free DNA"/><FilterOption id="9" count="6" label="Cellular tumor antigen p53"/><FilterOption id="3914" count="6" label="Chitotriosidase-1"/><FilterOption id="36136" count="6" label="Cytokines"/><FilterOption id="332" count="6" label="Diastolic blood pressure"/><FilterOption id="12118" count="6" label="Liver"/><FilterOption id="11575" count="6" label="Spleen"/><FilterOption id="6993" count="5" label="Alpha-amylase 1"/><FilterOption id="71" count="5" label="CA-125 antigen"/><FilterOption id="83" count="5" label="Cell division protein kinase 4"/><FilterOption id="10306" count="5" label="Ejection fraction"/><FilterOption id="7895" count="5" label="Estimated glomerular filtration rate"/><FilterOption id="808" count="5" label="Insulin"/><FilterOption id="379" count="5" label="Insulin-like growth factor 1"/><FilterOption id="30214" count="5" label="Joint swelling"/><FilterOption id="30217" count="5" label="Joint tenderness"/><FilterOption id="147" count="5" label="Six-minute walk distance"/><FilterOption id="61523" count="5" label="Tumor mutational burden"/><FilterOption id="883" count="5" label="Vascular endothelial growth factor receptor-2"/><FilterOption id="150" count="4" label="Apolipoprotein(a)"/><FilterOption id="1175" count="4" label="B-lymphocyte antigen CD19"/><FilterOption id="4529" count="4" label="Bicarbonates"/><FilterOption id="3374" count="4" label="Bone mineral density"/><FilterOption id="8816" count="4" label="Chromosome 14"/><FilterOption id="102" count="4" label="Cyclin-dependent kinase inhibitor 2A"/><FilterOption id="1550" count="4" label="Hydroxyindoleacetic Acid"/><FilterOption id="29618" count="4" label="International Normalized Ratio"/><FilterOption id="2515" count="4" label="Magnesium"/><FilterOption id="106" count="4" label="N-terminal Pro Brain Natriuretic Peptide"/><FilterOption id="148" count="4" label="QT interval"/><FilterOption id="330" count="4" label="Systolic blood pressure"/><FilterOption id="2358" count="4" label="Urea nitrogen"/><FilterOption id="11563" count="4" label="Very low density lipoprotein cholesterol"/><FilterOption id="1456" count="3" label="Angiotensin converting enzyme"/><FilterOption id="9807" count="3" label="Basophils"/><FilterOption id="165" count="3" label="Beta-2-microglobulin"/><FilterOption id="9842" count="3" label="Birth weight"/></Filter><Filter label="Trial Terms Endpoint" name="trialTermsEndpoint" total="6"><FilterOption id="SIEEFC" count="384" label="Efficacy"/><FilterOption id="SIESFT" count="373" label="Safety"/><FilterOption id="SIEPCK" count="157" label="Pharmacokinetics"/><FilterOption id="SIEPCD" count="96" label="Pharmacodynamics"/><FilterOption id="SIEBEQ" count="3" label="Bioequivalence"/><FilterOption id="SIEBAV" count="1" label="Bioavailability"/></Filter><Filter label="Trial Interventions Primary In Regimen Name Display" name="trialInterventionsPrimaryInRegimenNameDisplay" total="100"><FilterOption id="3199" count="17" label="gemcitabine"/><FilterOption id="2953" count="16" label="docetaxel"/><FilterOption id="3803" count="16" label="paclitaxel"/><FilterOption id="72699" count="15" label="atezolizumab"/><FilterOption id="8047" count="15" label="bevacizumab"/><FilterOption id="44383" count="14" label="carboplatin"/><FilterOption id="3792" count="14" label="oxaliplatin"/><FilterOption id="27572" count="11" label="lenalidomide"/><FilterOption id="29016" count="10" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="6736" count="9" label="rituximab"/><FilterOption id="3313" count="8" label="fulvestrant"/><FilterOption id="12205" count="7" label="capecitabine"/><FilterOption id="2784" count="7" label="letrozole"/><FilterOption id="6386" count="7" label="trastuzumab"/><FilterOption id="13022" count="6" label="epirubicin"/><FilterOption id="12646" count="6" label="panitumumab"/><FilterOption id="10388" count="5" label="cetuximab"/><FilterOption id="3072" count="5" label="etoposide phosphate"/><FilterOption id="54804" count="5" label="nivolumab"/><FilterOption id="10271" count="5" label="palbociclib"/><FilterOption id="28532" count="5" label="pertuzumab"/><FilterOption id="15954" count="4" label="bortezomib"/><FilterOption id="2871" count="4" label="irinotecan"/><FilterOption id="53227" count="4" label="obinutuzumab"/><FilterOption id="10309" count="3" label="abiraterone"/><FilterOption id="47000" count="3" label="bendamustine"/><FilterOption id="56544" count="3" label="cobimetinib"/><FilterOption id="66051" count="3" label="ipatasertib dihydrochloride"/><FilterOption id="11519" count="3" label="mitoxantrone"/><FilterOption id="3536" count="3" label="pemetrexed disodium"/><FilterOption id="44314" count="3" label="tamoxifen"/><FilterOption id="54469" count="3" label="vemurafenib"/><FilterOption id="3321" count="2" label="anastrozole"/><FilterOption id="54601" count="2" label="carfilzomib"/><FilterOption id="2836" count="2" label="clopidogrel"/><FilterOption id="32981" count="2" label="darunavir"/><FilterOption id="81193" count="2" label="durvalumab"/><FilterOption id="10172" count="2" label="efavirenz"/><FilterOption id="11961" count="2" label="erlotinib"/><FilterOption id="3081" count="2" label="exemestane"/><FilterOption id="36630" count="2" label="ipilimumab"/><FilterOption id="3474" count="2" label="lamivudine"/><FilterOption id="45841" count="2" label="lenvatinib mesylate"/><FilterOption id="66417" count="2" label="napabucasin"/><FilterOption id="13460" count="2" label="oseltamivir"/><FilterOption id="23625" count="2" label="peginterferon alfa-2a"/><FilterOption id="70667" count="2" label="pembrolizumab"/><FilterOption id="70732" count="2" label="polatuzumab vedotin"/><FilterOption id="27696" count="2" label="pomalidomide"/><FilterOption id="5369" count="2" label="ribavirin"/><FilterOption id="7310" count="2" label="ritonavir"/><FilterOption id="8050" count="2" label="thalidomide, Celgene"/><FilterOption id="77347" count="2" label="tislelizumab"/><FilterOption id="7810" count="2" label="trifluridine + tipiracil hydrochloride (oral), Taiho"/><FilterOption id="70895" count="2" label="venetoclax"/><FilterOption id="44258" count="1" label="aciclovir"/><FilterOption id="85684" count="1" label="adalimumab biosimilar, Pfizer"/><FilterOption id="54449" count="1" label="afatinib"/><FilterOption id="69066" count="1" label="alectinib"/><FilterOption id="2716" count="1" label="alemtuzumab"/><FilterOption id="65085" count="1" label="alirocumab"/><FilterOption id="83774" count="1" label="andecaliximab"/><FilterOption id="83065" count="1" label="avelumab"/><FilterOption id="39209" count="1" label="axitinib"/><FilterOption id="57182" count="1" label="azacitidine (oral tablet, cancer), Celgene"/><FilterOption id="83119" count="1" label="aztreonam + avibactam, Pfizer"/><FilterOption id="91188" count="1" label="baloxavir marboxil"/><FilterOption id="60328" count="1" label="bemarituzumab"/><FilterOption id="66828" count="1" label="bemcentinib"/><FilterOption id="78484" count="1" label="bevacizumab biosimilar, Boehringer Ingelheim"/><FilterOption id="88687" count="1" label="bimatoprost (ophthalmic implant, glaucoma), Allergan"/><FilterOption id="55305" count="1" label="binimetinib"/><FilterOption id="15322" count="1" label="boceprevir"/><FilterOption id="39172" count="1" label="brentuximab vedotin"/><FilterOption id="41860" count="1" label="brivudine (oral, cancer/infectious diseases), RESprotect/Kwang Dong"/><FilterOption id="9829" count="1" label="Busulfex"/><FilterOption id="63839" count="1" label="calmangafodipir"/><FilterOption id="5999" count="1" label="ciclosporin, Novartis"/><FilterOption id="24343" count="1" label="dabigatran etexilate"/><FilterOption id="53133" count="1" label="dabrafenib"/><FilterOption id="53200" count="1" label="daratumumab"/><FilterOption id="13239" count="1" label="decitabine"/><FilterOption id="58908" count="1" label="demcizumab"/><FilterOption id="49721" count="1" label="denosumab"/><FilterOption id="7126" count="1" label="dexrazoxane"/><FilterOption id="2935" count="1" label="didanosine"/><FilterOption id="72524" count="1" label="dinutuximab"/><FilterOption id="4563" count="1" label="doxorubicin (liposome formulation), Cephalon"/><FilterOption id="69403" count="1" label="enadenotucirev"/><FilterOption id="73843" count="1" label="encorafenib"/><FilterOption id="70942" count="1" label="enfortumab vedotin (iv, cancer), Agensys/Seattle Genetics"/><FilterOption id="53981" count="1" label="enzalutamide"/><FilterOption id="13340" count="1" label="everolimus"/><FilterOption id="83144" count="1" label="evinacumab"/><FilterOption id="65240" count="1" label="evolocumab"/><FilterOption id="3130" count="1" label="filgrastim"/><FilterOption id="5202" count="1" label="gemtuzumab ozogamicin"/><FilterOption id="82426" count="1" label="humanized anti-CD47 antibody (cancer), Stanford University/Forty Seven/Oxford University"/><FilterOption id="4705" count="1" label="ibritumomab tiuxetan"/><FilterOption id="70606" count="1" label="IMM-101"/></Filter><Filter label="Trial Document Source" name="trialDocumentSource" total="5"><FilterOption id="OTHER" count="174" label="Other Publications"/><FilterOption id="PR" count="164" label="Press Releases"/><FilterOption id="SERIAL" count="129" label="Serial Publications"/><FilterOption id="CORPORATE" count="62" label="Corporate Publications"/><FilterOption id="CONFERENCE" count="34" label="Conference Reports"/></Filter><Filter label="Trial Interventions Primary Alone Name Display" name="trialInterventionsPrimaryAloneNameDisplay" total="100"><FilterOption id="72699" count="11" label="atezolizumab"/><FilterOption id="43738" count="7" label="pazopanib"/><FilterOption id="9313" count="5" label="lanreotide"/><FilterOption id="27572" count="5" label="lenalidomide"/><FilterOption id="64962" count="5" label="ozanimod"/><FilterOption id="12973" count="5" label="sunitinib"/><FilterOption id="64571" count="4" label="bococizumab"/><FilterOption id="57369" count="4" label="etrolizumab"/><FilterOption id="6386" count="4" label="trastuzumab"/><FilterOption id="36669" count="4" label="trastuzumab emtansine"/><FilterOption id="69066" count="3" label="alectinib"/><FilterOption id="57182" count="3" label="azacitidine (oral tablet, cancer), Celgene"/><FilterOption id="28035" count="3" label="cabazitaxel"/><FilterOption id="12205" count="3" label="capecitabine"/><FilterOption id="53981" count="3" label="enzalutamide"/><FilterOption id="87792" count="3" label="mirikizumab"/><FilterOption id="62073" count="3" label="mongersen"/><FilterOption id="70667" count="3" label="pembrolizumab"/><FilterOption id="6259" count="3" label="tocilizumab (intravenous), Roche/Chugai"/><FilterOption id="47399" count="3" label="velaglucerase alfa"/><FilterOption id="72538" count="2" label="abemaciclib"/><FilterOption id="54449" count="2" label="afatinib"/><FilterOption id="44897" count="2" label="apremilast"/><FilterOption id="8047" count="2" label="bevacizumab"/><FilterOption id="55798" count="2" label="crizotinib"/><FilterOption id="24343" count="2" label="dabigatran etexilate"/><FilterOption id="2953" count="2" label="docetaxel"/><FilterOption id="58762" count="2" label="empagliflozin"/><FilterOption id="63187" count="2" label="entrectinib"/><FilterOption id="28773" count="2" label="eribulin mesylate"/><FilterOption id="3081" count="2" label="exemestane"/><FilterOption id="67629" count="2" label="filgotinib"/><FilterOption id="42857" count="2" label="golimumab"/><FilterOption id="9443" count="2" label="levosimendan"/><FilterOption id="88045" count="2" label="lorlatinib"/><FilterOption id="52854" count="2" label="macitentan"/><FilterOption id="3791" count="2" label="miglustat"/><FilterOption id="29245" count="2" label="motavizumab"/><FilterOption id="50341" count="2" label="neratinib"/><FilterOption id="54804" count="2" label="nivolumab"/><FilterOption id="16063" count="2" label="olaparib"/><FilterOption id="29016" count="2" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="10271" count="2" label="palbociclib"/><FilterOption id="9953" count="2" label="pitavastatin"/><FilterOption id="17814" count="2" label="pregabalin"/><FilterOption id="61979" count="2" label="relamorelin"/><FilterOption id="29831" count="2" label="sorafenib"/><FilterOption id="55979" count="2" label="taliglucerase alfa"/><FilterOption id="42858" count="2" label="ustekinumab"/><FilterOption id="36216" count="1" label="abagovomab"/><FilterOption id="7982" count="1" label="abetimus"/><FilterOption id="62126" count="1" label="abicipar pegol"/><FilterOption id="10309" count="1" label="abiraterone"/><FilterOption id="14163" count="1" label="adalimumab"/><FilterOption id="6747" count="1" label="adefovir dipivoxil"/><FilterOption id="50518" count="1" label="aldoxorubicin (cancer), NantCell"/><FilterOption id="57452" count="1" label="alisertib"/><FilterOption id="62965" count="1" label="allopurinol (topical cream, palmar-plantar erythrodysesthesia), Helsinn"/><FilterOption id="3321" count="1" label="anastrozole"/><FilterOption id="75699" count="1" label="AP-101, Amryt Pharma"/><FilterOption id="89991" count="1" label="AR-101, Aimmune Therapeutics"/><FilterOption id="44280" count="1" label="atenolol"/><FilterOption id="89583" count="1" label="avapritinib"/><FilterOption id="83065" count="1" label="avelumab"/><FilterOption id="106427" count="1" label="AVX-012"/><FilterOption id="39209" count="1" label="axitinib"/><FilterOption id="37370" count="1" label="azacitidine"/><FilterOption id="37150" count="1" label="AZD-9056"/><FilterOption id="83119" count="1" label="aztreonam + avibactam, Pfizer"/><FilterOption id="65988" count="1" label="bermekimab"/><FilterOption id="76653" count="1" label="BI-1467335"/><FilterOption id="12838" count="1" label="bimatoprost"/><FilterOption id="98616" count="1" label="bintrafusp alfa"/><FilterOption id="44372" count="1" label="bisoprolol fumarate"/><FilterOption id="5871" count="1" label="bosentan"/><FilterOption id="8324" count="1" label="canfosfamide"/><FilterOption id="39893" count="1" label="capsaicin dermal patch, NeurogesX/Astellas/Acorda/Grunenthal"/><FilterOption id="8955" count="1" label="carvedilol"/><FilterOption id="50340" count="1" label="catumaxomab"/><FilterOption id="35340" count="1" label="cediranib"/><FilterOption id="53133" count="1" label="dabrafenib"/><FilterOption id="55705" count="1" label="dacomitinib"/><FilterOption id="19300" count="1" label="deferasirox"/><FilterOption id="63913" count="1" label="dexamethasone + povidone (adenoviral conjunctivitis), Shire"/><FilterOption id="14851" count="1" label="Diamyd (subcutaneous, type 1 diabetes), Diamyd Medical"/><FilterOption id="40735" count="1" label="dovitinib"/><FilterOption id="49460" count="1" label="E-7107"/><FilterOption id="51255" count="1" label="edoxaban"/><FilterOption id="34449" count="1" label="eliglustat tartrate"/><FilterOption id="4728" count="1" label="emtricitabine"/><FilterOption id="69403" count="1" label="enadenotucirev"/><FilterOption id="13486" count="1" label="entecavir"/><FilterOption id="60512" count="1" label="erdafitinib"/><FilterOption id="11961" count="1" label="erlotinib"/><FilterOption id="17518" count="1" label="escitalopram"/><FilterOption id="25898" count="1" label="eslicarbazepine acetate"/><FilterOption id="4567" count="1" label="etanercept"/><FilterOption id="13340" count="1" label="everolimus"/><FilterOption id="13572" count="1" label="exenatide"/><FilterOption id="72254" count="1" label="fluticasone propionate (ODT, eosinophilic esophagitis), Adare Pharmaceuticals"/></Filter><Filter label="Trial Interventions Control In Regimen Name Display" name="trialInterventionsControlInRegimenNameDisplay" total="53"><FilterOption id="44383" count="16" label="carboplatin"/><FilterOption id="2953" count="12" label="docetaxel"/><FilterOption id="3199" count="12" label="gemcitabine"/><FilterOption id="12205" count="9" label="capecitabine"/><FilterOption id="3792" count="9" label="oxaliplatin"/><FilterOption id="8047" count="8" label="bevacizumab"/><FilterOption id="3803" count="8" label="paclitaxel"/><FilterOption id="6386" count="7" label="trastuzumab"/><FilterOption id="3536" count="6" label="pemetrexed disodium"/><FilterOption id="13022" count="5" label="epirubicin"/><FilterOption id="3072" count="4" label="etoposide phosphate"/><FilterOption id="29016" count="4" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="6736" count="4" label="rituximab"/><FilterOption id="33591" count="3" label="lapatinib"/><FilterOption id="27572" count="3" label="lenalidomide"/><FilterOption id="6408" count="3" label="vinorelbine"/><FilterOption id="15954" count="2" label="bortezomib"/><FilterOption id="32981" count="2" label="darunavir"/><FilterOption id="3130" count="2" label="filgrastim"/><FilterOption id="48181" count="2" label="lamivudine + abacavir, GlaxoSmithKline"/><FilterOption id="21374" count="2" label="pegfilgrastim"/><FilterOption id="28532" count="2" label="pertuzumab"/><FilterOption id="7310" count="2" label="ritonavir"/><FilterOption id="8050" count="2" label="thalidomide, Celgene"/><FilterOption id="15130" count="2" label="vinflunine"/><FilterOption id="10309" count="1" label="abiraterone"/><FilterOption id="14163" count="1" label="adalimumab"/><FilterOption id="72699" count="1" label="atezolizumab"/><FilterOption id="37370" count="1" label="azacitidine"/><FilterOption id="47000" count="1" label="bendamustine"/><FilterOption id="2836" count="1" label="clopidogrel"/><FilterOption id="13239" count="1" label="decitabine"/><FilterOption id="28773" count="1" label="eribulin mesylate"/><FilterOption id="6156" count="1" label="fludarabine"/><FilterOption id="3195" count="1" label="ganciclovir (oral), Roche Bioscience"/><FilterOption id="2871" count="1" label="irinotecan"/><FilterOption id="3488" count="1" label="leflunomide"/><FilterOption id="14681" count="1" label="lopinavir + ritonavir"/><FilterOption id="3616" count="1" label="meropenem"/><FilterOption id="11519" count="1" label="mitoxantrone"/><FilterOption id="54804" count="1" label="nivolumab"/><FilterOption id="53227" count="1" label="obinutuzumab"/><FilterOption id="43738" count="1" label="pazopanib"/><FilterOption id="23625" count="1" label="peginterferon alfa-2a"/><FilterOption id="5369" count="1" label="ribavirin"/><FilterOption id="12973" count="1" label="sunitinib"/><FilterOption id="44314" count="1" label="tamoxifen"/><FilterOption id="10084" count="1" label="tegafur + gimeracil + oteracil potassium"/><FilterOption id="49219" count="1" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"/><FilterOption id="36332" count="1" label="ticagrelor"/><FilterOption id="25182" count="1" label="valganciclovir"/><FilterOption id="12150" count="1" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"/><FilterOption id="44375" count="1" label="warfarin"/></Filter><Filter label="Trial Category" name="trialCategory" total="13"><FilterOption id="4" count="303" label="Small molecule"/><FilterOption id="3" count="194" label="Biological"/><FilterOption id="8" count="25" label="Medical device"/><FilterOption id="9" count="25" label="Medical procedure"/><FilterOption id="16" count="14" label="Behavioral intervention"/><FilterOption id="15" count="13" label="Radiation therapy"/><FilterOption id="5" count="10" label="Vaccine"/><FilterOption id="18" count="7" label="Pathophysiology"/><FilterOption id="11" count="6" label="Dietary supplement"/><FilterOption id="17" count="4" label="Biomarker identification"/><FilterOption id="14" count="3" label="Diagnostic"/><FilterOption id="6" count="2" label="Cell therapy"/><FilterOption id="7" count="2" label="Gene therapy"/></Filter><Filter label="Trial Outcome Available" name="trialOutcomesAvailable" total="2"><FilterOption id="NO" count="251" label="No"/><FilterOption id="YES" count="207" label="Yes"/></Filter><Filter label="Trial Actions Primary Interventions Primary" name="trialActionsPrimaryInterventionsPrimary" total="100"><FilterOption id="14007" count="30" label="Programmed cell death ligand 1 inhibitor"/><FilterOption id="3808" count="28" label="Kit tyrosine kinase inhibitor"/><FilterOption id="3846" count="27" label="VEGF-1 receptor antagonist"/><FilterOption id="3848" count="26" label="VEGF-2 receptor antagonist"/><FilterOption id="3850" count="25" label="VEGF-3 receptor antagonist"/><FilterOption id="740" count="21" label="Epidermal growth factor receptor antagonist"/><FilterOption id="3756" count="20" label="Erbb2 tyrosine kinase receptor inhibitor"/><FilterOption id="48492" count="19" label="PDGF receptor beta antagonist"/><FilterOption id="48489" count="17" label="PDGF receptor alpha antagonist"/><FilterOption id="12521" count="17" label="VEGF ligand inhibitor"/><FilterOption id="372" count="15" label="Thymidylate synthase inhibitor"/><FilterOption id="5085" count="14" label="B-lymphocyte antigen CD20 inhibitor"/><FilterOption id="3682" count="14" label="FGF1 receptor antagonist"/><FilterOption id="3688" count="14" label="FGF3 receptor antagonist"/><FilterOption id="67136" count="14" label="Programmed cell death protein 1 inhibitor"/><FilterOption id="385" count="14" label="Protein tyrosine kinase inhibitor"/><FilterOption id="3816" count="13" label="RET tyrosine kinase receptor family inhibitor"/><FilterOption id="142" count="13" label="Topoisomerase II inhibitor"/><FilterOption id="76" count="11" label="Aromatase inhibitor"/><FilterOption id="286" count="11" label="Estrogen receptor antagonist"/><FilterOption id="3806" count="11" label="Flt3 tyrosine kinase inhibitor"/><FilterOption id="948" count="10" label="PDGF receptor antagonist"/><FilterOption id="3154" count="9" label="CSF-1 antagonist"/><FilterOption id="4314" count="9" label="Cyclin-dependent kinase-4 inhibitor"/><FilterOption id="4318" count="9" label="Cyclin-dependent kinase-6 inhibitor"/><FilterOption id="3754" count="9" label="EGFR family tyrosine kinase receptor inhibitor"/><FilterOption id="4548" count="9" label="Raf B protein kinase inhibitor"/><FilterOption id="3736" count="8" label="Anaplastic lymphoma kinase receptor inhibitor"/><FilterOption id="3594" count="8" label="Itk tyrosine kinase inhibitor"/><FilterOption id="3584" count="8" label="Lck tyrosine kinase inhibitor"/><FilterOption id="3738" count="8" label="Ltk tyrosine kinase receptor inhibitor"/><FilterOption id="3760" count="7" label="Erbb4 tyrosine kinase receptor inhibitor"/><FilterOption id="3685" count="7" label="FGF2 receptor antagonist"/><FilterOption id="4917" count="7" label="Proteasome inhibitor"/><FilterOption id="19467" count="7" label="Retinoblastoma associated protein modulator"/><FilterOption id="3851" count="6" label="ALK tyrosine kinase receptor family inhibitor"/><FilterOption id="82444" count="6" label="DNA helicase inhibitor"/><FilterOption id="138" count="6" label="DNA polymerase inhibitor"/><FilterOption id="3755" count="6" label="Erbb2 tyrosine kinase receptor modulator"/><FilterOption id="10240" count="6" label="mTOR inhibitor"/><FilterOption id="1722" count="6" label="VEGF receptor antagonist"/><FilterOption id="60" count="5" label="Androgen receptor antagonist"/><FilterOption id="7472" count="5" label="Cytochrome P450 17 inhibitor"/><FilterOption id="135" count="5" label="DHFR inhibitor"/><FilterOption id="3758" count="5" label="Erbb3 tyrosine kinase receptor inhibitor"/><FilterOption id="7163" count="5" label="Glucosylceramidase stimulator"/><FilterOption id="1016" count="5" label="HIV-1 reverse transcriptase inhibitor"/><FilterOption id="9748" count="5" label="IL-23 antagonist"/><FilterOption id="3252" count="5" label="Insulin-like growth factor 1 receptor antagonist"/><FilterOption id="4762" count="5" label="MEK-1 protein kinase inhibitor"/><FilterOption id="4764" count="5" label="MEK-2 protein kinase inhibitor"/><FilterOption id="38283" count="5" label="Poly ADP ribose polymerase 1 inhibitor"/><FilterOption id="38286" count="5" label="Poly ADP ribose polymerase 2 inhibitor"/><FilterOption id="4550" count="5" label="Raf 1 protein kinase inhibitor"/><FilterOption id="3826" count="5" label="Ros1 tyrosine kinase receptor inhibitor"/><FilterOption id="1120" count="5" label="Somatostatin receptor agonist"/><FilterOption id="8519" count="5" label="Sphingosine-1-phosphate receptor-1 agonist"/><FilterOption id="8540" count="5" label="Sphingosine-1-phosphate receptor-5 agonist"/><FilterOption id="541" count="5" label="Tubulin receptor antagonist"/><FilterOption id="76469" count="4" label="26S proteasome complex inhibitor"/><FilterOption id="3859" count="4" label="AKT protein kinase inhibitor"/><FilterOption id="13571" count="4" label="Bcr protein inhibitor"/><FilterOption id="7423" count="4" label="Cytochrome P450 3A4 stimulator"/><FilterOption id="18889" count="4" label="DNA binding protein inhibitor"/><FilterOption id="6512" count="4" label="DNA methyltransferase inhibitor"/><FilterOption id="770" count="4" label="Endothelin ET-A receptor antagonist"/><FilterOption id="3691" count="4" label="FGF4 receptor antagonist"/><FilterOption id="471" count="4" label="IL-6 receptor antagonist"/><FilterOption id="3058" count="4" label="IL-6 receptor modulator"/><FilterOption id="23014" count="4" label="Insulin ligand"/><FilterOption id="400" count="4" label="Insulin receptor agonist"/><FilterOption id="2950" count="4" label="Integrin alpha-4/beta-7 antagonist"/><FilterOption id="5391" count="4" label="Integrin alpha-E antagonist"/><FilterOption id="6137" count="4" label="Integrin beta-7 antagonist"/><FilterOption id="4760" count="4" label="MEK protein kinase inhibitor"/><FilterOption id="1832" count="4" label="Nucleoside reverse transcriptase inhibitor"/><FilterOption id="48843" count="4" label="Proprotein convertase PC9 inhibitor"/><FilterOption id="35354" count="4" label="Prostate specific antigen modulator"/><FilterOption id="4542" count="4" label="Raf protein kinase inhibitor"/><FilterOption id="381" count="4" label="TNF alpha ligand inhibitor"/><FilterOption id="38" count="3" label="Beta adrenoceptor antagonist"/><FilterOption id="5482" count="3" label="Cytotoxic T-lymphocyte protein-4 inhibitor"/><FilterOption id="771" count="3" label="Endothelin ET-B receptor antagonist"/><FilterOption id="111" count="3" label="Factor IIa antagonist"/><FilterOption id="9237" count="3" label="Fatty acid transport protein inhibitor"/><FilterOption id="181" count="3" label="GAR transformylase inhibitor"/><FilterOption id="3009" count="3" label="Glucosylceramide synthase inhibitor"/><FilterOption id="21072" count="3" label="Growth hormone ligand"/><FilterOption id="204" count="3" label="HIV protease inhibitor"/><FilterOption id="3562" count="3" label="Jak1 tyrosine kinase inhibitor"/><FilterOption id="76090" count="3" label="mTOR complex 1 inhibitor"/><FilterOption id="1833" count="3" label="Non-nucleoside reverse transcriptase inhibitor"/><FilterOption id="3818" count="3" label="Ret tyrosine kinase receptor inhibitor"/><FilterOption id="551" count="3" label="RNA DNA polymerase inhibitor"/><FilterOption id="12974" count="3" label="SMAD-7 inhibitor"/><FilterOption id="3699" count="3" label="TGF beta 1 ligand inhibitor"/><FilterOption id="721" count="3" label="TNF binding agent"/><FilterOption id="141" count="3" label="Topoisomerase I inhibitor"/><FilterOption id="78089" count="3" label="Translocation associated protein inhibitor"/><FilterOption id="3524" count="2" label="Abl tyrosine kinase inhibitor"/></Filter><Filter label="Trial Company Collaborator" name="trialCompaniesCollaborator" total="100"><FilterOption id="19446" count="18" label="Roche Holding AG"/><FilterOption id="15331" count="9" label="Celgene Corp"/><FilterOption id="18767" count="9" label="Pfizer Inc"/><FilterOption id="14109" count="8" label="Amgen Inc"/><FilterOption id="14190" count="7" label="AstraZeneca plc"/><FilterOption id="1033112" count="6" label="Hospital Universitario 12 de Octubre"/><FilterOption id="15065" count="5" label="Bristol-Myers Squibb Co"/><FilterOption id="17810" count="5" label="Eli Lilly &amp; Co"/><FilterOption id="28355" count="5" label="GlaxoSmithKline plc"/><FilterOption id="1061163" count="4" label="Abbott Vascular"/><FilterOption id="1072507" count="4" label="AbbVie Inc"/><FilterOption id="1065900" count="4" label="Apices Soluciones, S.L."/><FilterOption id="1013295" count="4" label="Astellas Pharma Inc"/><FilterOption id="1042255" count="4" label="Breast International Group"/><FilterOption id="26178" count="4" label="F Hoffmann-La Roche AG"/><FilterOption id="19453" count="4" label="Genentech Inc"/><FilterOption id="1045910" count="4" label="Hospital Clinico San Carlos"/><FilterOption id="20300" count="4" label="Takeda Pharmaceutical Co Ltd"/><FilterOption id="19864" count="3" label="Adir &amp; Co"/><FilterOption id="1091345" count="3" label="Complejo Hospitalario de Navarra"/><FilterOption id="1017506" count="3" label="Daiichi Sankyo Co Ltd"/><FilterOption id="1017818" count="3" label="Instituto de Salud Carlos III"/><FilterOption id="17416" count="3" label="Janssen LP"/><FilterOption id="1057369" count="3" label="La Paz University Hospital (Madrid)"/><FilterOption id="1059823" count="3" label="Merck Sharp &amp; Dohme Corp"/><FilterOption id="23137" count="3" label="Novartis AG"/><FilterOption id="19087" count="3" label="Pierre Fabre SA"/><FilterOption id="1067340" count="3" label="Pivotal SL"/><FilterOption id="25554" count="3" label="Seattle Genetics Inc"/><FilterOption id="1114403" count="3" label="TFS Trial Form Support"/><FilterOption id="21082" count="3" label="Walter and Eliza Hall Institute of Medical Research"/><FilterOption id="1154033" count="2" label="Aragonese Institute of Health Sciences"/><FilterOption id="25902" count="2" label="Array BioPharma Inc"/><FilterOption id="1052569" count="2" label="B Braun Surgical Sa"/><FilterOption id="1056053" count="2" label="Celgene International Sarl"/><FilterOption id="23119" count="2" label="European Organisation for Research and Treatment of Cancer (EORTC)"/><FilterOption id="27741" count="2" label="Galapagos NV"/><FilterOption id="1043325" count="2" label="German Breast Group"/><FilterOption id="1039086" count="2" label="Germans Trias i Pujol Hospital"/><FilterOption id="1039423" count="2" label="Hospital Clinic of Barcelona"/><FilterOption id="1040862" count="2" label="Hospital General Universitario Gregorio Marañon"/><FilterOption id="1034433" count="2" label="Hospital Miguel Servet"/><FilterOption id="1006639" count="2" label="Hospital Universitario Ramon y Cajal"/><FilterOption id="1119275" count="2" label="Instituto de Investigación Sanitaria Hospital Universitario de La Princesa"/><FilterOption id="1045581" count="2" label="Italian Sarcoma Group"/><FilterOption id="1020988" count="2" label="NSABP Foundation Inc"/><FilterOption id="1116693" count="2" label="Productos Roche, S.A. de C.V."/><FilterOption id="1009547" count="2" label="Sanofi SA"/><FilterOption id="28185" count="2" label="St Jude Medical Inc"/><FilterOption id="20341" count="2" label="Terumo Corp"/><FilterOption id="1058777" count="2" label="Trial Form Support S.L"/><FilterOption id="13601" count="1" label="Abbott Laboratories"/><FilterOption id="13640" count="1" label="Abbott Laboratorios SA"/><FilterOption id="1125317" count="1" label="ADIR Association"/><FilterOption id="1006151" count="1" label="Alcon Research Ltd"/><FilterOption id="1005508" count="1" label="Allergan Sales LLC"/><FilterOption id="1122164" count="1" label="Amgen Limited"/><FilterOption id="1097931" count="1" label="Andalusian Initiative for Advanced Therapies"/><FilterOption id="1115154" count="1" label="Angsana Molecular &amp; Diagnostics Laboratory Pte Ltd"/><FilterOption id="1058483" count="1" label="Arbeitsgemeinschaft Gynaekologische Onkologie"/><FilterOption id="1173657" count="1" label="Arbeitsgemeinschaft Gynaekologische Onkologie Austria"/><FilterOption id="1012397" count="1" label="Arisaph Pharmaceuticals Inc"/><FilterOption id="1079784" count="1" label="Asociacion Colaboracion Cochrane Iberoamericana"/><FilterOption id="1158336" count="1" label="AstraZeneca AB, spain"/><FilterOption id="1045256" count="1" label="Austrian Breast &amp; Colorectal Cancer Study Group"/><FilterOption id="14438" count="1" label="Baxter Healthcare Corp"/><FilterOption id="31284" count="1" label="Baxter Healthcare SA"/><FilterOption id="14437" count="1" label="Baxter International Inc"/><FilterOption id="14455" count="1" label="Bayer AG"/><FilterOption id="1058486" count="1" label="Belgian Gynaecological Oncology Group (BGOG)"/><FilterOption id="1005244" count="1" label="Biogen Inc"/><FilterOption id="1166885" count="1" label="Biomedical Advanced Research and Development Authority (BARDA)"/><FilterOption id="14881" count="1" label="Boehringer Ingelheim International GmbH"/><FilterOption id="22576" count="1" label="Boehringer Ingelheim SA de CV"/><FilterOption id="21048" count="1" label="Brigham &amp; Women's Hospital"/><FilterOption id="1120666" count="1" label="Canadian Cancer Trials Group"/><FilterOption id="1034426" count="1" label="Canadian Institutes of Health Research"/><FilterOption id="1040381" count="1" label="Cancer and Leukemia Group B"/><FilterOption id="1042289" count="1" label="Cancer International Research Group"/><FilterOption id="29469" count="1" label="Cancer Research UK"/><FilterOption id="31154" count="1" label="Centre Leon Berard"/><FilterOption id="1063176" count="1" label="Centro De Investigación Biomédica En Red De Enfermedades Respiratorias (Ciberes)"/><FilterOption id="1067220" count="1" label="Centro Medico Teknon"/><FilterOption id="1017946" count="1" label="Centro Nacional de Investigaciones Oncologicas"/><FilterOption id="15358" count="1" label="Cephalon Inc"/><FilterOption id="15414" count="1" label="Chugai Pharmaceutical Co Ltd"/><FilterOption id="1034434" count="1" label="Clínica Quiron de Zaragoza"/><FilterOption id="1085587" count="1" label="Consortium for Biomedical Research Support Network"/><FilterOption id="1078925" count="1" label="CROMSOURCE"/><FilterOption id="1069026" count="1" label="Effice Servicios Para la Investigacion"/><FilterOption id="19620" count="1" label="Eisai Inc"/><FilterOption id="14913" count="1" label="Eisai Ltd"/><FilterOption id="1037063" count="1" label="Eisai Medical Research Inc"/><FilterOption id="1035512" count="1" label="EMD Serono Inc"/><FilterOption id="1115997" count="1" label="European Clinical Research Infrastructure Network"/><FilterOption id="1059977" count="1" label="European Commission"/><FilterOption id="1100814" count="1" label="European Neuroendocrine Tumor Society"/><FilterOption id="1112024" count="1" label="Experior"/><FilterOption id="1073758" count="1" label="Fondo de Investigacion Sanitaria"/><FilterOption id="1120033" count="1" label="Forty Seven Inc"/></Filter><Filter label="Trial Actions Secondary Interventions Control" name="trialActionsSecondaryInterventionsControl" total="59"><FilterOption id="1545" count="94" label="Anticancer"/><FilterOption id="767" count="41" label="Cell cycle inhibitor"/><FilterOption id="140" count="32" label="DNA synthesis inhibitor"/><FilterOption id="1569" count="30" label="Anticancer antimetabolite"/><FilterOption id="55685" count="29" label="Anticancer monoclonal antibody"/><FilterOption id="50" count="28" label="Anticancer alkylating agent"/><FilterOption id="62255" count="25" label="Anticancer protein kinase inhibitor"/><FilterOption id="61" count="23" label="Angiogenesis inhibitor"/><FilterOption id="2953" count="22" label="Anti-inflammatory"/><FilterOption id="2575" count="21" label="Microtubule inhibitor"/><FilterOption id="2576" count="19" label="Microtubule stabilizer"/><FilterOption id="1589" count="18" label="Apoptosis stimulator"/><FilterOption id="991" count="16" label="Antiviral"/><FilterOption id="2660" count="14" label="Vasoprotectant"/><FilterOption id="750" count="8" label="DNA intercalator"/><FilterOption id="805" count="7" label="Folate modulator"/><FilterOption id="1596" count="7" label="Immunomodulator"/><FilterOption id="62254" count="6" label="Anticancer hormone antagonist"/><FilterOption id="393" count="5" label="Immunostimulant"/><FilterOption id="7761" count="5" label="T-lymphocyte stimulator"/><FilterOption id="382" count="5" label="TNF alpha synthesis inhibitor"/><FilterOption id="399" count="4" label="Hypoglycemic agent"/><FilterOption id="15148" count="4" label="Ocular antineovascularisation agent"/><FilterOption id="7293" count="4" label="Synergist"/><FilterOption id="15184" count="4" label="Systemic antipsoriatic product"/><FilterOption id="2946" count="3" label="Analgesic"/><FilterOption id="1594" count="3" label="Antibacterial"/><FilterOption id="2657" count="3" label="Antihypertensive"/><FilterOption id="396" count="3" label="Immunosuppressant"/><FilterOption id="563" count="3" label="Microtubule modulator"/><FilterOption id="15128" count="3" label="Ophthalmological agent"/><FilterOption id="1532" count="3" label="Viral replication inhibitor"/><FilterOption id="15135" count="2" label="Antiglaucoma agent"/><FilterOption id="2659" count="2" label="Cardioprotectant"/><FilterOption id="659" count="2" label="Coagulation inhibitor"/><FilterOption id="610" count="2" label="Hematopoietic stimulator"/><FilterOption id="747" count="2" label="HIV replication inhibitor"/><FilterOption id="38211" count="2" label="Human insulin fast acting product"/><FilterOption id="1129" count="2" label="Non-steroid hormone receptor antagonist"/><FilterOption id="937" count="1" label="Androgen synthesis inhibitor"/><FilterOption id="2667" count="1" label="Antiarteriosclerotic"/><FilterOption id="71" count="1" label="Antihypercholesterolemic agent"/><FilterOption id="72" count="1" label="Antihyperlipidemic agent"/><FilterOption id="104" count="1" label="Bacterial cell wall synthesis inhibitor"/><FilterOption id="1535" count="1" label="Beta lactam antibiotic"/><FilterOption id="73547" count="1" label="Carbapenem"/><FilterOption id="2833" count="1" label="CMV replication inhibitor"/><FilterOption id="7251" count="1" label="Female contraceptive"/><FilterOption id="1332" count="1" label="Gastrointestinal system agent"/><FilterOption id="38215" count="1" label="Human insulin long acting product"/><FilterOption id="211" count="1" label="Inotropic agent"/><FilterOption id="3246" count="1" label="Insulin release stimulator"/><FilterOption id="1615" count="1" label="Neuroprotectant"/><FilterOption id="284" count="1" label="Nootropic agent"/><FilterOption id="312" count="1" label="Platelet aggregation inhibitor"/><FilterOption id="439" count="1" label="RNA synthesis inhibitor"/><FilterOption id="38205" count="1" label="Sulphonylurea antidiabetic product"/><FilterOption id="15187" count="1" label="Systemic dermatological antibacterial product"/><FilterOption id="59620" count="1" label="Unspecified drug target"/></Filter><Filter label="Biomarker Type" name="trialBiomarkerTypes" total="7"><FilterOption id="37" count="260" label="Proteomic"/><FilterOption id="38" count="259" label="Genomic"/><FilterOption id="32" count="96" label="Biochemical"/><FilterOption id="31" count="89" label="Physiological"/><FilterOption id="75" count="69" label="Cellular"/><FilterOption id="40" count="45" label="Structural (imaging)"/><FilterOption id="39" count="40" label="Anthropomorphic"/></Filter><Filter label="Biomarker Role" name="trialBiomarkerRoles" total="4"><FilterOption id="695863716" count="234" label="Therapeutic effect marker"/><FilterOption id="1571666123" count="158" label="Disease marker"/><FilterOption id="730490367" count="74" label="Toxic effect marker"/><FilterOption id="3242045531" count="1" label="Not determined"/></Filter><Filter label="Interventions" name="trialInterventions" total="100"><FilterOption id="72699" count="25" label="atezolizumab"/><FilterOption id="2953" count="17" label="docetaxel"/><FilterOption id="3199" count="17" label="gemcitabine"/><FilterOption id="8047" count="16" label="bevacizumab"/><FilterOption id="27572" count="16" label="lenalidomide"/><FilterOption id="3803" count="16" label="paclitaxel"/><FilterOption id="44383" count="14" label="carboplatin"/><FilterOption id="3792" count="14" label="oxaliplatin"/><FilterOption id="29016" count="12" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="6386" count="11" label="trastuzumab"/><FilterOption id="12205" count="10" label="capecitabine"/><FilterOption id="6736" count="10" label="rituximab"/><FilterOption id="3313" count="8" label="fulvestrant"/><FilterOption id="2784" count="8" label="letrozole"/><FilterOption id="43738" count="8" label="pazopanib"/><FilterOption id="10271" count="7" label="palbociclib"/><FilterOption id="13022" count="6" label="epirubicin"/><FilterOption id="54804" count="6" label="nivolumab"/><FilterOption id="12646" count="6" label="panitumumab"/><FilterOption id="12973" count="6" label="sunitinib"/><FilterOption id="10388" count="5" label="cetuximab"/><FilterOption id="3072" count="5" label="etoposide phosphate"/><FilterOption id="9313" count="5" label="lanreotide"/><FilterOption id="64962" count="5" label="ozanimod"/><FilterOption id="70667" count="5" label="pembrolizumab"/><FilterOption id="28532" count="5" label="pertuzumab"/><FilterOption id="10309" count="4" label="abiraterone"/><FilterOption id="69066" count="4" label="alectinib"/><FilterOption id="64571" count="4" label="bococizumab"/><FilterOption id="15954" count="4" label="bortezomib"/><FilterOption id="53981" count="4" label="enzalutamide"/><FilterOption id="57369" count="4" label="etrolizumab"/><FilterOption id="3081" count="4" label="exemestane"/><FilterOption id="2871" count="4" label="irinotecan"/><FilterOption id="53227" count="4" label="obinutuzumab"/><FilterOption id="6259" count="4" label="tocilizumab (intravenous), Roche/Chugai"/><FilterOption id="36669" count="4" label="trastuzumab emtansine"/><FilterOption id="54449" count="3" label="afatinib"/><FilterOption id="3321" count="3" label="anastrozole"/><FilterOption id="57182" count="3" label="azacitidine (oral tablet, cancer), Celgene"/><FilterOption id="47000" count="3" label="bendamustine"/><FilterOption id="28035" count="3" label="cabazitaxel"/><FilterOption id="56544" count="3" label="cobimetinib"/><FilterOption id="24343" count="3" label="dabigatran etexilate"/><FilterOption id="11961" count="3" label="erlotinib"/><FilterOption id="66051" count="3" label="ipatasertib dihydrochloride"/><FilterOption id="3474" count="3" label="lamivudine"/><FilterOption id="45841" count="3" label="lenvatinib mesylate"/><FilterOption id="87792" count="3" label="mirikizumab"/><FilterOption id="11519" count="3" label="mitoxantrone"/><FilterOption id="62073" count="3" label="mongersen"/><FilterOption id="50341" count="3" label="neratinib"/><FilterOption id="16063" count="3" label="olaparib"/><FilterOption id="3536" count="3" label="pemetrexed disodium"/><FilterOption id="29831" count="3" label="sorafenib"/><FilterOption id="44314" count="3" label="tamoxifen"/><FilterOption id="77347" count="3" label="tislelizumab"/><FilterOption id="72538" count="2" label="abemaciclib"/><FilterOption id="44897" count="2" label="apremilast"/><FilterOption id="83065" count="2" label="avelumab"/><FilterOption id="39209" count="2" label="axitinib"/><FilterOption id="54601" count="2" label="carfilzomib"/><FilterOption id="2836" count="2" label="clopidogrel"/><FilterOption id="55798" count="2" label="crizotinib"/><FilterOption id="32981" count="2" label="darunavir"/><FilterOption id="81193" count="2" label="durvalumab"/><FilterOption id="10172" count="2" label="efavirenz"/><FilterOption id="58762" count="2" label="empagliflozin"/><FilterOption id="63187" count="2" label="entrectinib"/><FilterOption id="28773" count="2" label="eribulin mesylate"/><FilterOption id="13340" count="2" label="everolimus"/><FilterOption id="67629" count="2" label="filgotinib"/><FilterOption id="42857" count="2" label="golimumab"/><FilterOption id="4705" count="2" label="ibritumomab tiuxetan"/><FilterOption id="36630" count="2" label="ipilimumab"/><FilterOption id="9443" count="2" label="levosimendan"/><FilterOption id="55852" count="2" label="linagliptin"/><FilterOption id="88045" count="2" label="lorlatinib"/><FilterOption id="62139" count="2" label="lurbinectedin"/><FilterOption id="52854" count="2" label="macitentan"/><FilterOption id="3791" count="2" label="miglustat"/><FilterOption id="29245" count="2" label="motavizumab"/><FilterOption id="66417" count="2" label="napabucasin"/><FilterOption id="13460" count="2" label="oseltamivir"/><FilterOption id="23625" count="2" label="peginterferon alfa-2a"/><FilterOption id="9953" count="2" label="pitavastatin"/><FilterOption id="70732" count="2" label="polatuzumab vedotin"/><FilterOption id="27696" count="2" label="pomalidomide"/><FilterOption id="17814" count="2" label="pregabalin"/><FilterOption id="52978" count="2" label="quizartinib dihydrochloride"/><FilterOption id="5369" count="2" label="ribavirin"/><FilterOption id="52196" count="2" label="tivozanib"/><FilterOption id="9112" count="2" label="trabectedin"/><FilterOption id="7810" count="2" label="trifluridine + tipiracil hydrochloride (oral), Taiho"/><FilterOption id="47399" count="2" label="velaglucerase alfa"/><FilterOption id="54469" count="2" label="vemurafenib"/><FilterOption id="36216" count="1" label="abagovomab"/><FilterOption id="7982" count="1" label="abetimus"/><FilterOption id="62126" count="1" label="abicipar pegol"/><FilterOption id="44258" count="1" label="aciclovir"/></Filter><Filter label="Endpoint Index Primary" name="trialEndpointIndexPrimary" total="100"><FilterOption id="8713" count="14" label="Breast tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8714" count="13" label="Breast tumor - Assessment of Disease Free Survival (DFS)"/><FilterOption id="8489" count="13" label="Lung tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="9153" count="10" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="8744" count="9" label="Breast tumor - Assessment of Disease Progression"/><FilterOption id="8721" count="9" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="8505" count="9" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"/><FilterOption id="8719" count="8" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="7547" count="8" label="Lymphoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8523" count="7" label="Lung tumor - Assessment of Disease Progression"/><FilterOption id="8481" count="7" label="Lung tumor - Assessment of Overall Survival (OS)"/><FilterOption id="7045" count="7" label="Prostate tumor - Assessment of Overall Survival (OS)"/><FilterOption id="11542" count="7" label="Soft tissue sarcoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="6339" count="6" label="Crohns disease - Crohn's Disease Activity Assessed by Indices/Scores - Crohn's disease activity index (CDAI) score"/><FilterOption id="7360" count="6" label="Multiple myeloma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="12148" count="6" label="Stomach tumor - Assessment of Overall Survival (OS)"/><FilterOption id="11778" count="5" label="Bladder cancer - Assessment of Mortality/Death Rates"/><FilterOption id="11717" count="5" label="Bladder cancer - Assessment of Overall Survival (OS)"/><FilterOption id="8739" count="5" label="Breast tumor - Assessment of Disease Relapse/Recurrence"/><FilterOption id="8720" count="5" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="8163" count="5" label="Colorectal tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="2622" count="5" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"/><FilterOption id="6407" count="5" label="Crohns disease - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="8555" count="5" label="Lung tumor - Assessment of Mortality/Death Rates"/><FilterOption id="42974" count="5" label="Other gastrointestinal disease - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="10545" count="5" label="Renal cell carcinoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="11728" count="4" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)"/><FilterOption id="8754" count="4" label="Breast tumor - Assessment of Mortality/Death Rates"/><FilterOption id="8996" count="4" label="Breast tumor - Assessment of Safety and Tolerability"/><FilterOption id="8759" count="4" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="6451" count="4" label="Crohns disease - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="6318" count="4" label="Crohns disease - Assessment of Remission - Crohn's disease activity index (CDAI) score &lt; 150"/><FilterOption id="16634" count="4" label="Glaucoma - Assessment of ocular function - Assessment of intraocular pressure(IOP)"/><FilterOption id="9213" count="4" label="HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels"/><FilterOption id="23916" count="4" label="Hypercholesterolemia - Assessment of Low-Density Lipoprotein (LDL)"/><FilterOption id="7879" count="4" label="Leukemia - Assessment of Overall Survival (OS)"/><FilterOption id="3883" count="4" label="Rheumatoid arthritis - American College of Rheumatology (ACR) 20 Response"/><FilterOption id="2853" count="3" label="Acute coronary syndrome - Assessment of Cardiovascular Events"/><FilterOption id="2981" count="3" label="Acute coronary syndrome - Assessment of Mortality/Death Rates - Cardiovascular mortality"/><FilterOption id="11793" count="3" label="Bladder cancer - Assessment of Disease Progression"/><FilterOption id="8757" count="3" label="Breast tumor - Assessment of Mortality/Death Rates - Assessment of time to all cause mortality"/><FilterOption id="8730" count="3" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of histo-pathologic response"/><FilterOption id="8997" count="3" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of serious adverse events"/><FilterOption id="8998" count="3" label="Breast tumor - Assessment of adverse events"/><FilterOption id="8451" count="3" label="Colorectal tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="2492" count="3" label="Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)"/><FilterOption id="2774" count="3" label="Coronary artery disease - Assessment of hospitalization"/><FilterOption id="11950" count="3" label="Esophagus tumor - Assessment of Overall Survival (OS)"/><FilterOption id="6863" count="3" label="Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics"/><FilterOption id="2" count="3" label="Hypertension - Assessment of Blood Pressure (BP) - BP control rate"/><FilterOption id="23051" count="3" label="Lipid metabolism disorder - Assessment of Low-Density Lipoprotein (LDL)"/><FilterOption id="7563" count="3" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="11685" count="3" label="Neuroendocrine tumor - Assessment of Disease Progression"/><FilterOption id="11643" count="3" label="Neuroendocrine tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="11645" count="3" label="Neuroendocrine tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"/><FilterOption id="43393" count="3" label="Other gastrointestinal disease - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="13354" count="3" label="Pancreas tumor - Assessment of Disease Progression"/><FilterOption id="13357" count="3" label="Pancreas tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"/><FilterOption id="2859" count="2" label="Acute coronary syndrome - Assessment of Cardiovascular Events - Non fatal myocardial infarction"/><FilterOption id="2864" count="2" label="Acute coronary syndrome - Assessment of Cardiovascular Events - Unstable angina"/><FilterOption id="2980" count="2" label="Acute coronary syndrome - Assessment of Mortality/Death Rates"/><FilterOption id="2957" count="2" label="Acute coronary syndrome - Assessment of Reperfusion/Revascularization"/><FilterOption id="2871" count="2" label="Acute coronary syndrome - Assessment of Thrombotic/Thromboembolic Events - Non-fatal Stroke"/><FilterOption id="2952" count="2" label="Acute coronary syndrome - Assessment of hospitalization"/><FilterOption id="17316" count="2" label="Anemia - Assessment of Therapy Related Outcomes - Assessment of transfusion-independence"/><FilterOption id="9510" count="2" label="Atrial fibrillation - Assessment of Hemorrhagic Complications - Assessment of major bleeding events"/><FilterOption id="9519" count="2" label="Atrial fibrillation - Assessment of Thrombotic/Thromboembolic Events - Assessment of systemic thromboembolism"/><FilterOption id="11722" count="2" label="Bladder cancer - Assessment of Progression Free Survival (PFS)"/><FilterOption id="11730" count="2" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="11729" count="2" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="11773" count="2" label="Bladder cancer - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="11455" count="2" label="Bone tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="9122" count="2" label="Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="8722" count="2" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)"/><FilterOption id="8725" count="2" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"/><FilterOption id="9001" count="2" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of cardiac toxicity"/><FilterOption id="37161" count="2" label="Breast tumor - Assessment of Tumor Related Parameters"/><FilterOption id="9316" count="2" label="Breast tumor - Imaging/Radiological Assessments - Computed tomography (CT)/ PET scans"/><FilterOption id="9030" count="2" label="Breast tumor - Pharmacogenetic/Pharmacogenomics Analysis - Assessment of gene expression profile/signature"/><FilterOption id="45181" count="2" label="Cancer supportive care - Clinical Assessments"/><FilterOption id="19282" count="2" label="Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="19412" count="2" label="Cancer supportive care - Protocol Specified Other Endpoints - Assessment of Other Treatment or Procedure Related Outcomes"/><FilterOption id="2178" count="2" label="Cardiac failure - Assessment of Device Related Endpoints"/><FilterOption id="983" count="2" label="Cardiac failure - Assessment of Mortality/Death Rates - Other cardiovascular mortality"/><FilterOption id="8182" count="2" label="Colorectal tumor - Assessment of Disease Progression"/><FilterOption id="45714" count="2" label="Colorectal tumor - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="8151" count="2" label="Colorectal tumor - Assessment of Overall Survival (OS)"/><FilterOption id="8166" count="2" label="Colorectal tumor - Assessment of Progression Free Survival (PFS) - Assessment of progression free survival at 6 months"/><FilterOption id="8187" count="2" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)"/><FilterOption id="9371" count="2" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of clinical/pathological response"/><FilterOption id="8436" count="2" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"/><FilterOption id="8453" count="2" label="Colorectal tumor - Assessment of Therapy Related Outcomes - Efficacy/feasibility Assessment"/><FilterOption id="10165" count="2" label="Colorectal tumor - Imaging/Radiological Assessments"/><FilterOption id="2609" count="2" label="Coronary artery disease - Assessment of Other Cardiovascular Events"/><FilterOption id="2749" count="2" label="Coronary artery disease - Assessment of Therapy Related Outcomes - Efficacy/feasibility Assessment"/><FilterOption id="6320" count="2" label="Crohns disease - Assessment of Remission - Proportion of patients achieving clinical remission"/><FilterOption id="6433" count="2" label="Crohns disease - Assessment of use of Rescue Medication"/><FilterOption id="22539" count="2" label="End stage renal disease - Assessment of Cardiac Function"/><FilterOption id="22587" count="2" label="End stage renal disease - Assessment of Disease Progression"/><FilterOption id="22543" count="2" label="End stage renal disease - Assessment of lipid profiles"/></Filter><Filter label="Sponsors/Collaborators" name="trialCompanies" total="100"><FilterOption id="19446" count="67" label="Roche Holding AG"/><FilterOption id="26178" count="47" label="F Hoffmann-La Roche AG"/><FilterOption id="15331" count="37" label="Celgene Corp"/><FilterOption id="18767" count="37" label="Pfizer Inc"/><FilterOption id="15414" count="20" label="Chugai Pharmaceutical Co Ltd"/><FilterOption id="1042061" count="15" label="Spanish Breast Cancer Research Group"/><FilterOption id="14881" count="14" label="Boehringer Ingelheim International GmbH"/><FilterOption id="17810" count="11" label="Eli Lilly &amp; Co"/><FilterOption id="1045582" count="11" label="Grupo Espanol de Investigacion en Sarcomas"/><FilterOption id="19453" count="10" label="Genentech Inc"/><FilterOption id="1038736" count="10" label="PETHEMA Foundation"/><FilterOption id="1042371" count="10" label="Spanish Oncology Genito-Urinary Group"/><FilterOption id="14109" count="9" label="Amgen Inc"/><FilterOption id="14190" count="9" label="AstraZeneca plc"/><FilterOption id="15065" count="8" label="Bristol-Myers Squibb Co"/><FilterOption id="17259" count="8" label="Ipsen"/><FilterOption id="1154033" count="7" label="Aragonese Institute of Health Sciences"/><FilterOption id="1056053" count="7" label="Celgene International Sarl"/><FilterOption id="1043659" count="7" label="Grupo Espanol Multidisciplinario del Cancer Digestivo"/><FilterOption id="1059410" count="7" label="Grupo Espanol de Tumores Neuroendocrinos"/><FilterOption id="1090417" count="7" label="Roche Singapore Pte Ltd"/><FilterOption id="1013295" count="6" label="Astellas Pharma Inc"/><FilterOption id="22546" count="6" label="Boehringer Ingelheim GmbH"/><FilterOption id="1045513" count="6" label="Spanish Lung Cancer Group"/><FilterOption id="1061163" count="5" label="Abbott Vascular"/><FilterOption id="1065900" count="5" label="Apices Soluciones, S.L."/><FilterOption id="1103352" count="5" label="Boehringer Ingelheim Espana Sa"/><FilterOption id="1042255" count="5" label="Breast International Group"/><FilterOption id="28355" count="5" label="GlaxoSmithKline plc"/><FilterOption id="19461" count="5" label="Hoffmann-La Roche Inc"/><FilterOption id="1034433" count="5" label="Hospital Miguel Servet"/><FilterOption id="1033112" count="5" label="Hospital Universitario 12 de Octubre"/><FilterOption id="1084801" count="5" label="Medica Scientia Innovation Research"/><FilterOption id="1059823" count="5" label="Merck Sharp &amp; Dohme Corp"/><FilterOption id="1072507" count="4" label="AbbVie Inc"/><FilterOption id="23780" count="4" label="Actelion Ltd"/><FilterOption id="1088700" count="4" label="Allergan plc"/><FilterOption id="22545" count="4" label="Boehringer Ingelheim AB"/><FilterOption id="1017946" count="4" label="Centro Nacional de Investigaciones Oncologicas"/><FilterOption id="14913" count="4" label="Eisai Ltd"/><FilterOption id="1039086" count="4" label="Germans Trias i Pujol Hospital"/><FilterOption id="1045910" count="4" label="Hospital Clinico San Carlos"/><FilterOption id="18101" count="4" label="Merck KGaA"/><FilterOption id="1082374" count="4" label="ROCHE Espana"/><FilterOption id="24652" count="4" label="Shire plc"/><FilterOption id="20300" count="4" label="Takeda Pharmaceutical Co Ltd"/><FilterOption id="13601" count="3" label="Abbott Laboratories"/><FilterOption id="19864" count="3" label="Adir &amp; Co"/><FilterOption id="14042" count="3" label="Allergan Inc"/><FilterOption id="14455" count="3" label="Bayer AG"/><FilterOption id="1063251" count="3" label="BeiGene Co Ltd"/><FilterOption id="22555" count="3" label="Boehringer Ingelheim Ellas AE"/><FilterOption id="22560" count="3" label="Boehringer Ingelheim Italia SpA"/><FilterOption id="27847" count="3" label="Boston Scientific Corp"/><FilterOption id="1067616" count="3" label="Clinica Universidad de Navarra"/><FilterOption id="1091345" count="3" label="Complejo Hospitalario de Navarra"/><FilterOption id="1017506" count="3" label="Daiichi Sankyo Co Ltd"/><FilterOption id="1020322" count="3" label="Daiichi Sankyo Inc"/><FilterOption id="19620" count="3" label="Eisai Inc"/><FilterOption id="23119" count="3" label="European Organisation for Research and Treatment of Cancer (EORTC)"/><FilterOption id="1052299" count="3" label="Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla"/><FilterOption id="16450" count="3" label="Gilead Sciences Inc"/><FilterOption id="1089015" count="3" label="Grupo Espanol Multidisciplinar de Melanoma"/><FilterOption id="1042252" count="3" label="Grupo Espanol de Linfomas y Transplante Autologo de Medula Osea"/><FilterOption id="1047068" count="3" label="Grupo Español de Tratamiento de Tumores de Cabeza y Cuello"/><FilterOption id="1072647" count="3" label="Institut de Recherches Internationales Servier (France)"/><FilterOption id="1017818" count="3" label="Instituto de Salud Carlos III"/><FilterOption id="1067538" count="3" label="Janssen Research &amp; Development LLC"/><FilterOption id="1091809" count="3" label="Janssen-Cilag International NV (BE)"/><FilterOption id="1057369" count="3" label="La Paz University Hospital (Madrid)"/><FilterOption id="1020988" count="3" label="NSABP Foundation Inc"/><FilterOption id="1065375" count="3" label="Puma Biotechnology Inc"/><FilterOption id="1091820" count="3" label="Roche China Co Ltd"/><FilterOption id="26327" count="3" label="Roche Diagnostics GmbH"/><FilterOption id="1109598" count="3" label="Roche Products India Pvt Ltd"/><FilterOption id="1063946" count="3" label="Syneos Health Inc"/><FilterOption id="1114403" count="3" label="TFS Trial Form Support"/><FilterOption id="22598" count="3" label="Unilfarma Lda"/><FilterOption id="28611" count="2" label="Actelion Pharmaceuticals Ltd"/><FilterOption id="1144031" count="2" label="Allergan Limited"/><FilterOption id="1090105" count="2" label="Allergan Singapore PTE Ltd"/><FilterOption id="1097931" count="2" label="Andalusian Initiative for Advanced Therapies"/><FilterOption id="25902" count="2" label="Array BioPharma Inc"/><FilterOption id="20972" count="2" label="Astellas Pharma Europe Ltd"/><FilterOption id="1052569" count="2" label="B Braun Surgical Sa"/><FilterOption id="22549" count="2" label="Boehringer Ingelheim Austria GmbH"/><FilterOption id="22554" count="2" label="Boehringer Ingelheim BV"/><FilterOption id="22556" count="2" label="Boehringer Ingelheim France SARL"/><FilterOption id="22563" count="2" label="Boehringer Ingelheim Ltd"/><FilterOption id="1038949" count="2" label="Boston Biomedical Inc"/><FilterOption id="15141" count="2" label="Bristol-Myers Squibb (Singapore) Pte Ltd"/><FilterOption id="1050177" count="2" label="Fondazione Michelangelo"/><FilterOption id="1046331" count="2" label="Fundacion SEIMC-GESIDA"/><FilterOption id="1075419" count="2" label="Fundació Althaia"/><FilterOption id="1079783" count="2" label="FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU"/><FilterOption id="1161122" count="2" label="Fundación EPIC"/><FilterOption id="27741" count="2" label="Galapagos NV"/><FilterOption id="1064355" count="2" label="Grupo Espanol de Investigacion del Cancer de Mama"/><FilterOption id="1056260" count="2" label="Grupo Espanol de Investigacion en Cancer de Ovario"/><FilterOption id="1053468" count="2" label="Grupo Español de Investigación en Neurooncología"/></Filter><Filter label="Last Changed Date By Day" name="trialDateChangeLastByDay" total="100"><FilterOption count="16" label="2019-01-24"/><FilterOption count="13" label="2019-07-02"/><FilterOption count="11" label="2018-10-15"/><FilterOption count="11" label="2019-06-28"/><FilterOption count="9" label="2019-07-01"/><FilterOption count="8" label="2019-01-25"/><FilterOption count="8" label="2019-03-07"/><FilterOption count="8" label="2019-06-12"/><FilterOption count="8" label="2019-06-20"/><FilterOption count="7" label="2019-06-27"/><FilterOption count="7" label="2019-07-03"/><FilterOption count="6" label="2019-01-26"/><FilterOption count="6" label="2019-06-06"/><FilterOption count="6" label="2019-06-07"/><FilterOption count="6" label="2019-06-14"/><FilterOption count="6" label="2019-06-19"/><FilterOption count="5" label="2018-10-12"/><FilterOption count="5" label="2018-10-14"/><FilterOption count="5" label="2019-04-05"/><FilterOption count="5" label="2019-06-10"/><FilterOption count="5" label="2019-06-17"/><FilterOption count="5" label="2019-06-18"/><FilterOption count="5" label="2019-06-24"/><FilterOption count="5" label="2019-06-26"/><FilterOption count="4" label="2018-10-13"/><FilterOption count="4" label="2018-10-16"/><FilterOption count="4" label="2019-02-21"/><FilterOption count="4" label="2019-04-02"/><FilterOption count="4" label="2019-04-09"/><FilterOption count="4" label="2019-05-17"/><FilterOption count="4" label="2019-06-05"/><FilterOption count="3" label="2013-12-02"/><FilterOption count="3" label="2018-04-25"/><FilterOption count="3" label="2018-12-05"/><FilterOption count="3" label="2018-12-17"/><FilterOption count="3" label="2019-03-21"/><FilterOption count="3" label="2019-04-06"/><FilterOption count="3" label="2019-04-23"/><FilterOption count="3" label="2019-05-02"/><FilterOption count="3" label="2019-05-23"/><FilterOption count="3" label="2019-05-27"/><FilterOption count="3" label="2019-05-31"/><FilterOption count="3" label="2019-06-03"/><FilterOption count="3" label="2019-06-04"/><FilterOption count="3" label="2019-06-13"/><FilterOption count="2" label="2013-09-13"/><FilterOption count="2" label="2013-09-14"/><FilterOption count="2" label="2017-04-17"/><FilterOption count="2" label="2017-06-19"/><FilterOption count="2" label="2017-09-07"/><FilterOption count="2" label="2018-02-01"/><FilterOption count="2" label="2018-03-01"/><FilterOption count="2" label="2018-03-07"/><FilterOption count="2" label="2018-05-19"/><FilterOption count="2" label="2018-05-29"/><FilterOption count="2" label="2018-06-23"/><FilterOption count="2" label="2018-06-28"/><FilterOption count="2" label="2018-07-06"/><FilterOption count="2" label="2018-10-23"/><FilterOption count="2" label="2018-11-17"/><FilterOption count="2" label="2018-11-26"/><FilterOption count="2" label="2018-11-28"/><FilterOption count="2" label="2018-11-29"/><FilterOption count="2" label="2018-12-01"/><FilterOption count="2" label="2018-12-14"/><FilterOption count="2" label="2018-12-20"/><FilterOption count="2" label="2019-01-08"/><FilterOption count="2" label="2019-01-19"/><FilterOption count="2" label="2019-02-02"/><FilterOption count="2" label="2019-02-08"/><FilterOption count="2" label="2019-02-22"/><FilterOption count="2" label="2019-03-14"/><FilterOption count="2" label="2019-03-26"/><FilterOption count="2" label="2019-03-30"/><FilterOption count="2" label="2019-04-12"/><FilterOption count="2" label="2019-04-18"/><FilterOption count="2" label="2019-04-26"/><FilterOption count="2" label="2019-05-07"/><FilterOption count="2" label="2019-05-09"/><FilterOption count="2" label="2019-05-10"/><FilterOption count="2" label="2019-05-14"/><FilterOption count="2" label="2019-05-24"/><FilterOption count="2" label="2019-05-28"/><FilterOption count="2" label="2019-06-22"/><FilterOption count="2" label="2019-06-25"/><FilterOption count="1" label="2012-11-22"/><FilterOption count="1" label="2013-11-22"/><FilterOption count="1" label="2013-11-28"/><FilterOption count="1" label="2014-01-22"/><FilterOption count="1" label="2014-02-21"/><FilterOption count="1" label="2014-03-25"/><FilterOption count="1" label="2015-10-28"/><FilterOption count="1" label="2016-02-08"/><FilterOption count="1" label="2016-04-22"/><FilterOption count="1" label="2016-06-15"/><FilterOption count="1" label="2016-06-28"/><FilterOption count="1" label="2016-11-29"/><FilterOption count="1" label="2017-02-02"/><FilterOption count="1" label="2017-02-13"/><FilterOption count="1" label="2017-02-15"/></Filter><Filter label="Trial Date End By Month" name="trialDateEndByMonth" total="100"><FilterOption count="12" label="201912"/><FilterOption count="8" label="201712"/><FilterOption count="8" label="202109"/><FilterOption count="8" label="202112"/><FilterOption count="7" label="201804"/><FilterOption count="7" label="201811"/><FilterOption count="7" label="201812"/><FilterOption count="7" label="201911"/><FilterOption count="7" label="202002"/><FilterOption count="7" label="202007"/><FilterOption count="6" label="201212"/><FilterOption count="6" label="201604"/><FilterOption count="6" label="201908"/><FilterOption count="6" label="201910"/><FilterOption count="6" label="202001"/><FilterOption count="6" label="202009"/><FilterOption count="6" label="202011"/><FilterOption count="5" label="201512"/><FilterOption count="5" label="201803"/><FilterOption count="5" label="201810"/><FilterOption count="5" label="201905"/><FilterOption count="5" label="201906"/><FilterOption count="5" label="201909"/><FilterOption count="5" label="202003"/><FilterOption count="5" label="202012"/><FilterOption count="5" label="202206"/><FilterOption count="5" label="202209"/><FilterOption count="5" label="202210"/><FilterOption count="4" label="200910"/><FilterOption count="4" label="201002"/><FilterOption count="4" label="201401"/><FilterOption count="4" label="201505"/><FilterOption count="4" label="201601"/><FilterOption count="4" label="201607"/><FilterOption count="4" label="201704"/><FilterOption count="4" label="201801"/><FilterOption count="4" label="202105"/><FilterOption count="4" label="202301"/><FilterOption count="3" label="201207"/><FilterOption count="3" label="201309"/><FilterOption count="3" label="201312"/><FilterOption count="3" label="201409"/><FilterOption count="3" label="201412"/><FilterOption count="3" label="201502"/><FilterOption count="3" label="201506"/><FilterOption count="3" label="201602"/><FilterOption count="3" label="201605"/><FilterOption count="3" label="201609"/><FilterOption count="3" label="201611"/><FilterOption count="3" label="201702"/><FilterOption count="3" label="201703"/><FilterOption count="3" label="201705"/><FilterOption count="3" label="201806"/><FilterOption count="3" label="201808"/><FilterOption count="3" label="201901"/><FilterOption count="3" label="201907"/><FilterOption count="3" label="202005"/><FilterOption count="3" label="202006"/><FilterOption count="3" label="202010"/><FilterOption count="3" label="202205"/><FilterOption count="3" label="202212"/><FilterOption count="3" label="202304"/><FilterOption count="3" label="202312"/><FilterOption count="2" label="200611"/><FilterOption count="2" label="200712"/><FilterOption count="2" label="200807"/><FilterOption count="2" label="200812"/><FilterOption count="2" label="200906"/><FilterOption count="2" label="200912"/><FilterOption count="2" label="201108"/><FilterOption count="2" label="201112"/><FilterOption count="2" label="201209"/><FilterOption count="2" label="201302"/><FilterOption count="2" label="201410"/><FilterOption count="2" label="201501"/><FilterOption count="2" label="201504"/><FilterOption count="2" label="201507"/><FilterOption count="2" label="201511"/><FilterOption count="2" label="201610"/><FilterOption count="2" label="201612"/><FilterOption count="2" label="201706"/><FilterOption count="2" label="201707"/><FilterOption count="2" label="201708"/><FilterOption count="2" label="201709"/><FilterOption count="2" label="201710"/><FilterOption count="2" label="201805"/><FilterOption count="2" label="201807"/><FilterOption count="2" label="202004"/><FilterOption count="2" label="202008"/><FilterOption count="2" label="202101"/><FilterOption count="2" label="202107"/><FilterOption count="2" label="202108"/><FilterOption count="2" label="202111"/><FilterOption count="2" label="202201"/><FilterOption count="2" label="202203"/><FilterOption count="2" label="202204"/><FilterOption count="2" label="202208"/><FilterOption count="2" label="202307"/><FilterOption count="2" label="202404"/><FilterOption count="1" label="200001"/></Filter><Filter label="Trial Date Start By Month" name="trialDateStartByMonth" total="100"><FilterOption count="8" label="201810"/><FilterOption count="7" label="201304"/><FilterOption count="7" label="201606"/><FilterOption count="7" label="201703"/><FilterOption count="7" label="201707"/><FilterOption count="7" label="201803"/><FilterOption count="7" label="201806"/><FilterOption count="6" label="200707"/><FilterOption count="6" label="201001"/><FilterOption count="6" label="201405"/><FilterOption count="6" label="201501"/><FilterOption count="6" label="201506"/><FilterOption count="6" label="201510"/><FilterOption count="6" label="201612"/><FilterOption count="6" label="201709"/><FilterOption count="6" label="201904"/><FilterOption count="5" label="201111"/><FilterOption count="5" label="201112"/><FilterOption count="5" label="201312"/><FilterOption count="5" label="201401"/><FilterOption count="5" label="201407"/><FilterOption count="5" label="201602"/><FilterOption count="5" label="201604"/><FilterOption count="5" label="201701"/><FilterOption count="5" label="201704"/><FilterOption count="5" label="201706"/><FilterOption count="4" label="200912"/><FilterOption count="4" label="201102"/><FilterOption count="4" label="201201"/><FilterOption count="4" label="201303"/><FilterOption count="4" label="201310"/><FilterOption count="4" label="201408"/><FilterOption count="4" label="201410"/><FilterOption count="4" label="201411"/><FilterOption count="4" label="201504"/><FilterOption count="4" label="201511"/><FilterOption count="4" label="201611"/><FilterOption count="4" label="201705"/><FilterOption count="4" label="201710"/><FilterOption count="4" label="201711"/><FilterOption count="4" label="201804"/><FilterOption count="4" label="201805"/><FilterOption count="4" label="201809"/><FilterOption count="4" label="201812"/><FilterOption count="3" label="200708"/><FilterOption count="3" label="200711"/><FilterOption count="3" label="200810"/><FilterOption count="3" label="200901"/><FilterOption count="3" label="200904"/><FilterOption count="3" label="200910"/><FilterOption count="3" label="201003"/><FilterOption count="3" label="201004"/><FilterOption count="3" label="201010"/><FilterOption count="3" label="201101"/><FilterOption count="3" label="201103"/><FilterOption count="3" label="201110"/><FilterOption count="3" label="201202"/><FilterOption count="3" label="201211"/><FilterOption count="3" label="201301"/><FilterOption count="3" label="201309"/><FilterOption count="3" label="201403"/><FilterOption count="3" label="201406"/><FilterOption count="3" label="201412"/><FilterOption count="3" label="201505"/><FilterOption count="3" label="201507"/><FilterOption count="3" label="201512"/><FilterOption count="3" label="201607"/><FilterOption count="3" label="201708"/><FilterOption count="3" label="201712"/><FilterOption count="3" label="201807"/><FilterOption count="3" label="201808"/><FilterOption count="3" label="201902"/><FilterOption count="2" label="200411"/><FilterOption count="2" label="200503"/><FilterOption count="2" label="200509"/><FilterOption count="2" label="200510"/><FilterOption count="2" label="200603"/><FilterOption count="2" label="200702"/><FilterOption count="2" label="200705"/><FilterOption count="2" label="200706"/><FilterOption count="2" label="200802"/><FilterOption count="2" label="200804"/><FilterOption count="2" label="200805"/><FilterOption count="2" label="200806"/><FilterOption count="2" label="200807"/><FilterOption count="2" label="200809"/><FilterOption count="2" label="200902"/><FilterOption count="2" label="200903"/><FilterOption count="2" label="200907"/><FilterOption count="2" label="200909"/><FilterOption count="2" label="200911"/><FilterOption count="2" label="201005"/><FilterOption count="2" label="201006"/><FilterOption count="2" label="201007"/><FilterOption count="2" label="201011"/><FilterOption count="2" label="201012"/><FilterOption count="2" label="201105"/><FilterOption count="2" label="201106"/><FilterOption count="2" label="201109"/><FilterOption count="2" label="201204"/></Filter><Filter label="Trial Phase" name="trialPhase" total="13"><FilterOption id="C3" count="187" label="Phase 3 Clinical"/><FilterOption id="C2" count="100" label="Phase 2 Clinical"/><FilterOption id="C4" count="54" label="Phase 4 Clinical"/><FilterOption id="PNA" count="53" label="Phase Not Applicable"/><FilterOption id="C12" count="15" label="Phase 1/Phase 2 Clinical"/><FilterOption id="NS" count="14" label="Phase not specified"/><FilterOption id="C23" count="11" label="Phase 2/Phase 3 Clinical"/><FilterOption id="C3B" count="10" label="Phase 3b Clinical"/><FilterOption id="C2B" count="8" label="Phase 2b Clinical"/><FilterOption id="C1" count="3" label="Phase 1 Clinical"/><FilterOption id="C1A" count="1" label="Phase 1a Clinical"/><FilterOption id="C1B" count="1" label="Phase 1b Clinical"/><FilterOption id="C2A" count="1" label="Phase 2a Clinical"/></Filter><Filter label="Inclusion Criteria Index" name="trialInclusionCriteriaIndex" total="100"><FilterOption id="4879" count="39" label="Breast tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="4880" count="39" label="Breast tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="3976" count="28" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="3977" count="28" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="3957" count="27" label="Lung tumor - Subjects Confirmed of Lung Cancer by Specific Modes - Subjects with cytologically/histologically confirmed diagnosis of lung cancer"/><FilterOption id="22417" count="26" label="Breast tumor - Subjects with Locally Advanced Cancer/Tumor"/><FilterOption id="4840" count="24" label="Breast tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="4814" count="24" label="Breast tumor - Subjects with HER-2 Negative Breast Cancer"/><FilterOption id="3900" count="24" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)"/><FilterOption id="4527" count="21" label="Colorectal tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="4528" count="21" label="Colorectal tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="3936" count="21" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage IV lung cancer"/><FilterOption id="4808" count="18" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer"/><FilterOption id="4928" count="18" label="Breast tumor - Subjects with Protocol Specified Compliance Status - Subjects able to comply with the study protocol procedures/ requirements"/><FilterOption id="4483" count="18" label="Colorectal tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="4813" count="17" label="Breast tumor - Subjects with HER-2 Positive Breast Cancer"/><FilterOption id="4877" count="17" label="Breast tumor - Subjects with Protocol Specified Life Expectancy"/><FilterOption id="3914" count="17" label="Lung tumor - Subjects with Measurable Disease - Subjects with measurable disease as per RECIST criteria"/><FilterOption id="4041" count="17" label="Lung tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"/><FilterOption id="4817" count="16" label="Breast tumor - Postmenopausal Breast Cancer Women"/><FilterOption id="4894" count="16" label="Breast tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer chemotherapy"/><FilterOption id="4864" count="16" label="Breast tumor - Subjects with Normal/Acceptable Organ Function - Subjects with acceptable hematological test values"/><FilterOption id="4024" count="16" label="Lung tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"/><FilterOption id="4032" count="16" label="Lung tumor - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="4955" count="15" label="Breast tumor - Subjects with Protocol Specified Participation Status - Subjects willing/able to provide informed consent/assent"/><FilterOption id="22418" count="14" label="Breast tumor - Subjects with Early Breast Cancer"/><FilterOption id="4866" count="14" label="Breast tumor - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="22381" count="14" label="Lung tumor - Protocol Specified Other Inclusion Criteria - Protocol specified inclusion criteria for females"/><FilterOption id="4809" count="13" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Progesterone receptor positive (PR+) breast cancer"/><FilterOption id="4857" count="13" label="Breast tumor - Subjects with Measurable Disease - Subjects with measurable disease as per RECIST criteria"/><FilterOption id="4865" count="13" label="Breast tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"/><FilterOption id="3940" count="13" label="Lung tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="3978" count="13" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"/><FilterOption id="3537" count="13" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="3538" count="13" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="4870" count="12" label="Breast tumor - Subjects with History/Scheduled for Surgery/Intervention"/><FilterOption id="3989" count="12" label="Lung tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer chemotherapy"/><FilterOption id="3539" count="12" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"/><FilterOption id="7091" count="12" label="Prostate tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="7441" count="11" label="Bladder cancer - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="4922" count="11" label="Breast tumor - Subjects with Progressive/Treatment Refractory Disease"/><FilterOption id="4545" count="11" label="Colorectal tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer chemotherapy"/><FilterOption id="4569" count="11" label="Colorectal tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematopoetic/marrow function"/><FilterOption id="4564" count="11" label="Colorectal tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"/><FilterOption id="4529" count="11" label="Colorectal tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"/><FilterOption id="4565" count="11" label="Colorectal tumor - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="3938" count="11" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with advanced stage lung cancer"/><FilterOption id="8817" count="11" label="Pancreas tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="3738" count="11" label="Prostate tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod status 0-2"/><FilterOption id="7227" count="11" label="Soft tissue sarcoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="7228" count="11" label="Soft tissue sarcoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="7440" count="10" label="Bladder cancer - Subjects with Locally Advanced Cancer/Tumor"/><FilterOption id="22362" count="10" label="Bladder cancer - Subjects with Urothelial Cell/Transitional Cell Bladder Cancer"/><FilterOption id="4856" count="10" label="Breast tumor - Subjects with Measurable Disease"/><FilterOption id="4957" count="10" label="Breast tumor - Subjects with Protocol Specified Reproductive Status - Subjects with adequate contraception"/><FilterOption id="4824" count="10" label="Breast tumor - TNM Stage II Breast Cancer"/><FilterOption id="4827" count="10" label="Breast tumor - TNM Stage III Breast Cancer"/><FilterOption id="4578" count="10" label="Colorectal tumor - Subjects with Protocol Specified Participation Status - Subjects able/willing to provide written informed consent"/><FilterOption id="3162" count="10" label="Crohns disease - Subjects with Active Crohn's Disease"/><FilterOption id="5086" count="10" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="5087" count="10" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="4098" count="10" label="Lung tumor - Protocol Specified Other Inclusion Criteria - Subjects recovered from all prior therapies and/or their toxic/adverse effects"/><FilterOption id="4073" count="10" label="Lung tumor - Protocol Specified Other Inclusion Criteria"/><FilterOption id="32043" count="10" label="Lung tumor - Subjects with Protocol Specified Participation Status - Subjects able/willing to provide written informed consent"/><FilterOption id="3935" count="10" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage IIIB lung cancer"/><FilterOption id="3987" count="10" label="Lung tumor - Treatment Naive Subjects"/><FilterOption id="4691" count="10" label="Multiple myeloma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="4692" count="10" label="Multiple myeloma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="8835" count="10" label="Pancreas tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="8836" count="10" label="Pancreas tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="7204" count="10" label="Soft tissue sarcoma - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="7464" count="9" label="Bladder cancer - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="7465" count="9" label="Bladder cancer - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="7450" count="9" label="Bladder cancer - Subjects with Unresectable Bladder Cancer"/><FilterOption id="4943" count="9" label="Breast tumor - Subjects with Protocol Specified Reproductive Status - Negative pregnancy test"/><FilterOption id="4815" count="9" label="Breast tumor - Subjects with Triple Negative Breast Cancer"/><FilterOption id="22416" count="9" label="Breast tumor - Subjects with Unresectable Breast Cancer"/><FilterOption id="4828" count="9" label="Breast tumor - TNM Stage III Breast Cancer - TNM stage IIIA Breast Cancer"/><FilterOption id="4509" count="9" label="Colorectal tumor - Subjects with Histologically Confirmed Colorectal Cancer"/><FilterOption id="4467" count="9" label="Colorectal tumor - Subjects with Rectal Cancer"/><FilterOption id="5088" count="9" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"/><FilterOption id="4074" count="9" label="Lung tumor - Subjects with Protocol Specified Compliance Status - Subjects able to comply with the study protocol procedures/ requirements"/><FilterOption id="4106" count="9" label="Lung tumor - Subjects with Protocol Specified Reproductive Status - Men with adequate contraception"/><FilterOption id="3933" count="9" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage III lung cancer"/><FilterOption id="22393" count="8" label="Breast tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of targeted therapy for breast cancer"/><FilterOption id="4471" count="8" label="Colorectal tumor - Subjects with Measurable Disease - Subjects with measurable disease as per modified RECIST Criteria"/><FilterOption id="4592" count="8" label="Colorectal tumor - Subjects with Protocol Specified Reproductive Status - Women with adequate contraception/Negative pregnancy test/Non-lactating women"/><FilterOption id="4345" count="8" label="Crohns disease - Subjects with Moderate to Severe Crohn's Disease"/><FilterOption id="4104" count="8" label="Lung tumor - Protocol Specified Other Inclusion Criteria - Subjects with tumor tissue/blood sample available for analysis/further assessment"/><FilterOption id="4676" count="8" label="Multiple myeloma - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="7485" count="7" label="Bladder cancer - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"/><FilterOption id="4816" count="7" label="Breast tumor - Premenopausal Breast Cancer Women"/><FilterOption id="22398" count="7" label="Breast tumor - Subjects with Resectable Tumor"/><FilterOption id="4468" count="7" label="Colorectal tumor - Subjects with Colon Cancer"/><FilterOption id="4470" count="7" label="Colorectal tumor - Subjects with Measurable Disease"/><FilterOption id="4579" count="7" label="Colorectal tumor - Subjects with Protocol Specified Compliance Status - Subjects able to comply with the study protocol procedures/ requirements"/><FilterOption id="3548" count="7" label="Lymphoma - Subjects Diagnosed Based on Histo-Pathological Examination"/><FilterOption id="7334" count="7" label="Neuroendocrine tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="4893" count="6" label="Breast tumor - Subjects with History of Anti Cancer Therapy"/><FilterOption id="22399" count="6" label="Breast tumor - Subjects with Invasive Breast Cancer"/></Filter><Filter label="Trial Interventions Control Alone Name Display" name="trialInterventionsControlAloneNameDisplay" total="54"><FilterOption id="2953" count="6" label="docetaxel"/><FilterOption id="3803" count="6" label="paclitaxel"/><FilterOption id="3313" count="5" label="fulvestrant"/><FilterOption id="2784" count="4" label="letrozole"/><FilterOption id="3199" count="3" label="gemcitabine"/><FilterOption id="2871" count="3" label="irinotecan"/><FilterOption id="22395" count="3" label="ranibizumab"/><FilterOption id="29831" count="3" label="sorafenib"/><FilterOption id="4577" count="3" label="topotecan"/><FilterOption id="3321" count="2" label="anastrozole"/><FilterOption id="55798" count="2" label="crizotinib"/><FilterOption id="13239" count="2" label="decitabine"/><FilterOption id="7934" count="2" label="doxorubicin (liposomal, STEALTH), Alza"/><FilterOption id="7456" count="2" label="imiglucerase"/><FilterOption id="13460" count="2" label="oseltamivir"/><FilterOption id="8747" count="2" label="palivizumab"/><FilterOption id="70667" count="2" label="pembrolizumab"/><FilterOption id="44315" count="2" label="timolol"/><FilterOption id="14163" count="1" label="adalimumab"/><FilterOption id="53547" count="1" label="aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer"/><FilterOption id="72699" count="1" label="atezolizumab"/><FilterOption id="2807" count="1" label="atorvastatin"/><FilterOption id="37370" count="1" label="azacitidine"/><FilterOption id="47000" count="1" label="bendamustine"/><FilterOption id="8047" count="1" label="bevacizumab"/><FilterOption id="55126" count="1" label="bimatoprost + timolol (ophthalmic, glaucoma), Allergan"/><FilterOption id="12205" count="1" label="capecitabine"/><FilterOption id="2992" count="1" label="donepezil hydrochloride"/><FilterOption id="13928" count="1" label="enoxaparin sodium"/><FilterOption id="53981" count="1" label="enzalutamide"/><FilterOption id="11961" count="1" label="erlotinib"/><FilterOption id="4567" count="1" label="etanercept"/><FilterOption id="11603" count="1" label="gefitinib"/><FilterOption id="8832" count="1" label="glimepiride"/><FilterOption id="6850" count="1" label="infliximab"/><FilterOption id="10411" count="1" label="insulin aspart"/><FilterOption id="10252" count="1" label="insulin glargine"/><FilterOption id="3353" count="1" label="insulin lispro"/><FilterOption id="3360" count="1" label="interferon beta-1a, Biogen"/><FilterOption id="64783" count="1" label="mesalazine (oral delayed-release, ulcerative colitis), Tillotts/Allergan"/><FilterOption id="10634" count="1" label="milrinone"/><FilterOption id="3669" count="1" label="mycophenolate mofetil"/><FilterOption id="29016" count="1" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="3536" count="1" label="pemetrexed disodium"/><FilterOption id="54624" count="1" label="regorafenib"/><FilterOption id="55759" count="1" label="somatropin, Pfizer"/><FilterOption id="12973" count="1" label="sunitinib"/><FilterOption id="49219" count="1" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"/><FilterOption id="8050" count="1" label="thalidomide, Celgene"/><FilterOption id="6386" count="1" label="trastuzumab"/><FilterOption id="23239" count="1" label="ulipristal"/><FilterOption id="54469" count="1" label="vemurafenib"/><FilterOption id="15130" count="1" label="vinflunine"/><FilterOption id="8424" count="1" label="zanamivir"/></Filter><Filter label="Trial Actions Primary Interventions Control" name="trialActionsPrimaryInterventionsControl" total="100"><FilterOption id="372" count="17" label="Thymidylate synthase inhibitor"/><FilterOption id="142" count="11" label="Topoisomerase II inhibitor"/><FilterOption id="3756" count="10" label="Erbb2 tyrosine kinase receptor inhibitor"/><FilterOption id="3846" count="10" label="VEGF-1 receptor antagonist"/><FilterOption id="3848" count="10" label="VEGF-2 receptor antagonist"/><FilterOption id="374" count="8" label="Transferase inhibitor"/><FilterOption id="12521" count="8" label="VEGF ligand inhibitor"/><FilterOption id="135" count="7" label="DHFR inhibitor"/><FilterOption id="181" count="7" label="GAR transformylase inhibitor"/><FilterOption id="3808" count="7" label="Kit tyrosine kinase inhibitor"/><FilterOption id="3850" count="7" label="VEGF-3 receptor antagonist"/><FilterOption id="76" count="6" label="Aromatase inhibitor"/><FilterOption id="740" count="6" label="Epidermal growth factor receptor antagonist"/><FilterOption id="286" count="6" label="Estrogen receptor antagonist"/><FilterOption id="48492" count="6" label="PDGF receptor beta antagonist"/><FilterOption id="3816" count="6" label="RET tyrosine kinase receptor family inhibitor"/><FilterOption id="141" count="6" label="Topoisomerase I inhibitor"/><FilterOption id="1722" count="6" label="VEGF receptor antagonist"/><FilterOption id="5085" count="5" label="B-lymphocyte antigen CD20 inhibitor"/><FilterOption id="82444" count="5" label="DNA helicase inhibitor"/><FilterOption id="3806" count="5" label="Flt3 tyrosine kinase inhibitor"/><FilterOption id="4548" count="5" label="Raf B protein kinase inhibitor"/><FilterOption id="4550" count="4" label="Raf 1 protein kinase inhibitor"/><FilterOption id="721" count="4" label="TNF binding agent"/><FilterOption id="814" count="4" label="Tubulin modulator"/><FilterOption id="38" count="3" label="Beta adrenoceptor antagonist"/><FilterOption id="138" count="3" label="DNA polymerase inhibitor"/><FilterOption id="204" count="3" label="HIV protease inhibitor"/><FilterOption id="1016" count="3" label="HIV-1 reverse transcriptase inhibitor"/><FilterOption id="23014" count="3" label="Insulin ligand"/><FilterOption id="400" count="3" label="Insulin receptor agonist"/><FilterOption id="1832" count="3" label="Nucleoside reverse transcriptase inhibitor"/><FilterOption id="48489" count="3" label="PDGF receptor alpha antagonist"/><FilterOption id="948" count="3" label="PDGF receptor antagonist"/><FilterOption id="67136" count="3" label="Programmed cell death protein 1 inhibitor"/><FilterOption id="4542" count="3" label="Raf protein kinase inhibitor"/><FilterOption id="381" count="3" label="TNF alpha ligand inhibitor"/><FilterOption id="76469" count="2" label="26S proteasome complex inhibitor"/><FilterOption id="3851" count="2" label="ALK tyrosine kinase receptor family inhibitor"/><FilterOption id="3736" count="2" label="Anaplastic lymphoma kinase receptor inhibitor"/><FilterOption id="39" count="2" label="Beta 1 adrenoceptor antagonist"/><FilterOption id="41" count="2" label="Beta 2 adrenoceptor antagonist"/><FilterOption id="3154" count="2" label="CSF-1 antagonist"/><FilterOption id="7424" count="2" label="Cytochrome P450 3A4 inhibitor"/><FilterOption id="6515" count="2" label="Cytosine DNA methyltransferase inhibitor"/><FilterOption id="48389" count="2" label="Echinoderm microtubule like protein 4 inhibitor"/><FilterOption id="3754" count="2" label="EGFR family tyrosine kinase receptor inhibitor"/><FilterOption id="447" count="2" label="Exo-alpha sialidase inhibitor"/><FilterOption id="3151" count="2" label="GCSF receptor agonist"/><FilterOption id="7163" count="2" label="Glucosylceramidase stimulator"/><FilterOption id="675" count="2" label="Hepatocyte growth factor receptor antagonist"/><FilterOption id="768" count="2" label="HIV-1 protease inhibitor"/><FilterOption id="3796" count="2" label="MET tyrosine kinase receptor family inhibitor"/><FilterOption id="2506" count="2" label="PARP modulator"/><FilterOption id="14007" count="2" label="Programmed cell death ligand 1 inhibitor"/><FilterOption id="4917" count="2" label="Proteasome inhibitor"/><FilterOption id="385" count="2" label="Protein tyrosine kinase inhibitor"/><FilterOption id="52108" count="2" label="Respiratory syncytial virus protein F modulator"/><FilterOption id="3826" count="2" label="Ros1 tyrosine kinase receptor inhibitor"/><FilterOption id="19" count="1" label="Acetylcholinesterase inhibitor"/><FilterOption id="60" count="1" label="Androgen receptor antagonist"/><FilterOption id="7303" count="1" label="Caspase-3 stimulator"/><FilterOption id="7321" count="1" label="Caspase-9 stimulator"/><FilterOption id="7472" count="1" label="Cytochrome P450 17 inhibitor"/><FilterOption id="7423" count="1" label="Cytochrome P450 3A4 stimulator"/><FilterOption id="1716" count="1" label="Dihydroorotate dehydrogenase inhibitor"/><FilterOption id="782" count="1" label="Dihydropyrimidine dehydrogenase inhibitor"/><FilterOption id="18889" count="1" label="DNA binding protein inhibitor"/><FilterOption id="6512" count="1" label="DNA methyltransferase inhibitor"/><FilterOption id="51708" count="1" label="DNA polymerase alpha inhibitor"/><FilterOption id="6830" count="1" label="DNA primase inhibitor"/><FilterOption id="111" count="1" label="Factor IIa antagonist"/><FilterOption id="113" count="1" label="Factor IX antagonist"/><FilterOption id="114" count="1" label="Factor VII antagonist"/><FilterOption id="119" count="1" label="Factor X antagonist"/><FilterOption id="168" count="1" label="FGF receptor antagonist"/><FilterOption id="3682" count="1" label="FGF1 receptor antagonist"/><FilterOption id="3688" count="1" label="FGF3 receptor antagonist"/><FilterOption id="21072" count="1" label="Growth hormone ligand"/><FilterOption id="205" count="1" label="HMG CoA reductase inhibitor"/><FilterOption id="629" count="1" label="Inosine monophosphate dehydrogenase inhibitor"/><FilterOption id="214" count="1" label="Interferon alpha 2 ligand"/><FilterOption id="481" count="1" label="Interferon beta ligand"/><FilterOption id="3594" count="1" label="Itk tyrosine kinase inhibitor"/><FilterOption id="3584" count="1" label="Lck tyrosine kinase inhibitor"/><FilterOption id="1741" count="1" label="Low molecular weight heparin"/><FilterOption id="3738" count="1" label="Ltk tyrosine kinase receptor inhibitor"/><FilterOption id="6661" count="1" label="Orotate phosphoribosyltransferase inhibitor"/><FilterOption id="4913" count="1" label="P2Y12 purinoceptor antagonist"/><FilterOption id="302" count="1" label="PDE 3 inhibitor"/><FilterOption id="48490" count="1" label="PDGF receptor beta modulator"/><FilterOption id="66340" count="1" label="Penicillin binding protein inhibitor"/><FilterOption id="15904" count="1" label="Placenta growth factor ligand inhibitor"/><FilterOption id="1449" count="1" label="Progesterone receptor modulator"/><FilterOption id="317" count="1" label="Prostanoid receptor agonist"/><FilterOption id="35354" count="1" label="Prostate specific antigen modulator"/><FilterOption id="11778" count="1" label="PurH purine biosynthesis protein inhibitor"/><FilterOption id="346" count="1" label="Ribonucleotide reductase inhibitor"/><FilterOption id="3834" count="1" label="Tek tyrosine kinase receptor inhibitor"/><FilterOption id="3832" count="1" label="TIE tyrosine kinase receptor inhibitor"/></Filter><Filter label="Trial Indications Adverse" name="trialIndicationsAdverse" total="100"><FilterOption id="102" count="54" label="Diarrhea"/><FilterOption id="829" count="54" label="Fatigue"/><FilterOption id="1991" count="52" label="Neutropenia"/><FilterOption id="17" count="47" label="Anemia"/><FilterOption id="226" count="43" label="Nausea"/><FilterOption id="324" count="34" label="Thrombocytopenia"/><FilterOption id="110" count="29" label="Emesis"/><FilterOption id="3795" count="26" label="Febrile neutropenia"/><FilterOption id="3038" count="23" label="Appetite loss"/><FilterOption id="404" count="23" label="Constipation"/><FilterOption id="360" count="23" label="Pneumonia"/><FilterOption id="2439" count="22" label="Arthralgia"/><FilterOption id="680" count="21" label="Leukopenia"/><FilterOption id="3020" count="21" label="Skin rash"/><FilterOption id="148" count="20" label="Headache"/><FilterOption id="1833" count="19" label="Fever"/><FilterOption id="746" count="19" label="Infectious disease"/><FilterOption id="178" count="17" label="Hypertension"/><FilterOption id="3472" count="16" label="Abdominal pain"/><FilterOption id="2400" count="16" label="Dyspnea"/><FilterOption id="259" count="14" label="Peripheral neuropathy"/><FilterOption id="82" count="13" label="Cough"/><FilterOption id="3062" count="12" label="Death"/><FilterOption id="13" count="10" label="Alopecia"/><FilterOption id="1039" count="10" label="Myalgia"/><FilterOption id="2274" count="10" label="Rhinopharyngitis"/><FilterOption id="1016" count="9" label="Stomatitis"/><FilterOption id="1009" count="9" label="Urinary tract infection"/><FilterOption id="3221" count="8" label="Back pain"/><FilterOption id="402" count="8" label="Edema"/><FilterOption id="1821" count="8" label="Hyperglycemia"/><FilterOption id="181" count="7" label="Hypokalemia"/><FilterOption id="182" count="7" label="Hypothyroidism"/><FilterOption id="114" count="7" label="Sepsis"/><FilterOption id="516" count="7" label="Upper respiratory tract infection"/><FilterOption id="1992" count="6" label="Lymphocytopenia"/><FilterOption id="224" count="6" label="Myocardial infarction"/><FilterOption id="20" count="6" label="Pain"/><FilterOption id="279" count="6" label="Pruritus"/><FilterOption id="3454" count="5" label="Dizziness"/><FilterOption id="2576" count="5" label="Dysgeusia"/><FilterOption id="1078" count="5" label="Lung embolism"/><FilterOption id="552" count="4" label="Bleeding"/><FilterOption id="574" count="4" label="Deep vein thrombosis"/><FilterOption id="432" count="4" label="Dyspepsia"/><FilterOption id="129" count="4" label="Gastrointestinal disease"/><FilterOption id="505" count="4" label="Hypersensitivity"/><FilterOption id="1280" count="4" label="Hypophosphatemia"/><FilterOption id="408" count="4" label="Hypotension"/><FilterOption id="1263" count="4" label="Mucositis"/><FilterOption id="358" count="4" label="Muscle spasm"/><FilterOption id="69" count="4" label="Renal failure"/><FilterOption id="2441" count="4" label="Vision disorder"/><FilterOption id="2955" count="4" label="Weight loss"/><FilterOption id="6832" count="3" label="Acral erythema"/><FilterOption id="55" count="3" label="Cardiac failure"/><FilterOption id="1072" count="3" label="Colitis"/><FilterOption id="95" count="3" label="Dermatological disease"/><FilterOption id="3073" count="3" label="Drowsiness"/><FilterOption id="2024" count="3" label="Erythema"/><FilterOption id="2184" count="3" label="Gastrointestinal bleeding"/><FilterOption id="626" count="3" label="Heart disease"/><FilterOption id="2236" count="3" label="Hypertriglyceridemia"/><FilterOption id="2733" count="3" label="Hypomagnesemia"/><FilterOption id="750" count="3" label="Insomnia"/><FilterOption id="277" count="3" label="Proteinuria"/><FilterOption id="65" count="3" label="Stroke"/><FilterOption id="2954" count="3" label="Weight gain"/><FilterOption id="3868" count="3" label="Xerosis"/><FilterOption id="1063" count="3" label="Xerostomia"/><FilterOption id="412" count="2" label="Bradycardia"/><FilterOption id="50" count="2" label="Bronchitis"/><FilterOption id="1557" count="2" label="Cardiac arrest"/><FilterOption id="57" count="2" label="Cardiovascular disease"/><FilterOption id="3050" count="2" label="Chill"/><FilterOption id="94" count="2" label="Dermatitis"/><FilterOption id="97" count="2" label="Diabetes mellitus"/><FilterOption id="2696" count="2" label="Dysphonia"/><FilterOption id="1835" count="2" label="Epistaxis"/><FilterOption id="2558" count="2" label="Folliculitis"/><FilterOption id="2099" count="2" label="Gastralgia"/><FilterOption id="142" count="2" label="Hematological disease"/><FilterOption id="154" count="2" label="Hepatitis"/><FilterOption id="1087" count="2" label="Hepatotoxicity drug-induced"/><FilterOption id="174" count="2" label="Hypercholesterolemia"/><FilterOption id="2738" count="2" label="Hyperkalemia"/><FilterOption id="3098" count="2" label="Hypoalbuminemia"/><FilterOption id="188" count="2" label="Inflammatory disease"/><FilterOption id="191" count="2" label="Influenza virus infection"/><FilterOption id="2466" count="2" label="Interstitial lung disease"/><FilterOption id="56" count="2" label="Ischemic heart disease"/><FilterOption id="201" count="2" label="Liver disease"/><FilterOption id="2440" count="2" label="Musculoskeletal pain"/><FilterOption id="221" count="2" label="Mycobacterium tuberculosis infection"/><FilterOption id="678" count="2" label="Neuropathy"/><FilterOption id="686" count="2" label="Ocular inflammation"/><FilterOption id="3209" count="2" label="Oral mucositis"/><FilterOption id="2859" count="2" label="Osteonecrosis"/><FilterOption id="2469" count="2" label="Paresthesia"/><FilterOption id="2145" count="2" label="Paronychia"/></Filter></Filters><SearchResults><Trial Id="4178"><Indications><Indication>Rheumatoid arthritis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>P2X7 purinoceptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>AstraZeneca plc</Company></CompaniesSponsor><Countries><Country>Mexico</Country><Country>US</Country><Country>Belgium</Country><Country>Poland</Country><Country>Sweden</Country><Country>Canada</Country><Country>Argentina</Country><Country>France</Country><Country>Russian Federation</Country><Country>Romania</Country><Country>Slovakia</Country><Country>Czech Republic</Country><Country>Australia</Country></Countries><DateChangeLast>2018-05-29T00:00:00Z</DateChangeLast><DateEnd>2009-03-31T00:00:00Z</DateEnd><DateStart>2007-08-31T00:00:00Z</DateStart><Identifiers><Identifier>2007-001420-12</Identifier><Identifier>D1520C00001</Identifier><Identifier>NCT00520572</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>AZD-9056 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>385</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to confirm that AZD-9056 was effective in treating rheumatoid arthritis with regard to signs and symptoms and to determine a favourable dose over a 6-month treatment period. Patients would receive background treatment with either methotrexate or sulphasalazine. The primary objective of the study was to evaluate the dose response relationship across four doses of AZD-9056 (50, 100, 200 and 400 mg) on signs and symptoms of rheumatoid arthritis (RA), as measured by the</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function - Assessment by American College of Rheumatology Criteria(ACR)</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions</EndpointIndex><EndpointIndex>Rheumatoid arthritis - American College of Rheumatology (ACR) 20 Response</EndpointIndex><EndpointIndex>Rheumatoid arthritis - American College of Rheumatology (ACR) 50 Response</EndpointIndex><EndpointIndex>Rheumatoid arthritis - American College of Rheumatology (ACR) 70 Response</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Rheumatoid arthritis - DAS-28 (Disease Activity Score) Response</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Evaluation of Joints - Swollen joint count</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Evaluation of Joints - Tender joint count</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Patient Reported Outcomes/Quality of Life Assessments - Health Assessment Questionnaire-Disability Index (HAQ-DI)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A 6-Month, Randomized, Double-Blind, Open-Arm Comparator, Phase IIb, With AZD-9056, in Patients With Rheumatoid Arthritis</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Somatic Pain - Subjects with arthritic pain</PatientSegment><PatientSegment>Rheumatoid arthritis - Active Rheumatoid Arthritis</PatientSegment><PatientSegment>Rheumatoid arthritis - Rheumatoid Arthritis with Specific Patterns Based on Disease Behavior - Erosive rheumatoid arthritis</PatientSegment><PatientSegment>Rheumatoid arthritis - Subjects on Rheumatoid Arthritis Therapy - Conventional DMARDs other than Methotrexate (MTX)</PatientSegment><PatientSegment>Rheumatoid arthritis - Subjects on Rheumatoid Arthritis Therapy - Methotrexate</PatientSegment><PatientSegment>Rheumatoid arthritis - Subjects with Sero-Positive Rheumatoid Arthritis - Rheumatoid factor (RF)</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>19 Months</TrialDuration><NumberOfSites>52</NumberOfSites><ContactNames><Name>Edward Keystone</Name><Name>Edward Keystone, MD, FRCPC</Name><Name>Zoltan Koroknai</Name></ContactNames></Trial><Trial Id="301040"><Indications><Indication>Metastatic non small cell lung cancer</Indication></Indications><ActionsPrimaryInterventionsControl><Action>DHFR inhibitor</Action><Action>GAR transformylase inhibitor</Action><Action>Thymidylate synthase inhibitor</Action><Action>Transferase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>ALK tyrosine kinase receptor family inhibitor</Action><Action>Anaplastic lymphoma kinase receptor inhibitor</Action><Action>Programmed cell death ligand 1 inhibitor</Action><Action>RET tyrosine kinase receptor family inhibitor</Action><Action>Ros1 tyrosine kinase receptor inhibitor</Action><Action>TrkA receptor antagonist</Action><Action>TrkB receptor antagonist</Action><Action>TrkC receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>Anticancer antimetabolite</Action><Action>Cell cycle inhibitor</Action><Action>DNA synthesis inhibitor</Action><Action>Folate modulator</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer monoclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody fragment</Technology><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immuno-oncology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Oral formulation</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Chugai Pharmaceutical Co Ltd</Company><Company>F Hoffmann-La Roche AG</Company><Company>Roche Holding AG</Company><Company>Roche Singapore Pte Ltd</Company></CompaniesSponsor><Countries><Country>Singapore</Country><Country>Brazil</Country><Country>Italy</Country><Country>Argentina</Country><Country>Israel</Country><Country>Poland</Country><Country>Switzerland</Country><Country>Taiwan</Country><Country>Panama</Country><Country>Chile</Country><Country>Netherlands</Country><Country>Peru</Country><Country>Spain</Country><Country>Serbia</Country><Country>France</Country><Country>Hong Kong</Country><Country>New Zealand</Country><Country>US</Country><Country>Japan</Country><Country>Turkey</Country><Country>Belgium</Country><Country>Costa Rica</Country><Country>Canada</Country><Country>Australia</Country><Country>Russian Federation</Country><Country>Thailand</Country><Country>Mexico</Country><Country>South Korea</Country><Country>Germany</Country></Countries><DateChangeLast>2019-06-06T00:00:00Z</DateChangeLast><DateEnd>2022-09-18T00:00:00Z</DateEnd><DateStart>2017-09-22T00:00:00Z</DateStart><Identifiers><Identifier>101038</Identifier><Identifier>2017-000076-28</Identifier><Identifier>B-FAST</Identifier><Identifier>BO29554</Identifier><Identifier>CTI_Umbrella</Identifier><Identifier>HKUCTR-2386</Identifier><Identifier>JapicCTI-183836</Identifier><Identifier>NCT03178552</Identifier><Identifier>UW 17-323</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Variable regimens including carboplatin , cisplatin , gemcitabine , pemetrexed disodium</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>alectinib alone</Intervention><Intervention>atezolizumab alone</Intervention><Intervention>entrectinib alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>580</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This was a phase II/III, global, multicenter, open-label, multicohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assays [ 2083840 ]. The primary objectives of</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Pulmonary Function - Assessment of pulmonary symptoms</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of duration of response</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity</EndpointIndex><EndpointIndex>Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</EndpointIndex><EndpointIndex>Lung tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-C30</EndpointIndex><EndpointIndex>Lung tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EQ-5D</EndpointIndex><EndpointIndex>Lung tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>B-FAST: A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with locally advanced/stage III lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)</PatientSegment><PatientSegment>Lung tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Lung tumor - Subjects with Unresectable/In-operable Lung Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>ALK receptor </BiomarkerName><BiomarkerName> Circulating tumor DNA </BiomarkerName><BiomarkerName> Proto-oncogene tyrosine-protein kinase ROS </BiomarkerName><BiomarkerName> Proto-oncogene tyrosine-protein kinase receptor Ret </BiomarkerName><BiomarkerName> Tumor mutational burden</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-02-13T00:00:00Z</PrimaryCompletionDate><TrialDuration>59 Months</TrialDuration><NumberOfSites>190</NumberOfSites><ContactNames><Name>Chugai Pharmaceutical Co., Ltd.</Name><Name>Dr Daniel Tan Shao Weng</Name><Name>Dr James Chung-man Ho</Name><Name>Dr Tan Chee Seng</Name><Name>HKUCTR Administrator</Name><Name>Trial Information Support Line-TISL</Name></ContactNames></Trial><Trial Id="22618"><Indications><Indication>Ulcerative colitis</Indication></Indications><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Gastrointestinal system agent</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Gastrointestinal system agent</Action><Action>Non-steroidal anti-inflammatory</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Controlled release formulation</Technology><Technology>Daily dosing</Technology><Technology>Enteric coated formulation</Technology><Technology>Local formulation unspecified</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Shire Pharmaceutical Development Ltd</Company></CompaniesSponsor><Countries><Country>Argentina</Country><Country>France</Country><Country>Peru</Country><Country>Sweden</Country><Country>Singapore</Country><Country>Taiwan</Country><Country>Brazil</Country><Country>Chile</Country><Country>Hungary</Country><Country>Netherlands</Country><Country>South Africa</Country><Country>Spain</Country><Country>Germany</Country><Country>Mexico</Country><Country>Poland</Country><Country>Czech Republic</Country><Country>Denmark</Country><Country>Russian Federation</Country><Country>New Zealand</Country><Country>Portugal</Country><Country>US</Country><Country>Belgium</Country><Country>Canada</Country><Country>South Korea</Country><Country>Australia</Country><Country>Romania</Country><Country>India</Country><Country>UK</Country></Countries><DateChangeLast>2018-11-27T00:00:00Z</DateChangeLast><DateEnd>2009-10-31T00:00:00Z</DateEnd><DateStart>2005-04-30T00:00:00Z</DateStart><Identifiers><Identifier>2004-004184-29</Identifier><Identifier>NCT00151892</Identifier><Identifier>SPD476-304</Identifier></Identifiers><InterventionsControlDisplay><Intervention>mesalazine (oral delayed-release, ulcerative colitis), Tillotts/Allergan alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>mesalazine (MMX, oral sustained release, ulcerative colitis), Giuliani/Shire/Mochida alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>829</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this trial was to study the safety and efficacy of SPD-476 in keeping ulcerative colitis in remission [ 1487704 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ulcerative colitis - Assessement of Disease Activity by Endoscopy</EndpointIndex><EndpointIndex>Ulcerative colitis - Assessment of Clinical Response - Assessment of rectal bleeding</EndpointIndex><EndpointIndex>Ulcerative colitis - Assessment of Clinical Response - Assessment of stool frequency</EndpointIndex><EndpointIndex>Ulcerative colitis - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Ulcerative colitis - Assessment of Remission - Assessment of endoscopic remission</EndpointIndex><EndpointIndex>Ulcerative colitis - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation</EndpointIndex><EndpointIndex>Ulcerative colitis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Inflammatory Bowel Disease Questionnaire (IBDQ)</EndpointIndex><EndpointIndex>Ulcerative colitis - Physician Global Assessment of Disease Activity</EndpointIndex><EndpointIndex>Ulcerative colitis - Ulcerative Colitis Assessed by Activity Indices - Assessment by Ulcerative Colitis Disease Activity Index (UCDAI)/Sutherland index</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of SPD-476 in Maintaining Remission in Patients With Ulcerative Colitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Ulcerative colitis - Ulcerative Colitis Subjects in Remission</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2009-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>54 Months</TrialDuration><NumberOfSites>141</NumberOfSites><ContactNames><Name>Professor D'Haens</Name><Name>Professor Geert D'Haens</Name><Name>William Sandborn</Name><Name>William Sandborn, MD</Name></ContactNames></Trial><Trial Id="11095"><Indications><Indication>Systemic lupus erythematosus</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Immunosuppressant</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antigen</Technology><Technology>Biological therapeutic</Technology><Technology>Oligonucleotide conjugated</Technology></Technologies><CompaniesSponsor><Company>La Jolla Pharmaceutical Co</Company></CompaniesSponsor><Countries><Country>Spain</Country><Country>Poland</Country><Country>Belarus</Country><Country>Sri Lanka</Country><Country>Czech Republic</Country><Country>Romania</Country><Country>Argentina</Country><Country>India</Country><Country>Portugal</Country><Country>Serbia</Country><Country>Ukraine</Country><Country>Lebanon</Country><Country>Australia</Country><Country>US</Country><Country>South Korea</Country><Country>Hong Kong</Country><Country>Puerto Rico</Country><Country>Indonesia</Country><Country>Brazil</Country><Country>Mexico</Country><Country>Germany</Country><Country>Italy</Country><Country>Thailand</Country><Country>Taiwan</Country><Country>Philippines</Country><Country>Bulgaria</Country><Country>Malaysia</Country><Country>Hungary</Country><Country>Slovakia</Country><Country>Georgia</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2009-02-28T00:00:00Z</DateEnd><DateStart>2004-10-31T00:00:00Z</DateStart><Identifiers><Identifier>1073</Identifier><Identifier>2006-000674-73</Identifier><Identifier>ASPEN</Identifier><Identifier>HKUCTR-319</Identifier><Identifier>LJP 394-90-14</Identifier><Identifier>NCT00089804</Identifier><Identifier>NMRR-07-801-1073</Identifier><Identifier>SLCTR/2008/006</Identifier><Identifier>UW 06-097 T/1122</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>abetimus alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>943</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Lack of Efficacy</Reason></ReasonForTrialDiscontinuation><Teaser>The purpose of this study is to determine the efficacy of abetimus (LJP-394) compared to placebo in delaying time to renal flare in SLE patients with a history of renal disease. The secondary objectives of the trial are to determine whether treatment with abetimus sodium is more effective than placebo: In reducing proteinuria. In delaying time to all major SLE flares. By February 2009, the trial had been stopped following an analysis of interim efficacy results [ 983587 ], [ 983641 ].</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Disease Progression</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Urinary Protein Excretion/Proteinuria - Assessment of proteinuria/albuminuria/macroalbuminuria</EndpointIndex><EndpointIndex>Systemic lupus erythematosus - Assessment of Flare(s) - Assessment of time to flare(s)</EndpointIndex><EndpointIndex>Systemic lupus erythematosus - Assessment of Urinary Protein Excretion/Proteinuria</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>ASPEN: Study of Abetimus (LJP-394) in Lupus Patients With History of Renal Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Subjects with Glomerular Disorder</PatientSegment><PatientSegment>Systemic lupus erythematosus - Subjects with Active Systemic Lupus Erythematosus (SLE)</PatientSegment><PatientSegment>Systemic lupus erythematosus - Subjects with Lupus Nephritis</PatientSegment><PatientSegment>Systemic lupus erythematosus - Subjects with Severe Systemic Lupus Erythematosus (SLE)</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>52 Months</TrialDuration><NumberOfSites>202</NumberOfSites><ContactNames><Name>Dr MOK Mo Yin Temy</Name><Name>HKUCTR Administrator</Name><Name>Matthew Linnik</Name><Name>Michael J Tansey, MD, Ph.D.</Name><Name>Priyadarshani Galappatthy</Name></ContactNames></Trial><Trial Id="77033"><Indications><Indication>HIV-1 infection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Cytochrome P450 3A4 inhibitor</Action><Action>HIV protease inhibitor</Action><Action>HIV-1 protease inhibitor</Action><Action>HIV-1 reverse transcriptase inhibitor</Action><Action>Nucleoside reverse transcriptase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>CCR5 chemokine antagonist</Action><Action>CD4 agonist</Action><Action>Cytochrome P450 3A4 inhibitor</Action><Action>HIV protease inhibitor</Action><Action>HIV-1 gp120 protein inhibitor</Action><Action>HIV-1 protease inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Antiviral</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>HIV fusion inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Peptidomimetic</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Pfizer Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>ViiV Healthcare Ltd</Company></CompaniesSponsor><Countries><Country>Austria</Country><Country>Finland</Country><Country>Italy</Country><Country>Brazil</Country><Country>Canada</Country><Country>Belgium</Country><Country>Poland</Country><Country>Argentina</Country><Country>Hungary</Country><Country>Denmark</Country><Country>Germany</Country><Country>Portugal</Country><Country>Netherlands</Country><Country>Puerto Rico</Country><Country>Spain</Country><Country>Switzerland</Country><Country>US</Country><Country>France</Country><Country>UK</Country><Country>Australia</Country><Country>Sweden</Country><Country>Czech Republic</Country><Country>Mexico</Country><Country>Colombia</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2014-01-31T00:00:00Z</DateEnd><DateStart>2011-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2010-021785-30</Identifier><Identifier>A4001095</Identifier><Identifier>MODERN</Identifier><Identifier>NCT01345630</Identifier><Identifier>UKCRN ID: 10266</Identifier></Identifiers><InterventionsControlDisplay><Intervention>tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences alone</Intervention><Intervention>darunavir plus ritonavir</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including darunavir , maraviroc , ritonavir</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>813</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Lack of Efficacy</Reason></ReasonForTrialDiscontinuation><Teaser>The purpose of this study was to assess whether maraviroc administered once-daily was non-inferior to Truvada also administered once-daily each in combination with darunavir / ritonavir in the treatment of antiretroviral-naive patients as evaluated at week 48 of treatment. Main objective of the trial was to assess whether maraviroc (SelzentryTM, Celsentri) administered once daily (QD) is non inferior to a reference regimen of Truvada administered orally each in combination with darunavir / ritonavir</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage</EndpointIndex><EndpointIndex>HIV infection - Assessment of CD8 Cell Responses - Assessment of CD8 cell count/percentage</EndpointIndex><EndpointIndex>HIV infection - Assessment of HIV Resistance</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV infection - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation</EndpointIndex><EndpointIndex>HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels</EndpointIndex><EndpointIndex>HIV infection - Assessment of Viral Tropism</EndpointIndex><EndpointIndex>HIV infection - Assessment of body fat distribution</EndpointIndex><EndpointIndex>HIV infection - Assessment of virological response</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>MODERN: Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment><PatientSegment>HIV infection - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alpha-1-antitrypsin </BiomarkerName><BiomarkerName> Bone mineral density </BiomarkerName><BiomarkerName> C-terminal telopeptide of collagen type I </BiomarkerName><BiomarkerName> Cytotoxic T-Lymphocytes </BiomarkerName><BiomarkerName> Osteocalcin </BiomarkerName><BiomarkerName> T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>28 Months</TrialDuration><NumberOfSites>218</NumberOfSites><ContactNames><Name>Anders Blaxhult</Name><Name>Brian Conway</Name><Name>Clinical Trials.gov Call Centre</Name><Name>ClinicalTrials.gov Call Centre</Name><Name>David Asmuth</Name><Name>Gary Blick</Name><Name>Jennifer Bartczak</Name><Name>Johannes Bogner</Name><Name>Kathleen Casey</Name><Name>Keikawus Arasteh</Name><Name>Paul Benson</Name><Name>Pfizer CT.gov Call Center</Name><Name>Thomas Campbell</Name></ContactNames></Trial><Trial Id="232917"><Indications><Indication>Rheumatoid arthritis</Indication></Indications><ActionsPrimaryInterventionsControl><Action>TNF alpha ligand inhibitor</Action><Action>TNF binding agent</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>TNF alpha ligand inhibitor</Action><Action>TNF binding agent</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Analgesic</Action><Action>Anti-inflammatory</Action><Action>Cardioprotectant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Biosimilar product</Technology><Technology>DNA technology</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Pfizer Mexico S.A. De C.V.</Company></CompaniesCollaborator><CompaniesSponsor><Company>Pfizer Inc</Company></CompaniesSponsor><Countries><Country>Peru</Country><Country>Spain</Country><Country>Colombia</Country><Country>Bulgaria</Country><Country>Czech Republic</Country><Country>Mexico</Country><Country>Hungary</Country><Country>Japan</Country><Country>Georgia</Country><Country>Germany</Country><Country>Croatia</Country><Country>UK</Country><Country>Australia</Country><Country>Ukraine</Country><Country>South Korea</Country><Country>US</Country><Country>Russian Federation</Country><Country>Brazil</Country><Country>New Zealand</Country><Country>Serbia</Country><Country>Poland</Country><Country>Taiwan</Country><Country>Estonia</Country><Country>South Africa</Country><Country>Lithuania</Country><Country>France</Country></Countries><DateChangeLast>2019-06-03T00:00:00Z</DateChangeLast><DateEnd>2017-12-06T00:00:00Z</DateEnd><DateStart>2015-06-25T00:00:00Z</DateStart><Identifiers><Identifier>114,729</Identifier><Identifier>2014-000352-29</Identifier><Identifier>212394</Identifier><Identifier>ADALIMUMAB</Identifier><Identifier>B5381002</Identifier><Identifier>JapicCTI-153018</Identifier><Identifier>NCT02480153</Identifier><Identifier>REFLECTIONS</Identifier><Identifier>REFLECTIONS B538-02</Identifier></Identifiers><IndicationsAdverse><Indication>Hypersensitivity</Indication><Indication>Infectious disease</Indication><Indication>Pneumonia</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>adalimumab plus methotrexate</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>adalimumab biosimilar, Pfizer plus methotrexate</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>597</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study assessed the efficacy, safety, and immunogenicity of PF-06410293 (adalimumab- Pfizer ) and Humira (adalimumab-EU) in combination with methotrexate in subjects with moderately to severly active rheumatoid arthritis who have had an inadequate response to methotrexate [ 1890434 ]. The primary objective of this study was to compare the treatment efficacy between adalimumab - Pfizer and adalimumab -EU in subjects with moderately to severely active RA who are treated with adalimumab in</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Rheumatoid arthritis - American College of Rheumatology (ACR) 20 Response</EndpointIndex><EndpointIndex>Rheumatoid arthritis - American College of Rheumatology (ACR) 50 Response</EndpointIndex><EndpointIndex>Rheumatoid arthritis - American College of Rheumatology (ACR) 70 Response</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C-reactive protein (CRP)/high sensitivity C-reactive protein (hs-CRP)</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Laboratory/Diagnostic Measures - Assessment of anti-drug antibodies</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Remission - DAS28 remission rate</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Treatment Response by EULAR Criteria</EndpointIndex><EndpointIndex>Rheumatoid arthritis - DAS-28 (Disease Activity Score) Response</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Evaluation of Joints - Swollen joint count</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Evaluation of Joints - Tender joint count</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Patient Reported Outcomes/Quality of Life Assessments - Health Assessment Questionnaire (HAQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>REFLECTIONS: A Study of PF-06410293 (adalimumab-Pfizer) and adalimumab (Humira) in Combination With methotrexate in Subjects With Active Rheumatoid Arthritis</TitleDisplay><PatientSegmentTerms><PatientSegment>Rheumatoid arthritis - Active Rheumatoid Arthritis</PatientSegment><PatientSegment>Rheumatoid arthritis - Moderate Rheumatoid Arthritis</PatientSegment><PatientSegment>Rheumatoid arthritis - Severe Rheumatoid Arthritis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Joint swelling </BiomarkerName><BiomarkerName> Joint tenderness</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>29 Months</TrialDuration><NumberOfSites>197</NumberOfSites><ContactNames><Name>Clinical Trials.gov Call Center</Name><Name>Pfizer CT.gov Call Center</Name></ContactNames></Trial><Trial Id="224975"><Indications><Indication>Crohns disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Integrin alpha-4/beta-7 antagonist</Action><Action>Integrin alpha-E antagonist</Action><Action>Integrin beta-7 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Gastrointestinal system agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>F Hoffmann-La Roche AG</Company><Company>Roche Holding AG</Company></CompaniesSponsor><Countries><Country>Lithuania</Country><Country>Estonia</Country><Country>South Africa</Country><Country>South Korea</Country><Country>Hungary</Country><Country>Turkey</Country><Country>Italy</Country><Country>Germany</Country><Country>Bulgaria</Country><Country>Canada</Country><Country>Slovakia</Country><Country>Serbia</Country><Country>Spain</Country><Country>Latvia</Country><Country>US</Country><Country>Australia</Country><Country>Romania</Country><Country>Russian Federation</Country><Country>Netherlands</Country><Country>Ukraine</Country><Country>Austria</Country><Country>Czech Republic</Country><Country>New Zealand</Country><Country>Argentina</Country><Country>France</Country><Country>Brazil</Country><Country>Sweden</Country><Country>Belgium</Country><Country>Croatia</Country><Country>Mexico</Country><Country>Poland</Country><Country>Israel</Country><Country>UK</Country><Country>Switzerland</Country></Countries><DateChangeLast>2019-07-02T00:00:00Z</DateChangeLast><DateEnd>2021-08-27T00:00:00Z</DateEnd><DateStart>2015-03-20T00:00:00Z</DateStart><Identifiers><Identifier>2014-003824-36</Identifier><Identifier>BERGAMOT</Identifier><Identifier>GA29144</Identifier><Identifier>NCT02394028</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>etrolizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1150</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This was a multicenter, phase III, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of etrolizumab during induction and maintenance treatment of moderate to severely active Crohn's disease (CD) in patients who were anti-tumor necrosis factor (TNF)-naive and in patients who are refractory or intolerant of  tumor necrosis factor inhibitors. Main objectives were: efficacy objectives: Induction phase (IP): to independently evaluate the efficacy of etrolizumab</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Crohns disease - Assessment of Clinical Response - Clinical response measured by crohn's disease activity index (CDAI) score by &gt; or = 100 points</EndpointIndex><EndpointIndex>Crohns disease - Assessment of Laboratory/Diagnostic Measures - Assessment of anti-drug antibodies</EndpointIndex><EndpointIndex>Crohns disease - Assessment of Remission - Proportion of patients achieving clinical remission</EndpointIndex><EndpointIndex>Crohns disease - Assessment of Safety and Tolerability - Drug related adverse event</EndpointIndex><EndpointIndex>Crohns disease - Crohn's Disease Activity Assessed by Indices/Scores - Crohn's disease activity index (CDAI) score</EndpointIndex><EndpointIndex>Crohns disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>BERGAMOT: A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD)</TitleDisplay><PatientSegmentTerms><PatientSegment>Crohns disease - Subjects with Active Crohns Disease</PatientSegment><PatientSegment>Crohns disease - Subjects with Moderate to Severe Crohns Disease</PatientSegment><PatientSegment>Crohns disease - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Crohns disease - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2021-06-04T00:00:00Z</PrimaryCompletionDate><TrialDuration>77 Months</TrialDuration><NumberOfSites>565</NumberOfSites><ContactNames><Name>Clinical Trials</Name><Name>Trial Information Support Line-TISL</Name></ContactNames></Trial><Trial Id="182966"><Indications><Indication>Ulcerative colitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Integrin alpha-4/beta-7 antagonist</Action><Action>Integrin alpha-E antagonist</Action><Action>Integrin beta-7 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Gastrointestinal system agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>F Hoffmann-La Roche AG</Company><Company>Roche Holding AG</Company><Company>Roche Products India Pvt Ltd</Company></CompaniesSponsor><Countries><Country>Romania</Country><Country>Greece</Country><Country>Hungary</Country><Country>Belgium</Country><Country>Denmark</Country><Country>Lithuania</Country><Country>Slovakia</Country><Country>Mexico</Country><Country>Italy</Country><Country>Sweden</Country><Country>Poland</Country><Country>Latvia</Country><Country>Norway</Country><Country>Philippines</Country><Country>Estonia</Country><Country>Australia</Country><Country>Croatia</Country><Country>Malaysia</Country><Country>Portugal</Country><Country>India</Country><Country>Bulgaria</Country><Country>Turkey</Country><Country>Spain</Country><Country>Argentina</Country><Country>Colombia</Country><Country>Germany</Country><Country>South Africa</Country><Country>France</Country><Country>Serbia</Country><Country>Vietnam</Country><Country>Brazil</Country><Country>New Zealand</Country><Country>Czech Republic</Country><Country>Singapore</Country><Country>Austria</Country><Country>Hong Kong</Country><Country>Ukraine</Country><Country>Netherlands</Country><Country>UK</Country><Country>Russian Federation</Country><Country>Switzerland</Country><Country>US</Country><Country>Canada</Country><Country>Israel</Country><Country>South Korea</Country></Countries><DateChangeLast>2019-07-03T00:00:00Z</DateChangeLast><DateEnd>2025-08-16T00:00:00Z</DateEnd><DateStart>2014-09-15T00:00:00Z</DateStart><Identifiers><Identifier>2013-004435-72</Identifier><Identifier>2014-CT0271</Identifier><Identifier>CTRI/2017/04/008364</Identifier><Identifier>Cottonwood</Identifier><Identifier>DRKS00007199</Identifier><Identifier>GA28951</Identifier><Identifier>GA28951 21686</Identifier><Identifier>NCT02118584</Identifier><Identifier>NMRR-14-962-21686</Identifier><Identifier>PHRR150518-001005</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>etrolizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2100</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This two-part, open-label extension (OLE) and safety monitoring (SM) study examined the efficacy and safety of continued etrolizumab (PRO-145223, RO-5490261) treatment in moderate to severe ulcerative colitis (UC) patients previously enrolled in etrolizumab phase II/III studies [ 1865365 ]. The main objective of this trial were: Part 1 (OLE): to assess the long-term, safety and efficacy of etrolizumab in eligible patients. Part 2 (SM): progressive multifocal leukoencephalopathy (PML) safety</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ulcerative colitis - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Ulcerative colitis - Assessment of Therapy Related Outcomes - Assessment of efficacy/effectiveness of intervention</EndpointIndex><EndpointIndex>Ulcerative colitis - Ulcerative Colitis Assessed by Activity Indices - Assessment by Mayo clinic score (MCS)/ disease activity index (DAI)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Cottonwood: Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies</TitleDisplay><PatientSegmentTerms><PatientSegment>Ulcerative colitis - Subjects with Moderate to Severe Ulcerative Colitis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2025-08-16T00:00:00Z</PrimaryCompletionDate><TrialDuration>131 Months</TrialDuration><NumberOfSites>871</NumberOfSites><ContactNames><Name>Arijit De</Name><Name>B Vishwanath Tantry</Name><Name>Chetan Mehta</Name><Name>Clinical Trials</Name><Name>Dr Aditi Parekh</Name><Name>Dr Amarender Singh Puri</Name><Name>Dr B Ramesh Kumar</Name><Name>Dr B Vishwanath Tantry</Name><Name>Dr Binay Swarup</Name><Name>Haribhakti Sanjiv Pravinbhai</Name><Name>Jose Sollano, Jr., MD</Name><Name>Mohd Aejaz Habeeb</Name><Name>Mukesh Kalla</Name><Name>Nachiket Avinash Duba</Name><Name>Nitin Vikas Pai</Name><Name>Philip Abraham</Name><Name>Prashant Vithalrao Rahate</Name><Name>Rakesh Tandon</Name><Name>Sarat Chandra Panigrahi</Name><Name>Saumin Prakashbhai Shah</Name><Name>Shrikant Vasantrao Mukewar</Name><Name>Sobhna Bhatia</Name><Name>Tee Hoi Poh</Name><Name>Trial Information Support Line-TISL</Name><Name>Vardaraj Pralhadarao Gokak</Name><Name>Vijay Dattatray Borgaonkar</Name><Name>Yeo Yee Chi</Name></ContactNames></Trial><Trial Id="225784"><Indications><Indication>Crohns disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Integrin alpha-4/beta-7 antagonist</Action><Action>Integrin alpha-E antagonist</Action><Action>Integrin beta-7 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Gastrointestinal system agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>F Hoffmann-La Roche AG</Company><Company>Roche Holding AG</Company></CompaniesSponsor><Countries><Country>Switzerland</Country><Country>Hungary</Country><Country>Turkey</Country><Country>Italy</Country><Country>Czech Republic</Country><Country>UK</Country><Country>Croatia</Country><Country>Israel</Country><Country>US</Country><Country>Brazil</Country><Country>Serbia</Country><Country>Lithuania</Country><Country>Canada</Country><Country>Belgium</Country><Country>Mexico</Country><Country>Latvia</Country><Country>Romania</Country><Country>Argentina</Country><Country>France</Country><Country>Germany</Country><Country>Slovakia</Country><Country>South Africa</Country><Country>Ukraine</Country><Country>New Zealand</Country><Country>Sweden</Country><Country>Bulgaria</Country><Country>Poland</Country><Country>Netherlands</Country><Country>Spain</Country><Country>Estonia</Country><Country>Austria</Country><Country>South Korea</Country><Country>Russian Federation</Country><Country>Australia</Country></Countries><DateChangeLast>2019-06-24T00:00:00Z</DateChangeLast><DateEnd>2024-04-19T00:00:00Z</DateEnd><DateStart>2015-06-08T00:00:00Z</DateStart><Identifiers><Identifier>2014-003855-76</Identifier><Identifier>GA29145</Identifier><Identifier>JUNIPER</Identifier><Identifier>NCT02403323</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>etrolizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>900</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This two-part, open-label, extension and safety monitoring study was to examine the safety and efficacy of continued etrolizumab treatment in patients with moderate to severely active Crohn's disease who would be previously enrolled in the etrolizumab, phase III study GA29144 . The objectives of this open-label extension−safety monitoring (OLE-SM) study would be as follows: Part 1 (open-label extension; OLE): To assess the long-term safety and efficacy of etrolizumab in patients eligible for part</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Crohns disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Crohns disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>JUNIPER: Open-Label, Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab, Phase III Study GA29144</TitleDisplay><PatientSegmentTerms><PatientSegment>Crohns disease - Subjects with Active Crohns Disease</PatientSegment><PatientSegment>Crohns disease - Subjects with Moderate to Severe Crohns Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2024-04-19T00:00:00Z</PrimaryCompletionDate><TrialDuration>106 Months</TrialDuration><NumberOfSites>562</NumberOfSites><ContactNames><Name>Clinical Trials</Name><Name>F. Hoffmann-La Roche Ltd</Name></ContactNames></Trial><Trial Id="342932"><Indications><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-23 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Humanized antibody</Technology><Technology>Immunoglobulin-G</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Eli Lilly &amp; Co</Company></CompaniesSponsor><Countries><Country>Taiwan</Country><Country>Canada</Country><Country>Japan</Country><Country>Italy</Country><Country>Hungary</Country><Country>Poland</Country><Country>Australia</Country><Country>Israel</Country><Country>UK</Country><Country>Mexico</Country><Country>South Korea</Country><Country>Spain</Country><Country>Puerto Rico</Country><Country>Argentina</Country><Country>Russian Federation</Country><Country>Czech Republic</Country><Country>France</Country><Country>US</Country><Country>Germany</Country></Countries><DateChangeLast>2019-06-07T00:00:00Z</DateChangeLast><DateEnd>2024-05-16T00:00:00Z</DateEnd><DateStart>2018-09-03T00:00:00Z</DateStart><Identifiers><Identifier>16491</Identifier><Identifier>2017-003299-30</Identifier><Identifier>I6T-MC-AMAH</Identifier><Identifier>JapicCTI-184202</Identifier><Identifier>NCT03556202</Identifier><Identifier>OASIS-3</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mirikizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1816</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this study will be to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis. Main objective of the study will be to access long-term maintenance of efficacy of mirikizumab in participants based upon static physicians global assessment (sPGA) (0, 1) and &gt;/= 90% improvement in psoriasis area and severity index (PASI) 90 among those who will enter study AMAH with sPGA (0, 1) and PASI 90 response. The secondary</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriasis - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Psoriasis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by Other Scales - Nail psoriasis severity index (NAPSI) and modified NAPSI score</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by Other Scales - Palmoplantar pustular psoriasis area and severity indices (PPPASI)</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by Other Scales - Psoriasis scalp severity indices (PSSI)</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - PASI-75 to 100 response</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Dermatology Life Quality Index (DLQI)</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by psoriatic symptom assessment(PSA)</EndpointIndex><EndpointIndex>Psoriasis - Physician Global Assessment of Disease Activity - Assessment by Investigator/Physician Global Assessment (PGA) Scale</EndpointIndex><EndpointIndex>Psoriasis - Protocol Specified Other Endpoints - Therapy/Intervention Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>OASIS-3: A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY-3074828 in Participants With Moderate-to-Severe Plaque Psoriasis</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriasis - Subjects with Moderate Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Plaque Psoriasis/Psoriasis Vulgaris</PatientSegment><PatientSegment>Psoriasis - Subjects with Severe Psoriasis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2024-05-16T00:00:00Z</PrimaryCompletionDate><TrialDuration>68 Months</TrialDuration><NumberOfSites>253</NumberOfSites><ContactNames><Name>Aaron K Pace</Name><Name>Aida Lugo-Somolinos</Name><Name>Akihiro Kume</Name><Name>Akimichi Morita</Name><Name>Alejandro M Lastra</Name><Name>Alejandro Maximiliano Lastra</Name><Name>Aleksandra Okuniewska</Name><Name>Alex Ortega Loayza</Name><Name>Alex Zvulunov</Name><Name>Alexa B Kimball</Name><Name>Alexey Kubanov</Name><Name>Alkes Khotko</Name><Name>Alma M Cruz Santana</Name><Name>Almudena Fernandez Orland</Name><Name>Andreas Kleinheinz</Name><Name>Andreas Pinter</Name><Name>Andrei Khariouzov</Name><Name>Andrew Blauvelt</Name><Name>Andrzej Kaszuba</Name><Name>Angeles Florez Menendez</Name><Name>Anna Dudek</Name><Name>Anna Rychlewska-Hanczewska</Name><Name>Annalisa Patrizi</Name><Name>Anne-Benedicte Duval-Modeste</Name><Name>Ansgar Weyergraf</Name><Name>Antonio Costanzo</Name><Name>Antonio Martorell Calatayud</Name><Name>Antonio Richetta</Name><Name>Aron Jeffrey Gewirtzman</Name><Name>Artis P Truett</Name><Name>Ashley N Bassford Cauthen</Name><Name>Athanasios Tsianakas</Name><Name>Atsuyuki Igarashi</Name><Name>Barbara Rewerska</Name><Name>Beatrice Gerlach</Name><Name>Beatrix Irinyi</Name><Name>Beatriz E Zazueta Montiel</Name><Name>Benjamin N. Lockshin</Name><Name>Boni Elizabeth Elewski</Name><Name>Brenda LaTowsky</Name><Name>Brent Boyce</Name><Name>Carle Paul</Name><Name>Carlos Ferrandiz Foraster</Name><Name>Catherine Hren</Name><Name>Catherine Maari</Name><Name>Celine Girard</Name><Name>Chao-Chun Yang</Name><Name>Charles W. Lynde</Name><Name>Cheng-Chung Wei</Name><Name>Chih-Ho H Hong</Name><Name>Chiharu Tateishi</Name><Name>Chika Ohata</Name><Name>Christine Feser</Name><Name>Christine Grigat</Name><Name>Christophe BEDANE</Name><Name>Chul Jong Park</Name><Name>Cindy E Owen</Name><Name>Corinne Howington</Name><Name>Craig L Leonardi</Name><Name>Craig Teller</Name><Name>David J Cohen</Name><Name>David M Pariser</Name><Name>David M Stoll</Name><Name>David Rosmarin</Name><Name>Delfina Guadalupe Villanueva Quintero</Name><Name>Diamant Thaci</Name><Name>Diana Marie Rubel</Name><Name>Dmitriy Ignatiev</Name><Name>Dong Hyun Kim</Name><Name>Douglass W Forsha</Name><Name>Edward Lain</Name><Name>Eisaku Ogawa</Name><Name>Eli Lilly Japan K.K.</Name><Name>Elizabeth A Barranco-Santana</Name><Name>Ellen H Frankel</Name><Name>Elva Dalia Rodriguez Acosta</Name><Name>Elzbieta Barbara Szymanska</Name><Name>Elzbieta Krolikowska</Name><Name>Eneida de la Torre</Name><Name>Eun So Lee</Name><Name>Eva Apostol</Name><Name>Eva Remenyik</Name><Name>Felix Pavlotsky</Name><Name>Francesca Prignano</Name><Name>Francisco A Kerdel</Name><Name>Francisco Javier Mataix Diaz</Name><Name>Fumiaki Shirasaki</Name><Name>Gabriel Alejandro Magarinos</Name><Name>Gabriel Alejandro Magariños</Name><Name>George Schmieder</Name><Name>Georgios Kokolakis</Name><Name>Gun Wook Kim</Name><Name>Hae Jun Song</Name><Name>Hagit Matz</Name><Name>Hai-Jin Park</Name><Name>Hidetoshi Takahashi</Name><Name>Hirohiko Sueki</Name><Name>Hiroyuki Okamoto</Name><Name>Holly Hake Harris</Name><Name>Hsien-Yi Chiu</Name><Name>Ignacio Dei-Cas</Name><Name>Inna Gudkova</Name><Name>Ira Hughes Thorla</Name><Name>Irina Andreeva</Name><Name>Ivan Orojan</Name><Name>James E Appel</Name><Name>James Krell</Name><Name>Jamie Debra Weisman</Name><Name>Jean-Philippe Lacour</Name><Name>Jeffrey James Crowley</Name><Name>Jeffrey M Sobell</Name><Name>Jeffrey Travers</Name><Name>Jennifer A Cather</Name><Name>Jerry Bagel</Name><Name>Jesus Abraham Simon Campos</Name><Name>Jeung-Hoon Lee</Name><Name>Ji-Chen Ho</Name><Name>John C. Browning</Name><Name>Jolanta Weglowska</Name><Name>Jonathan Wolfe</Name><Name>Joo Young Roh</Name><Name>Joo-Heung Lee</Name><Name>Jose Gonzalez-Chavez</Name><Name>Juan Alberto Ruano Ruiz</Name><Name>Jun Lu</Name><Name>Kamran Ghoreschi</Name><Name>Katarzyna Turek-Urasinska</Name><Name>Katsuhiko Tsukamoto</Name><Name>Kazuya Teramura</Name><Name>Keiichi Yamanaka</Name><Name>Kelly Tyler</Name><Name>Kenneth Gordon</Name><Name>Kenshi Yamasaki</Name><Name>Ketty Peris</Name><Name>Ki-Heon Jeong</Name><Name>Kim A. Papp</Name><Name>Kirk Allen Barber</Name><Name>Knut Schäkel</Name><Name>Koji Masuda</Name><Name>Koki Endo</Name><Name>Kristian D Reich</Name><Name>Kristian Dieter Johannes Reich</Name><Name>Kristina Callis-Duffin</Name><Name>Kurt A.J. Gebauer</Name><Name>Lajos Kemeny</Name><Name>Laszlo Biro</Name><Name>Laura K Ferris</Name><Name>Lawrence Green</Name><Name>Lev Pavlovsky</Name><Name>Levente P Kovago</Name><Name>Luca Bianchi</Name><Name>Lucie Petru</Name><Name>Luis Armando Ochoa Herrera</Name><Name>Luis Gerardo Vega Gonzalez</Name><Name>Luis Hernandez Batalla</Name><Name>Lyn Carol Chamberlain Guenther</Name><Name>Lyn Guenther</Name><Name>Lynda Jane Spelman</Name><Name>Magdalena Kolanko</Name><Name>Makoto Adachi</Name><Name>Malgorzata Janczylo-Jankowska</Name><Name>Marc Alexander Radtke</Name><Name>Margrit Simon</Name><Name>Mari Higashiyama</Name><Name>Maria Asuncion Ballester Martinez</Name><Name>Maria Laura Galimberti</Name><Name>Maria Poznanska</Name><Name>Marie Beylot-Barry</Name><Name>Marie Selerova</Name><Name>Mariko Seishima</Name><Name>Mark G. Lebwohl</Name><Name>Mark Jackson</Name><Name>Mark R Ling</Name><Name>Martin Alan Menter</Name><Name>Masaru Honma</Name><Name>Masatoshi Jinnin</Name><Name>Matthew Zirwas</Name><Name>Melinda J Gooderham</Name><Name>Michael Bukhalo</Name><Name>Michael Heffernan</Name><Name>Michael Sebastian</Name><Name>Michael Ziv</Name><Name>Michal Ramon</Name><Name>Min Geol Lee</Name><Name>Minyoung Yang</Name><Name>Mireille Ruer</Name><Name>Monika Slowinska</Name><Name>Nathalie BENETON</Name><Name>Navid Nami</Name><Name>Neil J Korman</Name><Name>Nicolas Leitz</Name><Name>Nina Magnolo</Name><Name>Noemi Bakos</Name><Name>Nora Noemi Kogan</Name><Name>Noriki Fujimoto</Name><Name>Norman R. Wasel</Name><Name>Olga Filipovska</Name><Name>Oliver Weirich</Name><Name>Osamu Ishikawa</Name><Name>Osao Arakaki</Name><Name>Otakar Komarek</Name><Name>Pablo J. Gonzalez</Name><Name>Pablo de la Cueva Dobao</Name><Name>Patricia C. Lee</Name><Name>Paul S Yamauchi</Name><Name>Paula Luna</Name><Name>Pedro Herranz Pinto</Name><Name>Peter Foley</Name><Name>Peter J Jenkin</Name><Name>Petr Arenberger</Name><Name>Phoebe Rich</Name><Name>Piergiorgio Malagoli</Name><Name>Piroska Dosa</Name><Name>Rafael Botella Estrada</Name><Name>Rafal Czajkowski</Name><Name>Rami Hamscho</Name><Name>Ramon Marla Pujol</Name><Name>Richard Graham Ballentyne Langley</Name><Name>Richard Langley</Name><Name>Richard Warren</Name><Name>Rocco Serrao</Name><Name>Rosa Izu Belloso</Name><Name>Ryan Harris</Name><Name>Sabatino Pallotta</Name><Name>Sakae Kaneko</Name><Name>Samuel Sanchez-Rivera</Name><Name>Sang-Woong Youn</Name><Name>Sascha Gerdes</Name><Name>Satomi Kobayashi</Name><Name>Satoru Arai</Name><Name>Scott A Fretzin</Name><Name>Scott L Gottlieb</Name><Name>Scott T Guenthner</Name><Name>Seong Jun Seo</Name><Name>Seth B Forman</Name><Name>Seung Chul Lee</Name><Name>Shireen Kaur Sidhu</Name><Name>Stacy R. Smith</Name><Name>Stefani Takahashi</Name><Name>Steven R Feldman</Name><Name>Tadashi Terui</Name><Name>Tae Yoon Kim</Name><Name>Tetsuya Higuchi</Name><Name>Todd Schlesinger</Name><Name>Tomasz Blicharski</Name><Name>Tomotaka Mabuchi</Name><Name>Tsen-Fang Tsai</Name><Name>Valerij Dubenskij</Name><Name>Vassilios A Dimitropoulos</Name><Name>Vivian Laquer</Name><Name>Viviana Parra</Name><Name>Vladimir Vasku</Name><Name>Wendy McFalda</Name><Name>William Cragun</Name><Name>Woan-Ruoh Lee</Name><Name>Yasuhiro Kawachi</Name><Name>Yasushi Suga</Name><Name>Yayoi Tada</Name><Name>Yong Beom Choe</Name><Name>Yoshiaki Kubo</Name><Name>Yoshihide Asano</Name><Name>Young Lee</Name><Name>Young Suck Ro</Name><Name>Yu Sung Choi</Name><Name>Yu-Huei Huang</Name><Name>Yu-Hui Huang</Name><Name>Yuichi Yamamoto</Name><Name>Yukari Okubo</Name><Name>Yukie Yamaguchi</Name><Name>Yukihiko Kato</Name><Name>Yuta Koike</Name><Name>Yutaka Shimomura</Name><Name>Zamira Faride Barragan Estudillo</Name><Name>Zoe Diana D Draelos</Name></ContactNames></Trial></SearchResults></trialResultsOutput>